 annual report
2020
annual report 2020
index
the big picture
2020 in brief
letter from the ceo
Össur at a glance
financial performance
five-year overview
performance in 2020
outlook for 2021
our business
markets
business model
innovation
strategy
people
risk management
corporate matters
shareholder information
corporate governance
csr
board of directors
executive management
consolidated financial 
statements
 
4
10
12
 
16
17
22
 
24
29
34
36
38
41
 
44
49
54
63
66
70
4
2020 in brief
the big picture
our shared passion for improving people’s 
mobility will ensure continued success as 
we embark on what will be Össur’s 50th 
anniversary year. a year where we can 
celebrate past achievements and make 
ambitious plans for the future.
5
annual report 2020
organic decline
cash generated 
by operations
ebitda margin
nibd/ebitda
10%
19%
15%
4.1x
annual report 2020
financial highlights
gender 
ratio
male    female
incident rate per 100 ftes
female in management 
positions
waste
recycled
65%
54%  46%
sustainability and csr highlights
female 
management
global employee 
satisfaction
incident rate
36%
4.4 of 5
0.7
6
the big picture
49%
9%
42%
americas
apac
emea
as % of sales
usd 307 million
organic growth: -14% 
ftes: ~1,300
as % of sales
usd 267 million
organic growth: -9% 
ftes: ~1,500
as % of sales
usd 55 million
organic growth: +2% 
ftes: ~200
hq ftes: ~500
7
annual report 2020
sales by segments
business segments 
prosthetics sales in 2020 amounted to usd 372 million and declined by 7% organic. sales of bionic products accounted 
for 20% of prosthetics component sales in 2020. bracing and supports (b&s) sales in 2020 amounted to usd 257 million 
and declined by 15% organic. 
in americas and key european markets, sales have gradually recovered from a low point in april. average sales during the 
year compared to the same period last year were as follows: january and february 2020 were around 100% of last year’s 
sales, march 80-90%, april 60-70%, may 70-80%, june 80-90%, and through the remainder of the year between 90-100%. 
the covid-19 pandemic has impacted prosthetics and b&s differently. throughout the covid-19 pandemic prosthetics 
sales have been more resilient than b&s. the demand for prosthetic solutions is, for the markets that Össur generates 
the majority of sales, mostly driven by servicing the existing amputee population with maintenance, renewals, and 
upgrades of their prosthesis. sale of mechanical prosthetic products is stable in 2020 compared to 2019, while bionics, 
which require more time for fitting and training have declined in sales more than the average for prosthetics. it is 
expected that there will be some pent-up demand in prosthetics for both mechanical and bionic products. the demand 
for b&s products is largely driven by injuries, surgeries, and prevalence of osteoarthritis (oa). the covid-19 pandemic 
and the associated lockdowns have had a significant impact on amateur sports and activity levels that have resulted in 
fewer injuries. recent data from hospital systems in europe show double-digit declines for various types of injuries to 
joints and ligaments. it is not expected that there will be pent-up demand for injury solutions. covid-19 has impacted 
volumes of elective surgeries such as knee replacement surgeries, that drive demand for post-operative bracing solutions. 
oa bracing sales have also been impacted, primarily due to limitations to physician access. some pent-up demand is 
expected for post-op and oa bracing.  
prosthetics 59%
bracing & supports 41%
sales by segments
revenue split by segments
8
june
Össur ambassador mike coots featured as 
ralph lauren’s first amputee model in their 
“the beach house” collection
Össur and nike sign new agreement 
regarding the co-development  
of the next generation of nike soles  
for the new sports feet, cheetah® xceed™, 
cheetah® xcel™ & cheetah® xpanse™ 
Össur acquisition of  
college park industries completed  
year in review
a historic year on many fronts, Össur had many memorable 
moments in 2020. at the forefront was the close partnership 
and commitment we enjoy with our customers and end-users 
around the world. 
january
may
february
april
march
team Össur member stefanie reid speaks 
at tedx london women – ‘why accessible 
design is for everyone’
rheo knee® xc wins the 2019 good 
design award 
Össur ambassador hunter woodhall on 
the ellen show 
Össur ambassador rudy garcia-
tolson featured in ny times 
article 
ot magazine interview with 
Össur ceo, jon sigurdsson    
Össur in how stuff works – how 
prosthetic limbs work.  
unloader one® x ft. in physical 
therapy products magazine and 
rehab management   
Össur article in jyllands-posten 
team Össur athletes 
featured in nike‘s 2020 team 
uniform unveiling 
new rebound® acl,  
balance™ foot s / balance™ 
foot s torsion and unloader 
one® x custom fully launched 
interview with hugh gill in 
o&p almanac‘s feature on 
upper limb prosthetics 
Össur donates work and components to 
the icelandic health authorities by custom 
manufacturing few mobile patient isolation 
units which are used to transport infected 
patients during covid-19  
Össur mexico recognized as „one of the  
best places to work for“ during covid-19 
Össur acquires scanning and design 
technology from standard cyborg 
ipc president andrew parsons visits Össur 
head office 
Össur ambassador hilmar snær Örvarsson 
wins alpine skiing european cup  
Össur ambassador hunter woodhall 
interviewed by espn 
i-limb® on swiss tv  
the big picture
9
annual report 2020
july
august
december
october
september
november
team Össur member femita ayanbeku ft.  
in runner’s world
Össur ceo jon sigurdsson interview in 
newsweek, in a special country report on 
iceland   
team Össur member daniel wagner ft. in  
the danish national broadcaster article 
Össur’s dr. anton johannesson honored by 
aopa with thranhardt award 
team Össur members  
featured in rising phoenix,  
a ground-breaking movie about 
the paralympic movement, 
premiered in over 190 countries 
worldwide on netflix 
Össur ambassador andrea lanfri 
and his friend massimo coda on 
the summit of mont blanc 
american actor david duchovny 
lends his pool to paralympic 
swimmer and Össur ambassador 
rudy garcia-tolson to train 
during covid-19 shutdowns 
Össur named one of the top 10 
orthopedic device firms by  
odt magazine 
Össur cheetah blades featured 
in triathlete article 
Össur featured in dutch 
how it’s done tv program 
Össur named a top workplace of 2020 
by the orange county register
Össur completed the divestment of 
entities focused on b&s sales in the us  
Össur recognized as one of the 
financially strongest companies 
in iceland, for the eleventh 
consecutive year in a row 
kusi’s good morning san diego: 
challenged athlete foundation 
(caf) surprises five amputees in 
five days with life-changing Össur 
running prosthetics 
Össur ambassador andrea lanfri 
from italy reached the top of the 
volcano etna 
Össur’s new e-commerce store for 
bracing launched in the us 
Össur announces establishment of 
Össur japan 
Össur completes divestment of 
gibaud sas in france 
Össur ambassador sandro 
borges featured on the 
cover of the november 
edition of ot magazine
team Össur 
member markus rehm who 
has been named 
germany’s paraathlete of 
the decade 
10
my sincere thanks to our employees, customers, end-
users, and shareholders for their partnership and 
support during this unprecedented year. our shared 
passion for improving people’s mobility will ensure 
continued success as we embark on what will be Össur’s 
50th anniversary year. a year where we can celebrate 
past achievements and make ambitious plans for the 
future. i’m proud to say that our 50th anniversary year 
will also be marked by our commitment to sustainable 
development. Össur will be carbon neutral in 2021. not 
a small endeavour and one of hopefully many more 
milestones that we can celebrate during the year. it’s time 
for a new chapter and the future is bright.
letter from the ceo
while sales were negatively impacted as social distancing 
and lockdown measures were implemented in all our 
major markets, we saw a gradual recovery towards the 
latter part of the year. our cost reduction initiatives 
enabled us to maintain a strong operating profit 
considering the impact on sales, which underlines that 
profitability will return to normalized levels as sales 
continue to recover. we remain confident that there will 
be no long-term change in the demand for our products 
and services.
we were able to overcome numerous challenges 
during the year and are proud of the new products we 
brought to market which include the balance™ foot s 
and connect™ tf socket, both ideal for the low active 
population as well as the cti® mission ligament knee 
brace. product development continues strong and we are 
excited about our healthy product pipeline. we were also 
pleased to close the acquisition of college park industries 
as well as the divestment of both gibaud and entities 
focused on b&s sales in the us.
our employees are our most valuable asset, and we were 
proud to yet again be voted one of orange county’s best 
workplaces and our annual workplace survey confirmed 
a high employee satisfaction score once again. certainly 
not something we take for granted, particularly during 
such challenging circumstances. we know the added 
personal and professional pressures have taken their 
toll this year and couldn’t be prouder of the strength and 
resilience our team has shown. 
jon sigurdsson
president and ceo
the big picture
the year 2020 will be remembered as no other. a year when words such as 
unprecedented, self-isolation and social distancing were spoken daily, and the 
world was impacted in ways that were unimaginable only a year ago.
our focus throughout the year has been to ensure business continuity and the 
safety of our employees and customers. our manufacturing and distribution 
employees, as well as the front-line employees in our clinics, have done an 
incredible job of keeping up service levels on site while office-based employees 
picked up and moved their desks to makeshift home offices. we were all required 
to think and act in new ways with our it infrastructure proving solid, and digital 
solutions used to their utmost for service, collaboration, and training purposes.
11
annual report 2020
sandro borges
football (soccer) is the most popular sport in portugal and the most practiced. 
with the national team often amongst the higher-rated teams in both europe 
and the world, portuguese children dream of joining the ranks of professional 
football.  with equal parts hard work and natural talent, sandro borges would 
have an opportunity to live his dream and play professionally for his beloved 
portugal.  unfortunately, a car accident at age 21 cut this dream short. 
his injuries were serious and potentially life threatening.  his left leg, damaged 
beyond repair, required immediate amputation. 
“the first reaction was a state of shock…the consequences of what had just 
happened, knowing that i would never more able to run, walk, go out at night 
with my friends or pick up my son from school, had a significant impact and 
shook my confidence in myself.” 
despite his shock and sadness, sandro promised himself that no matter how 
difficult, he would recover. he received his first prosthetic shortly after his 
surgery and began an aggressive rehabilitation effort. 
“above all, i wanted to get my life back and make up for lost time. so, i went 
back to the gym as often as possible and i concentrated all my efforts on 
recovery. i wanted to do better every time.” 
today, sandro is a boxing trainer who uses pro-flex xc torsion because, as he 
says, “it helps me move the way i want to move.” he continues to push himself 
in the ring and is an outspoken proponent of physical fitness, sport activities 
and a life without limitations. 
“i lead a perfectly normal life, both personally and professionally. life has given 
me the opportunity to try boxing after being a professional football player and i 
grabbed it, without doubts or hesitations.” 
user stories
12
Össur at a glance
we improve people’s mobility
Össur is a global leader in non-invasive orthopaedics; innovating, producing, and providing advanced technological 
solutions within the prosthetics and bracing & supports market. our mission is to improve the mobility of our users, so 
they can live their life without limitations®. 
Össur was founded in 1971 and has since grown through a healthy combination of organic development and acquisitions 
in both prosthetics and bracing & supports. today, Össur has a strong global position in the industry and key markets and 
in a good position to leverage future growth opportunities. Össur has been listed since 1999, has operations in over 27 
countries and more than 3,500 ftes. 
our users are at the core of everything we do
individuals can be living with limb loss or limb difference for a variety of reasons. vascular disease, diabetes, trauma, 
and congenital defects are some of the more common reasons. there are also individuals who develop knee pain, are 
diagnosed with osteoarthritis in their joints, incur fractures to their ligaments or injure themselves resulting in movement 
impairment. for years Össur has helped these individuals focus on new goals rather than limitations by offering 
comprehensive solutions that are designed with the needs of the user top of mind. 
world class innovation capabilities
Össur is a pioneer of advanced technology where our brand recognition is based on innovative and scientifically 
proven solutions that deliver effective clinical outcomes. by listening to and understanding people’s needs and pushing 
the boundaries of technology, we continue to create some of the best products and services available in the fields of 
prosthetics and bracing & supports. every year Össur invests the equivalent of 5% of sales in r&d efforts to work on new 
innovative products for the benefit of our users. in 2020 we introduced more than 20 new products to the market. 
the big picture
13
annual report 2020
our segments
Össur operates within two market segments of the orthopaedic market: bracing & supports and prosthetics. prosthetic 
products include artificial limbs and related products for amputees. bracing & supports products are primarily used to 
support joints and other body parts, both for preventive and therapeutic purposes.
prosthetics
bracing & supports
59%
of total sales
41%
of total sales
sub-segment
sub-segment
user profile
user profile
improving
mobility
improving
mobility
people living with 
lower extremity 
amputation
people living 
with lower and 
upper extremity 
amputation
people recovering 
from fractures, 
ligament injuries 
or need a post 
operative treatment
people living with 
osteoarthritis (oa)
mechanical 
products
bionic products
injury solutions
oa solutions
broad product 
offering for 
lower extremity 
prosthesis
advanced 
microprocessor 
controlled feet, 
knees, hands and 
fingers
products 
stabilizing joints 
and improving 
healing
non surgical 
treatment 
by unloading 
affected joint 
with braces
our segments
14
our products
prosthetic solutions
Össur’s prosthetics portfolio includes a full spectrum of premium lower and upper limb prosthetic components. the 
portfolio ranges from solutions to support low active individuals who may struggle to maintain the ideal balance of 
safety, comfort, and mobility all the way to solutions designed to enable especially active people to engage in high-impact 
endeavors.
bracing & supports
oa solutions
Össur’s osteoarthritis (oa) solutions are designed to enhance quality of life, reduce pain, and improve mobility for people 
living with osteoarthritis. Össur offers the unloader one® range of knee braces that relieve pain from knee osteoarthritis, 
as well as the unloader® hip which is designed to reduce pain by optimizing load dispersion for patients suffering from 
mild and moderate osteoarthritis of the hip. 
injury solutions
Össur’s injury solutions are designed for people recovering from fractures, ligament injuries or for those in need of 
post-operative treatment solutions. these solutions are designed to support the healing process of bone and soft tissue 
injuries. several of these products come with the functional healing seal that signifies a clinically validated healing 
solution that helps enhance the body’s natural healing process while maximizing mobility. 
the big picture
15
annual report 2020
prosthetic solutions
• 
high and low active lower-limb amputees
• 
upper-limb amputees
• 
children living with limb loss
• 
athletes living with limb loss
bracing & supports
• 
people that require post-operative treatment
• 
people in rehabilitation for pcl ruptures
• 
people requiring protection and joint stabilization
• 
people with foot and ankle injuries that require immobilization
• 
people with mild to severe osteoarthritis
• 
people seeking treatment for venous ulcers and swelling
who are the users 
that benefit from 
our solutions?
16
financial performance
five-year overview
five-year overview
usd m
2020
2019
2018
2017
2016
net sales
630 
686 
613 
569 
521 
gross profit
391 
439 
387 
355 
328 
operating expenses (excl. other income)
338 
341 
304 
280 
256 
ebitda
93 
141 
107 
97 
94 
ebitda before special items
93 
150
115
103
98
ebit
28 
98 
79 
75 
72 
net profit / (loss)
8 
69 
80 
58 
51 
sales growth
sales growth usd %
(8)
12 
8 
9 
8 
- organic growth %
(10)
5 
5 
5 
4 
- currency effect %
0
(4)
1 
0 
(1)
- acquired/divested business %
2 
11 
2 
4 
5 
balance sheet
total assets
1,214 
1,091 
914 
793 
746 
equity
577 
569 
538 
500 
467 
net interest-bearing debt (nibd)
381 
302 
180 
121 
119 
cash flow
cash generated by operations
119 
120 
92 
90 
88 
free cash flow
68 
63 
39 
55 
42 
key ratios
gross profit margin %
62 
64 
63 
62 
63 
ebit margin %
4 
14 
13 
13 
14 
ebitda margin %
15 
21 
18 
17 
18 
ebitda margin before special items %
15 
22
19
18
19
equity ratio %
48 
52 
59 
63 
63 
nibd to ebitda
4.1 
2.0 
1.6 
1.2 
1.2 
effective tax rate %
38 
24 
18 
16 
25 
return on equity %
1 
12 
15 
12 
11 
capex to net sales %
3.8 
4.6 
5.0 
3.4 
4.7 
full time employees on average
3,505
3,382
2,775
2,948
2,710
market
market value of equity
3,380 
3,340 
2,055 
1,871 
1,582 
number of shares in millions
423 
425 
431 
437 
443 
diluted eps in us cents
1.9 
16.2 
18.7 
13.3 
11.6 
17
annual report 2020
performance in 2020
financial performance in fy 2020 impacted by the covid-19 pandemic  
and m&a activity
• 
sales declined by 8% in local currency in 2020 and by 10% organic. sales were impacted by measures to control the covid-19 
pandemic but gradually recovered during the year.
• 
the prosthetics segment declined by 7% organic in 2020 and the b&s segment declined by 15%.
• 
gross profit margin for 2020 was 62% compared to 64% for 2019.
• 
ebitda margin for 2020 was 15% compared to an ebitda margin before special items of 22% for 2019. in addition to the impact of 
covid-19, ebitda was impacted by extraordinary items related to acquisitions, divestments, litigation, severance, and government grants.
• 
in 2017, Össur announced efficiency initiatives in the areas of manufacturing, distribution, and sourcing. the savings target of usd 
10 million in 2020 was reached, corresponding to usd 4 million in additional savings when compared to the previous year.
• 
net profit for 2020 amounted to usd 8 million and 1% of sales as it was impacted by extraordinary items related to divestments, 
acquisitions, litigation, severance, and government grants in addition to covid-19.
• 
cash flow was strong in 2020, mainly due to inventory management efforts and lower capital expenditure. cash generated by 
operations amounted to usd 118 million or 19% of sales in 2020 compared to usd 120 million or 17% of sales in 2019.
• 
Össur’s liquidity position remains strong. bank balances and cash equivalents in addition to undrawn facilities at the end of 2020 
amounted to usd 275 million. nibd/ebitda was 4.1x at end of 2020 primarily due to temporarily lower ebitda in 2020. the current 
nibd/ebitda is above the target ratio of 1.5x-2.5x.
• 
Össur purchased 1,295,450 of own shares during the year for usd 9 million. it should be noted that the share buyback program 
was temporarily put on-hold on 17 march 2020 due to the impact of covid-19, as the net interest-bearing debt to ebitda ratio is 
temporarily above the level in the capital structure and dividend policy.
• 
in 2020, Össur paid out cash dividends in the amount of usd 9 million, corresponding to dkk 0.15 per share or 13% of net profit in 
2019.
• 
Össur completed several acquisitions in 2020, including the prosthetics manufacturer college park industries, with combined annual 
sales of usd 59 million (incl. an acquisition in the first week of january 2021).
• 
Össur completed the divestment of gibaud in france and entities focused on b&s sales in the us in 2020. the sold entities 
generated a total of usd 71 million of sales.
• 
the financial guidance for the full year 2021 is 10-15% organic sales growth, 21-23% ebitda margin before special items, 3-4% 
capex of sales, and an effective tax rate of 23-24%.
key financials and guidance
usd million
2020
2019
guidance 2021
net sales
630
686
sales growth, organic
(10%)
5%
10-15%
gross profit margin
62%
64%
ebitda
93
141
ebitda margin
15%
21%
ebitda before special items
93
150
ebitda margin before special items
15%
22%
21-23%
capex as % of sales
4%
5%
3-4%
effective tax rate
38%
24%
23-24%
18
financial performance
sales performance
sales in 2020 amounted to usd 630 million compared to usd 686 million in 2019, corresponding to 10% decline organic, 
8% decline including acquisitions/divestments (local currency growth) and 8% decline reported (usd growth). 
currency movements in 2020 impacted sales growth negatively by usd 1 million, with a neutral effect on the reported 
growth rate.
Össur completed acquisitions and divestments in 2020. further information can be found in the section “acquisitions and 
divestments”.
operations
gross profit for 2020 amounted to usd 391 million or 62% of sales compared to usd 439 million or 64% of sales for 
2019. during a large part of 2020, manufacturing capacity was reduced due to lower sales in relation to covid-19, which 
resulted in a lower gross profit margin. utilization of manufacturing capacity has been increasing in line with sales 
recovery.
sales by regions
usd million
fy 2020 
organic 
growth*
acq. / div. 
curr. effect
usd growth*
americas
307
(14%)
+8%
0%
(6%)
emea
267
(9%)
-4%
0%
(12%)
apac
55
2%
-
-1%
1%
total 
630
(10%)
+2%
0%
(8%)
sales by segments
usd million
fy 2020 
organic 
growth*
acq. / div. 
curr. effect
usd growth*
prosthetics
372
(7%)
     +6%
0%
(1%)
bracing and supports
257
(15%)
-2%
0%
(16%)
total
630
(10%)
+2%
0%
(8%)
* growth/(decline)
* growth/(decline)
19
annual report 2020
operating expenses amounted to usd 363 million or 58% of sales for 2020 compared to usd 341 million or 50% of sales 
for 2019. excluding extraordinary items related to acquisitions, divestments, litigation, severance, and government grants, 
opex would have amounted to net usd 334 million or 53% of sales and declined by 2% compared to opex excluding 
special items in 2019. lower variable cost is a result of less traveling, lower marketing and selling costs, the efficiency 
initiatives which were announced in 2017, and cost-saving efforts implemented in september 2020.
• 
sales & marketing (s&m) expenses declined by 2% and amounted to 36% of sales compared to 34% of sales in 2019. 
• 
research & development (r&d) expenses declined by 1% and amounted to 5% of sales, the same as in 2019.
• 
general & administrative (g&a) expenses increased by 2% and amounted to 12% of sales compared to 11% of sales 
in 2019. excluding extraordinary items, g&a expenses would have declined.
management remains focused on managing cost in line with sales recovery with the ultimate objective to maintain and 
increase profitability as sales normalize.
efficiency initiatives
in september 2017, Össur announced efficiency initiatives in the areas of distribution, manufacturing, and sourcing, to 
further increase scalability and profitability. the savings target of usd 10 million in 2020 was reached, corresponding to 
usd 4 million in additional savings when compared to the previous year. 
operating profit
ebitda in 2020 amounted to usd 93 million or 15% of sales compared to ebitda before special items of usd 150 million 
or 22% of sales in 2019. currency impact on ebitda margin net of hedge was positive by about 60 basis points for 2020. it 
should be noted that the ebitda in 2020 was impacted by extraordinary items in the amount of net usd 11 million.
financial items, income tax and net profit
net financial expenses for 2020 amounted to usd 16 million, compared to usd 7 million in 2019.
income tax amounted to usd  5 million in 2020, corresponding to a 38% effective tax rate. the tax rate is impacted by 
non-deductible expenses for tax in relation to the divestments. excluding the impact from these items, the effective tax 
rate would have amounted to 25% in 2020, compared to 24% in 2019. it should however be noted that the tax rate is 
further impacted due to the impact that covid-19 is having on Össur’s operating results. all else equal, as sales and profit 
return to normalized levels, the effective tax rate is expected to return to levels comparable with 2019.
net profit in 2020 amounted to usd 8 million compared to usd 69 million profit in 2019. diluted earnings per share 
in 2020 amounted to 1.9 us cents compared to 16.2 us cents in 2019. net profit was impacted by extraordinary items 
related to divestments, acquisitions, litigation, severance, and government grants, in addition to covid-19.
20
financial performance
capital structure
net-interest bearing debt
net interest-bearing debt, including lease liabilities, at year-end 2020 amounted to usd 381 million compared to usd 302 
million at year-end 2019. net interest-bearing debt to ebitda corresponded to 4.1x at year-end 2020. due to the impact 
of covid-19, the net interest-bearing debt to ebitda ratio is temporarily above the level in the capital structure and 
dividend policy (1.5x-2.5x nibd/ebitda).
share buybacks and dividends
during 2020, Össur purchased 1,295,450 of own shares under share buyback programs. the total purchase price was 
usd 9 million. the purpose of the share buyback programs is to adjust the capital structure in line with a desired capital 
level of 1.5-2.5x net interest-bearing debt to ebitda outlined in Össur’s capital structure and dividend policy. it should be 
noted that the share buyback program was temporarily put on 17 march 2020 due to the impact of covid-19, as the net 
interest-bearing debt to ebitda ratio is temporarily above the level in the capital structure and dividend policy. at year-
end 2020, treasury shares totaled 902,277.
in 2020, Össur paid out cash dividends in the amount of usd 9 million, corresponding to dkk 0.15 per share or 13% of net 
profit in 2019.
acquisitions and divestments
divestment of gibaud in france
following the approval from employee representative bodies of gibaud and innothera, Össur completed the divestment 
of gibaud sas (gibaud) in france to innothera on 30 september. Össur’s bracing & supports business in france has 
mainly been operating under the brand name of gibaud, a local leader in the design, production, and distribution of 
bracing, soft goods, and compression therapy products, with primary focus on the pharmacy channel in france. gibaud’s 
cash flow
cash flow was strong in 2020 with a primary focus on inventory management and lower capital expenditures. cash 
generated by operations amounted to usd 119 million or 19% of sales for 2020 compared to usd 120 million or 17% of 
sales for 2019.
capital expenditures for 2020 amounted to usd 24 million or 4% of sales, compared to usd 32 million or 5% of sales for 
2019.
bank balances and cash equivalents amounted to usd 102 million at the end of 2020 and usd 173 million of existing 
facilities are undrawn. bank balances and cash equivalents in addition to undrawn credit facilities at the end of 2020, 
therefore, amounted to usd 275 million.
21
annual report 2020
sales amounted to usd 51 million in 2019. gibaud employs around 360 ftes and operates two production facilities in 
france. Össur remains committed to servicing its orthotic & prosthetics (o&p) customers in france from Össur’s offices 
in lyon. as a result of the divestment, Össur’s sales in france will primarily go through the o&p channel which is Össur’s 
primary sales channel in europe. gibaud and Össur will continue to be business partners for a selected b&s product range.
divestment of b&s sales entities
in 2008 and 2010 Össur acquired companies focused on sales of b&s products primarily in california and texas. the 
rationale for the investment was to strengthen market access in these important markets for b&s in the us. as a result 
of product rationalization in recent years and changes in reimbursement, the focus of these sales entities has gradually 
shifted away from selling products manufactured by Össur. in addition, Össur has in recent years increased focus on 
the o&p channel. Össur therefore decided to divest the entities which was completed on 29 december. the sold entities 
generated usd 20 million of sales in 2020 and in recent years ebit has been negative. the divested companies and Össur 
will continue to be business partners for a selected b&s product range.
acquisitions
Össur made good progress with the external growth strategy through several acquisitions during the year. the combined 
full year sales amount to around usd 59 million (including an acquisition in january 2021). these acquisitions are in line 
with Össur’s strategy to invest in companies that strengthen Össur’s position in regional markets.
impact of acquisitions and divestments
in 2019 and 2020, Össur has made several acquisitions and divestments. over these two years, acquired sales on a full-
year basis amount to usd 80 million while divested sales amount to usd 71 million.
using 2019 as a reference year, as it is not impacted by covid-19, and normalizing 2019 for pro-forma figures of acquired 
and divested companies, Össur’s sales in 2019 (reported figures in brackets) would have amounted to usd 696 million 
(usd 686 million) and organic growth would have been 6% (5%). gross profit margin would have been 64% (64%). ebitda 
margin before special items would have been 23% (22%). b&s sales would have amounted to 38% (45%) of total sales.
Össur’s sales in 2020 (reported figures in brackets) would have amounted to usd 628 million (usd 630 million) and 
organic decline would have been 10% (10%). gross profit margin would have been 62% (62%). ebitda margin before 
special items would have been 16% (15%). b&s sales would have amounted to 36% (41%) of total sales.
22
financial guidance for 2021
guidance fy 2021
actual fy 2020
sales growth/(decline), organic
10-15%
(10%)
ebitda margin before special items
21-23%
15%
capex as % of sales
3-4%
4%
effective tax rate
23-24%
38%
financial performance
outlook for 2021
the financial guidance assumes continued impact from covid-19 in 1h 2021, mainly in q1 and gradually subsiding in 
q2, while q3 and q4 are expected to be largely unaffected with some realized pent-up demand. no major fluctuation of 
main operating currencies is assumed. it is emphasized that the outlook for 2021 is more uncertain than usual as changes 
in measures to control the covid-19 pandemic in Össur’s main markets can have significant implications for financial 
performance in 2021. it should be noted that quarter one is, and has been historically, seasonally the weakest quarter of 
the year in terms of sales and profitability.
acquisitions and divestments in 2019 and 2020 have impacted Össur’s business mix. further information on the impact 
can be found in the section “acquisitions and divestments”.
given the current situation in Össur’s key markets, the organic sales growth outlook for 2021 is expected to be in the 
range of 10-15%. higher end of the guidance assumes continued recovery in sales during the first half of 2021 and a 
strong recovery in the second half with some realized pent-up demand while the lower end assumes slower recovery in 
1h and slower realization of pent-up demand.
ebitda margin before special items is expected to be in the range of 21-23%. underlying increase in profitability 
is expected as sales recover, supported by growth in higher margin products, divestments, and scalability in core 
operations. acquisitions are expected to have a slightly negative impact on the ebitda margin. at current foreign 
exchange rates, keeping all other variables constant, currency movements are expected to have a positive impact of 
around 50 basis points in 2021 when compared to 2020.
capex is expected to be in the range of 3-4% of sales. main capex items include maintenance capex in manufacturing, 
continuation of the implementation of a new crm software, investments in computer equipment, software, leasehold 
improvements, and fixtures.
based on the current mix of taxable income, the expectation is that the 2021 effective tax rate will be in the range of 23-24%.
23
annual report 2020
Össur will be carbon neutral in 2021
in recognition of our commitment to sustainable development and to commemorate the company‘s 50th anniversary, 
Össur will be carbon neutral in 2021 for energy and fuel consumption, waste generation, business travel and transportation 
of goods. this represents direct and indirect emissions (scope 1 and 2) and selected scope 3 emissions, according to the 
greenhouse gas protocol.    
Össur has partnered with first climate, a leading service provider of carbon emissions management, to achieve carbon 
neutrality. Össur aims to source all electricity from renewable sources and offset emissions through vcs and gold standard 
projects to support the un sustainable development goals. 
in the spotlight
annual report 2020
24
our business
markets
economic development around the world and global macrotrends in the market create demand and opportunities for 
growth. we have selected six trends that create opportunities for Össur:
1. 
the global population of 65 and older is increasing, and so is the amputee population
2. 
growing number of people afflicted by vascular disease, the leading cause of amputation
3. 
increased amount of fractures, joint instability and joint afflictions
1. 
new innovative technologies being accepted for reimbursement
2. 
gradual transition from volume to value-based payment in healthcare
3. 
increased acknowledgement of total healthcare economic benefits of bionics and oa bracing
1. 
global economic growth will be powered by emerging markets
2. 
disposable income increasing in emerging markets, willingness to pay out-of-pocket
3. 
increasing healthcare coverage in emerging markets
1. 
investments in people and processes to adapt to changing healthcare requirements
2. 
product development to meet prevailing regulatory requirements
3. 
increasing importance of digital and personal data security
1. 
healthcare providers increasing efforts to manage cost
2. 
demand for cost effective solutions without compromising quality
3. 
consolidation in patient care
1. 
earlier diabetic detection, limb salvage and alternative treatment options
2. 
surgery, wound care and easily accessible pain medication provide alternatives to bracing
3. 
increasing healthcare coverage and better access to patients
industry trends create opportunity
aging and more active 
population
increased penetration 
of new technologies and 
high-end products
growing middle class in 
emerging markets
increasing regulatory 
requirements
increased pressure on 
healthcare budgets
improved treatment 
options
25
annual report 2020
medical device market
Össur operates within the global non-invasive orthopaedic industry, delivering advanced and innovative solutions within 
the prosthetics and bracing & supports markets.
cardiovascular
arthroscopy
prosthetics
reconstructive
pain management
spinal
ancillary products
trauma
bone growth
bracing & supports
diagnostics
ophthalmology
imaging and other
general surgery
urology
neurological products
commodity supplies
orthopaedics
26
our business
the prosthetics market
prosthetics include artificial limbs and related products for individuals who were born without limbs or who have had 
limbs amputated. Össur offers a full range of premium lower- and upper-limb prosthetics, including feet, knees, hands, 
liners, and other components.
the size of the global prosthetics component market is estimated to be approximately usd 1.3-1.4 billion. Össur is the 
second largest company operating in prosthetics with a market share estimated at 23-24%. the share has increased from 
our previous estimates of 22-23%, largely due to the acquisition of the prosthetics manufacturer college park which was 
completed during the year.
the growth rate of the prosthetics market is estimated to be 3-5%. volume growth in the market is estimated to be 
moderate. volume growth is determined by a relatively stable global amputee population and a moderate increase in 
the number of new amputees that get fitted with a prosthesis every year. pricing in the prosthetics market is on average 
relatively stable. growth in the prosthetics industry is mainly driven by increased utilization of higher quality prosthetics 
that lead to increased mobility and quality of life for the users.
prosthetic market
market size
market share
market growth
primary sales 
channels
usd billion
1.3-1.4
23-24%
3-5%
moderate volume growth
relatively stable pricing 
positive product mix*
orthotic & 
prosthetic clinics 
(o&p)
source: Össur management estimates
note: estimates only account for component sales from providers to suppliers, i.e. not clinical services
* increased penetration of high-end innovative products
27
annual report 2020
the bracing & supports market
bracing & supports (b&s) include products used to support joints and other body parts for therapeutic and preventative 
purposes. the b&s market includes devices supporting spinal, knee, hip, foot, ankle, and hands. Össur offers a 
comprehensive line of products with primary focus on osteoarthritis and injury solutions.
the size of the global b&s product market is estimated to be approximately usd 2.7-3.0 billion. Össur’s market share 
is estimated at 5-7% compared to previous estimates of 6-8%. the change in market share is largely due to Össur’s 
divestment of gibaud which was completed during the year.
the growth rate of the b&s market is estimated to be 3-5%. market growth is driven by a healthy volume growth in the 
b&s market supported by global healthcare trends such as an aging and more active population. price levels are relatively 
stable as b&s products are fully reimbursed in most of the markets that Össur operates in. for some markets, there 
is moderate price pressure for selected product categories, mainly products of a lower innovation level. in addition, 
measures such as competitive bidding for off-the-shelf spinal and back braces in the us which came into effect in january 
2021 puts further pressure on pricing for certain products. increased utilization of high-end innovative products such as 
unloader bracing supports market growth in b&s.
bracing & supports market
market size
market share
market growth
primary sales 
channels
usd billion
2.7 - 3.0
5-7%
3 - 5%
healthy volume growth
moderate stable price pressure 
positive product mix*
orthotic & prosthetic 
clinics (o&p)
hospitals
orthopaedic clinics
source: Össur management estimates
note: estimates only account for component sales from providers to suppliers, i.e. not clinical services
* increased penetration of high-end innovative products
28
our business
orthopaedic industry stakeholders
in the orthopaedic industry, many stakeholders and decision makers are involved in the purchasing decision. 
stakeholders can be categorized into five groups.
jami goldman marseilles
in december 1987, jami and her good friend lisa were stranded during a brutal snowstorm in the 
arizona desert.  eleven days later, they were found dehydrated and near starving.  both women 
would fall victim to severe frostbite.  for jami, that would mean battling gangrene and eventual 
amputation of both legs below the knee.  within a matter of days, jami’s life was up ended as she 
experienced grief, sadness and loss.   
over the next several years, jami began an aggressive physical therapy routine, incorporated 
nutrition and wellness and learned how to walk again with the aid of prosthetics.  but that was just 
the beginning.  
“i was watching the 1996 paralympic games and decided then to become a professional paralympic 
runner,” said jami.  from that moment on, she became a runner. buoyed by a strong family support 
network and fitted with her now well-recognized prosthetic running blades, she began a rigorous 
training regime that would ultimately lead her to join the us paralympic track and field team and 
later compete in several triathlons, marathons and more. 
on october 11, 2015 jami became the first bi-lateral below knee female amputee to finish any 
marathon (chicago marathon), and on april 18, 2016 she became the first bi-lateral below knee 
female amputee to finish the boston marathon. 
as a wife, mother, teacher, philanthropist – and now, cancer-survivor – jami’s story serves as a 
remarkable testament to the power of hope, strength and gratitude. 
“overcoming is living your life full of love, passion and perseverance.” 
orthopaedic industry stakeholders
end-users
prescribers
providers
payers
influencers
individuals that use 
the products.
healthcare 
professionals 
who prescribe the 
products, based 
on the condition/
clinical indication of 
the user.
healthcare 
professionals who 
provide users with 
products, such as 
cpo’s, doctors, 
podiatrists.
public and 
private insurance 
companies. about 
95% of Össur 
products are 
reimbursed by a 
third party.
healthcare 
systems, insurance 
companies, medical 
associations, end-
users and their 
families.
user stories
29
annual report 2020
annual report 2020
Össur’s business model in brief
Össur develops, manufactures, and brings to market a wide range of prosthetics and bracing & supports solutions with 
high standards of quality. these high-end products are developed with the objective to improve the mobility of end-
users. the products are delivered to the end-users through healthcare providers who specialize in assisting individuals 
who suffer from movement impairment. Össur’s products are in most cases reimbursed by public or private insurance 
(payers). Össur makes a significant investment every year in r&d to further advance products and technologies for the 
benefit of all stakeholders. 
business model
business model
innovation
• technology trade-up
• high-end products
prescribers
• surgeons
• physicians
• doctors
providers
• o&p clinics
• hospitals
• retail
end-user
• oa
• amputation
• injuries
payers
• healthcare systems
• insurance companies
• out-of-pocket
manufacturing
• consolidated
  footprint
• high quality and
   sustainability
sales
• direct sales
• distribution
30
our business
the end-users
end-users include lower and upper extremity amputees who have lost a limb due to, for example, vascular diseases 
including diabetes, trauma, and cancer. they also include individuals who require support as they may have, for example, 
developed osteoarthritis in knee or hip ligaments, incurred temporary immobilization, or require enhanced healing after 
surgery.   
by collaborating closely with the end-users, Össur gains a better understanding of their needs and challenges. in 
turn, Össur improves their mobility by providing new technologically advanced products to achieve their goals. the 
involvement with the end-user is not limited to research and development as there is also an aim to provide them with 
quality services, directly through clinics operated by Össur or indirectly through customer service programs. 
prosthetic users
>750,000
30-40%
65-70
new lower limb 
amputees per year
of new amputees are fitted
with prosthetic solutions
is the average age
of the amputee population
vascular related diseases 70%
trauma 20%
other 10%
lower limb amputations
>25,000
new upper limb 
amputees per year
trauma 70%
other 30%
upper limb amputations
source: Össur managament estimates
31
annual report 2020
research & development
Össur develops prosthetics and bracing & supports, from an idea to a finished product. with every product, the aim is to 
deliver cost effective medical solutions that provide value for end-users and the healthcare system. when a product is 
designed, Össur accumulates medical and biomechanical data during the development process to verify product safety 
and efficacy before launch. also, to obtain independent clinical evidence for product outcomes as well as health economic 
data, Össur initiates and promotes clinical studies in cooperation with leading scientists, institutions, and healthcare 
professionals in the field. 
Össur supports open collaboration within the industry and academia. an example of such an initiative is the collaboration 
between Össur and the alfred mann foundation on the development and licensing of a myoelectric sensor system 
(imes®). the solution utilizes implantable sensors that collect signals from the amputee’s muscles and translate those into 
prosthetic movements. in other words, mind-controlled prosthetics. 
32
our business
manufacturing & quality
Össur maintains a strong global manufacturing function. manufacturing of advanced prosthetic solutions, including 
bionics, takes place in iceland and scotland. manufacturing of other prosthetics solutions, components and premium 
bracing solutions takes place in mexico. Össur outsources the manufacturing of soft goods to china. at Össur there is a 
continuous strive for profitability improvements, which includes finding ways to optimize the manufacturing process. 
great emphasis is placed on quality and it is highly important that quality is an intrinsic part of processes whereby 
Össur has had a certified quality system in place since 1993. Össur complies with various global quality and regulatory 
requirements for medical devices and is currently certified with the iso9001:2008/2015, iso14001:2015 and 
iso13485:2016 standards. 
sales & marketing
Össur operates within a highly specialized industry where the primary customers are specialized healthcare providers 
who provide and fit individuals with Össur products. in prosthetics these customers are orthopaedic and prosthetic 
(o&p) clinics and in bracing & supports it is a combination of o&p clinics, hospitals, and surgery centers. in a few 
selected markets, Össur operates its own o&p clinics. in most cases, when a user has been fitted with a product, Össur’s 
customers claim reimbursement from the relevant public institutions or private insurance companies. Össur largely sells 
its products through its own direct sales network.
manufacturing locations
33
annual report 2020
prosthetic users
1.000k
800k
600k
400k
200k
2000
2005
2010
2015
0
new major lower limb amputees
new amputees fitted with a prostheses
1%
>3%
payers, providers, and prescribers
prescribers include healthcare professionals who prescribe products based on the clinical indication of the users. these 
include orthopaedic surgeons, non-surgical physicians, and emergency physicians as well as other professionals providing 
medical diagnosis. 
providers are healthcare professionals who provide users with prosthetic and bracing products, and related services. 
these include certified prosthetists and orthotists (cpos) working at o&p clinics, durable medical equipment (dme) 
clinics, orthopaedic clinics, and hospitals. many providers not only recommend specific products but also fit and tailor-
make certain products. for non-reimbursed products, a provider can be a pharmacy or sports store. 
payers include government reimbursement or insurance companies, where over 95% of Össur’s products are estimated 
to be reimbursed by a third party. it should be noted that reimbursement systems vary substantially between countries. 
in other cases, the end-user would pay for the products out of pocket. 
34
1500
1750
752
869
1235
375
375
937
1323
374
379
1008
1500
404
352
1117
1660
1700
391
346
317
1000
500
2011
0
250
750
1250
our business
innovation
prosthetics
in 2020, Össur introduced three new product groups catering specifically for the less active amputees and facilitating 
functional trade-up through technology for this population. to continue Össur’s journey towards innovation for the 
elderly, development of the mobili knee™ has been one of the focus points in 2020. mobili knee is a microprocessor 
controlled, motorized prosthetic knee, based on Össur’s powered knee technology, to be launched in 2021. 
Össur first introduced powered technology to the prosthetics market in 2005 by launching the first generation of power 
knee™ which remains the only powered knee joint commercially available. the second generation was introduced in 2010 
and the third generation, which has been in development for the past years, will launch in 2021. this third generation 
2012
2016
2013
2017
2014
2018
2015
2019
2020
granted
pending
patent portfolio
353
strong intellectual property portfolio
Össur protects its investment in r&d by strategically growing its intellectual property portfolio. proprietary technologies 
and products are protected with various types of intellectual property rights, such as patents, design registrations 
and, trade secrets. the ip portfolio is well diversified and representative of the business areas and markets in which 
Össur operates. in recent years, the portfolio has grown around 10% annually, which is mostly contributed to in-house 
innovation efforts. in 2020 alone, Össur was granted 85 new patents in addition to filing 117 new patent applications. 
at year-end 2020, Össur had over 1,700 granted patents and some 317 patent applications pending. in addition, Össur’s 
brand is protected by more than 500 trademark registrations. 
35
annual report 2020
bracing & supports
Össur launched five new and exciting products within bracing & supports (b&s) during the year for both reimbursed 
channels as well as our direct-to-consumer (dtc) platform. throughout the year, the b&s team continued on its 
innovation journey with focus on products that are designed and built to fulfill the needs of our customers and end users 
all while continuing to offer competitive pricing without compromising patient care. 
a new walker boot is an excellent example of a product that is expected to set new standards in compliance, function, and 
biomechanisms within the b&s industry. when launched, this new walker boot will have a clear differentiation from other 
competing products and will address unmet needs in the marketplace. 
Össur launched a direct-to-consumer platform in 2020 offering braces, compression, sleeves, accessories, and parts. since 
launch Össur has focused on technology that provides the ultimate end user experience, for example with the cti ultra 
brace which is designed to offer best in class protection and stabilization of the knee joint. the development of the cti ultra 
has distilled decades of experience into Össur’s first ever dedicated dtc product and will come to market in 2021.
by listening to the needs of our customers and end users, Össur continues to be in the forefront of innovation within the 
b&s industry.
will cater for the higher active population as its predecessors and will continue to carry the name power knee. the knee 
is intended to facilitate symmetrical loading during various activities, provide confidence when negotiating obstacles and 
cover greater distances. another version of the third generation, the mobili knee, is specifically tailored to the needs of 
the low active population. the objective is to apply power to assist users to move from a seated position to a standing one 
and facilitate safe and assisted walking, allowing the amputee to ambulate in their desired environment and encouraging 
increased mobility. the launch of the mobili knee marks an important milestone in Össur’s ambition to bring innovation 
to this user group.  
innovation in powered prosthetics is based on Össur’s vision to replace lost muscle function by applying a specialized 
motor which is controlled by an internal computer. above knee amputees typically rely solely on their sound side limb 
and arms to lift themselves up from a chair, putting strain on the body and compromising balance throughout this 
activity. by utilizing powered knee extension, the power knee and mobili knee can extend the joint under load and lift 
the prosthetic wearer from a seated to a standing position. the technology enables the user to stand up in a symmetrical 
fashion, putting equal amount of load on both legs and therefore achieving improved balance.  
amputees, specifically lower active and elderly amputees, name stumbles and the risks of falling as their key fear and 
contribution to insecurity while walking. during ambulation, it is important to create enough space between the foot 
and the ground when swinging the leg through to avoid the toe from stubbing on the floor as this can lead to stumbles 
or falls. the motorized control of Össur’s powered knees allows for active control of the degree of knee flexion (against 
the gravity driven extension) during forward swing of the leg and thereby the possibility of influencing this important 
parameter of ground clearance of the foot, a major determinant for stumbles and falls. 
by applying the powered technology to prosthetics, Össur is living up to its mission to improve people’s mobility. 
36
our business
strategy
Össur is a pioneer of advanced technology and by listening to people’s needs and pushing the boundaries of technology, 
continues to create some of the best products and services available in the fields of prosthetics and bracing & supports. 
in the end, we strive to create a life without limitations for all our users. Össur’s mission is to improve people’s mobility 
and its vision is to be a leading company in the non-invasive orthopaedics market.
Össur will continue to generate value for individuals and healthcare systems by focusing our business strategy on 
successful product innovation, sustainable growth, and efficiency.
we embrace innovation in all our actions by creating value for our customers. we will be at the forefront of indication-
related innovation to ensure our consistently strong position in the market.
innovation
execute ideas that add value
in 2020, Össur continued to invest in research & development amounting to 5% of sales or usd 31 million. Össur launched more than 20 
new products and incremental updates to the market.
in 2020, Össur introduced new product groups catering specifically for the less active amputees and facilitating functional trade-up 
through technology for this population. these include the balance foot s and new direct socket tf and connect tf socket technologies. 
the balance foot s was developed to support less-active prosthetic users, ideal for people who want a lightweight, comfortable foot for 
everyday use. direct socket tf is a socket solution for transfemoral amputees of all activity levels. connect tf is an adjustable socket 
indicated for low active amputees, including an open socket donning feature.
Össur also launched new and exciting products within bracing & supports during the year for both reimbursed channels as well as our 
direct-to-consumer platform. product launches for example include the unloader one x custom knee brace, which is manufactured to fit 
the patient’s leg contour.
during the year, good progress continued to be made in research & development in new technologies for our users. for example, within 
powered prosthetics technology with products anticipated to be launched in 2021 and a new walker boot within b&s which will have a 
clear differentiation from other competing products and will address unmet needs in the marketplace.
37
annual report 2020
we strive to increase efficiency and drive continuous improvement. we run efficient operations in the most optimal 
locations, hire passionate employees and deliver strong profit and cash flow.
we will achieve growth by successfully commercializing our innovation through our local go-to-market strategy and 
commitment to our customers’ needs. we will further develop our business and leverage untapped market opportunities.
efficiency
growth
conduct business efficiently
maintain sustainable growth
ebitda margin for 2020 was 15%. profitability was strong despite the impact on topline due to covid-19 and underlines that profitability 
will return to normalized levels as sales recover.
gross profit for 2020 amounted to 62% of sales compared 64% of sales for 2019. during a large part of 2020, manufacturing capacity was 
reduced due to lower sales in relation to covid-19, which resulted in a lower gross profit margin.
good progress was made with the ongoing efficiency initiatives this year which are focused on distribution, manufacturing, and strategic 
sourcing. the savings target of usd 10 million in 2020 was reached, corresponding to usd 4 million in additional savings when compared 
to the previous year. 
Össur has been investing in an increasingly scalable infrastructure. as an example, the global manufacturing platform is consolidating 
with about 12 fewer locations since the year 2009. investments have been made in centralized procurement (strategic sourcing) and 
implementation of a new crm platform. the shared service center in poland supports around 60% of Össur’s entities and the global it 
department which is supporting majority of Össur‘s entities.
organic sales declined by 10% in 2020 as sales during the year were impacted in most markets by measures to control the covid-19 
pandemic. due to these measures, average sales compared to the same period last year were as follows during the year: january and 
february 2020 were around 100% of last year’s sales, march 80-90%, april 60-70%, may 70-80%, june 80-90%, and through the remainder 
of the year between 90-100%. the impact from the pandemic is expected to be short-term and that the long-term prospects and 
underlying fundamental drivers of the business are unchanged.
a key growth opportunity is within emerging markets where penetration of prosthetics and bracing is still relatively low. Össur continued 
to invest in selected emerging markets during the year by establishing direct sales and infrastructure. the goal in these markets is to 
drive conversion, technology trade-up, and offer partnership services.
Össur made good progress during the year with its partnership service model. these services include professional education, solutions 
to ease the reimbursement claim process, tools to enhance clinical outcomes, and outsourced fabrication.
Össur’s strategy furthermore includes exploring growth opportunities through acquisitions, and additionally divestments were made 
during the year to further focus the business. Össur completed the acquisition of the prosthetics manufacturer college park industries 
during the year and additionally acquired several other companies. the combined full year sales of these acquisitions amount to usd 
59 million (incl. an acquisition in the first week of january 2021). divestments completed during the year include gibaud in france and 
entities focused on b&s sales in the us. the combined full year sales of these divestments amount to usd 71 million.
38
our business
people
at Össur we nurture a spirit of innovation; we offer an open and vibrant environment where each employee can achieve 
his or her full potential. we live by a set of values that are the foundation for our strategy and success. our core values 
are honesty, frugality, and courage; and these values guide our decisions. we live these values every day in everything 
that we do—in our interactions with colleagues and customers, and in our work efforts.  
we have about 3,500 employees working in over 30 countries. while we are a diverse company, we work as one to 
improve people’s mobility. different ideas and points of view are beneficial to our business, and we believe in creating an 
environment where diversity, knowledge, skills, and strengths are fully utilized. as individuals, our employees can expect 
fair and equal treatment and equal opportunities for growth within Össur. our employees take responsibility, both for 
their current job and for their career advancement. we offer various learning opportunities, so employees can build 
lasting and rewarding careers with us.  
we measure our employees’ motivation once a year and we are proud that our employee satisfaction and motivation is 
high. our employees’ passion, drive, and capabilities to help our customers are our greatest assets.  
we have a competency framework within Össur that allows us to identify the behaviors that drive successful 
performance and supports business strategy. our competencies are collaboration, communication, driving results, 
customer focus and change. regular check-ins are encouraged between employees and managers to discuss both 
performance and development of these competencies which are supported by Össur‘s development guide that lists 
training and development opportunities for each competency. all employees regardless of their role or location, have 
access to thousands of on-line and virtual courses to learn and grow.  
Össur recruits competent and ambitious individuals that can work on demanding projects, and we are proud that 
we’ve been able to provide advancement opportunities for our talented employees. our hiring decisions are based 
39
annual report 2020
v a l u e s
stay true
make every step count
aim higher
on a potential employee’s skills and abilities. our global team of talented professionals is passionate about helping 
people live a life without limitations. while innovation drives us as we strive to be the leading company in non-invasive 
orthopaedics, it is the people that work at Össur that make this possible.  
if you are interested in joining our team you can view and apply for an open position on Össur’s applicant portal.  
40
our business
diversity and equality
every day we interact with people from a wide range of cultures and backgrounds. we do business in numerous locations 
around the world, working and communicating with many different colleagues, customers and other stakeholders in our 
industry.  
diversity and equality are extremely important to us. different ideas and points of view are beneficial to our business, and 
we believe in creating an environment where all our knowledge, skills and strengths are fully utilized. as individuals, we 
can expect equal treatment and equal opportunities for growth within Össur.   
diversity and equality
male 54%
female 46%
university degree 43%
other 45%
vocational or technical training 12%
16-25 8%
26-35 28%
36-45 30%
46-54 20%
55+ 14%
gender ratio
education
age
41
annual report 2020
description
most of Össur’s products and services are reimbursed by third-party payers, including government healthcare programs and 
private health insurance plans. all third-party payers continue to develop methods of controlling healthcare costs, including 
review of claims, selective contracting, and competitive bidding. 
potential impact
these cost-control methods may limit or even eliminate the coverage and the amount of payment for which third-party payers 
may be willing to pay for Össur‘s products and services. as a result, sales may decline significantly, and customers may reduce 
or eliminate purchases. reviews of claims may lead to repayment of prior sales. 
mitigative actions
Össur only brings products to the market that have medical indication and are clinically validated. Össur applies its 
reimbursement knowledge from the earliest stages of product development to the post-sale education of customers. Össur 
also pursues several strategies to manage the reimbursement of its products and services. 
risk management
four key risks
investment in Össur’s shares involves various risks where the business, financial conditions, and results of operations 
going forward rest upon certain assumptions and could be negatively affected if any of the factors described in this 
chapter occur. Össur has chosen to highlight four key risks which are currently considered most relevant (apart from the 
expected short-term impact of covid-19). Össur cannot ensure that given assumptions for the description of the risk is 
correct. furthermore, additional risks and uncertainties which are listed on Össur’s corporate website, or not presently 
known to Össur, or that the company currently deems immaterial, may adversely affect its business operations and 
financial results, to an even greater extent, than the four risks identified here.
changes in reimbursement
42
our business
description
Össur’s products are medical devices that are subject to extensive global regulations by the respective authorities in countries 
where Össur conducts its business. such regulations can restrict virtually all aspects of a medical device’s design and testing, 
manufacturing, safety, labeling, storage, recordkeeping, reporting, clearance and approval, promotion, distribution, and 
services. 
potential impact
failure to comply with the regulatory requirements of the applicable authority may subject Össur to sanctions ranging from 
warning letters to penalties and product withdrawal. Össur’s failure to comply with regulatory requirements or receive 
regulatory clearance and approval for its products or operations would adversely affect Össur’s sales and potential for future 
growth. 
mitigative actions
Össur maintains a robust global quality system that complies with international medical device standards and is an intrinsic 
part of internal processes. furthermore, employees actively monitor the medical device regulation landscape and stay on top of 
changes to international and local regulations in the countries where Össur markets and sells medical devices. 
description
Össur operates in markets that are characterized by rapid technological change, driven by extensive research that is carried out 
by market participants. technological innovation takes place at various stages in Össur’s value chain and may include individual 
components, design, and functionalities of Össur products, and patient care. 
potential impact
the development by any suppliers or competitors of substitute products or components that better satisfy market demands 
could have a material adverse effect on Össur’s business and results of operations. a failure to develop new products or 
enhance existing products could also have a material adverse effect on Össur’s operations and potential for future growth. 
mitigative actions
significant reinvestment into r&d and constant strive to find new technologies has resulted in a vast ip portfolio and enables 
a strong position to compete with potential new entries. external connections and appeal to universities, research institutes 
and investors provides the opportunity to stay informed and review emerging innovation as part of acquisitions or research 
cooperation initiatives. 
regulatory requirements
Össur may be unable to develop or secure 
the use of new technologies
43
annual report 2020
description
major shifts in Össur’s marketplace include the consolidation of prosthetics manufacturers in recent years and the additional 
momentum that forward integration is gaining in the industries where Össur operates. given the nature of acquisitions, it is 
uncertain to what degree Össur will be able to participate in further consolidation and to what degree forward integration will 
affect Össur‘s operations. 
potential impact
the consolidation has been a material contributor to the growth of Össur in the past. if Össur were not to participate in further 
consolidation or forward integration, it might limit Össur‘s potential for future growth. in addition, these shifts may impact the 
competitive landscape of the industries and the associated market shares. changes in the industry may furthermore impact 
Össur’s customers. 
mitigative actions
Össur continuously reviews value enhancing acquisition and investment opportunities in its business segments and keeps 
a good relationship with the relevant stakeholders in the industry. Össur operates its own clinics in certain regions and has 
partnership programs in place with patient care providers to offer end-users quality services. 
industry consolidation and forward integration
other relevant risk factors
for other relevant risk factors please see the investor relations section on our corporate website.
44
corporate matters
shareholder information
the Össur stock price decreased by 7% in 2020, compared to an increase of 36% of the omxc25gi index, a leading index 
for the danish equity market. Össur returned usd 18.6 million to its shareholders in 2020, in the form of usd 9.3 million 
share buybacks and usd 9.3 million in dividends. 
Össur‘s stock is listed on nasdaq copenhagen and was the 25th largest company listed on nasdaq copenhagen when 
measured in terms of market value at year-end 2020. 
the share capital of Össur is isk 423,000,000 nominal value, divided into the same number of shares. there is only one 
class of shares and all shares carry one vote. 
Össur’s largest shareholder is william demant invest a/s (wdi) which held 52% of the total shares and 52% of the voting 
rights at year-end 2020. wdi has been invested in Össur since 2004. according to an announcement by wdi, their 
intention is to hold between 50-60% of Össur’s shares going forward. apart from Össur, the fund’s investment activities 
include holdings in demant, a leading provider of hearing aids, vision rt, vitrolife, cellavision, revenio, jeudan, and 
borkum riffgrund. 
in addition, atp pension fund and the pension fund of commerce had announced holdings above 5% in Össur at year-
end 2020.  
at year-end, about ~87% of Össur‘s shareholders were located in scandinavia. the remaining ~13% of the shares are held 
by investors residing in other countries. 
key information table
market
isin
ticker
industry
nr. of shares
cph (dkk)
is0000000040
ossr
health care
423,000,000
45
annual report 2020
scandinavia 87%
usa 6% 
uk 1%
other 7%
shareholder information
ownership structure
william demant invest a/s invests in 
companies whose business models and 
structures resemble those of demant a/s, but 
are outside of demant a/s’ strategic sphere 
of interest which is hearing healthcare. 
when investing in new companies, william 
demant invest generally looks for the 
following industy and company traits:
• 
medtech/healtcare industries
• 
strong underlying market factors such as 
demographic trends and structural growth
• 
niche industries with consolidation potential
• 
companies and products with proof of 
concept and existing revenue, i.e. not 
biotechnology/clinical trials
• 
stable cash flow generation or the potential to 
achieve it in a short to medium term
william demant 
invest
demant
cellavision
revenio
jeudan
vitrolife
visionrt
borkum 
riffgrund
william demant
foundation
source: william demant invest website
46
corporate matters
stock performance
Össur’s share price decreased by 7% in 2020, from dkk 52.3 per share at year-end 2019 to dkk 48.5 per share at year-end 
2020. Össur’s market capitalization was dkk 20.5 billion (usd 3.4 billion) at year-end 2020 compared to dkk 22.2 billion 
(usd 3.3 billion) at year-end 2019. 
150
175
100
jan ‘20
50
75
125
mar ‘20
may ‘20
jul ‘20
sep ‘20
nov ‘20
jan ‘21
Össur
omx c25 gi
stock performance
share buybacks
during 2020, Össur purchased 1,295,450 of own shares (approx. 0.3% of outstanding shares) under share buyback 
programs. the total purchase price was dkk 63 million (usd 9 million). the purpose of the share buyback programs is 
to adjust the capital structure in line with a desired capital level of 1.5-2.5x net interest-bearing debt to ebitda outlined 
in Össur’s capital structure and dividend policy. it should be noted that the share buyback program was temporarily put 
on-hold on 17 march 2020 due to the impact of covid-19, as the net interest-bearing debt to ebitda ratio is temporarily 
above the level in the capital structure and dividend policy. at year-end 2020, treasury shares totaled 902,277.
 
the board of directors will not propose to the annual general meeting 2021 to reduce the share capital by way of 
cancelling shares as Össur’s current shareholding will be utilized to meet share option obligations.
47
annual report 2020
dividends
during 2020, Össur paid out cash dividends in the amount of dkk 64 million (usd 9 million), corresponding to dkk 0.15 
per share or 13% of net profit in 2019. 
the board of directors will not propose to the annual general meeting in 2021 that Össur pays cash dividends for the 
financial year 2020 as the net interest-bearing debt to ebitda ratio is temporarily above the level in the capital structure 
and dividend policy. 
50
37
44
35
39
18
40
20
0
10
30
2016
2017
2018
2019
2020
share buybacks
dividends
share buybacks and dividends
over the last five years, Össur has paid out usd 174 million to 
shareholders in the form of share buybacks and dividends.
8
28
37
26
30
9
9
9
9
7
48
corporate matters
financial calendar
annual general meeting 
 
 
 
 
 
8 march 2021
interim report q1 2021 
 
 
 
 
 
27 april 2021
interim report q2 2021 
 
 
 
 
 
22 july 2021
interim report q3 2021 
 
 
 
 
 
26 october 2021
interim report q4 2021 and annual report for 2021 
 
1 february 2022
annual general meeting 
 
 
 
 
 
8 march 2022
according to the articles of association, the annual general meeting (agm) shall be held before the end of april. 
the meeting is convened with at least three weeks’ notice. the agm results are sent to the news system of nasdaq 
immediately following the meeting and are also made available on the corporate website. Össur’s agm will be held on  
8 march 2021. 
investor relations
Össur’s policy is to disclose financial and corporate information to provide investors, analysts, and other stakeholders 
with comprehensive and accurate information to help them understand Össur’s current and expected outlook. six sell-
side equity analysts currently cover Össur. 
visit our website for financial reports, announcements, presentations, financial calendar, upcoming events, share 
information, and other information on Össur: ossur.com/investors 
contact investor relations 
e-mail: ir@ossur.com
tel.: +354 515 1300
49
annual report 2020
corporate governance
recommendations on corporate governance
Össur applies the danish recommendations on corporate governance (“recommendations”). the recommendations are 
the best practice guidelines for companies admitted to trading on a regulated market in denmark.  
each year the board of directors evaluates and decides to what extent the company should comply with the 
recommendations and consequently whether relevant rules, policies and processes should be adopted or amended. 
when reporting on corporate governance, Össur comments and provides information on each recommendation. in 
the few cases where Össur has decided to deviate from the recommendations, the “comply or explain” principle is 
applied, and well-founded explanations are provided why the relevant recommendation is not considered appropriate or 
desirable for the company. 
Össur’s corporate governance report is approved by the board of directors. the report includes both the statutory 
statement on corporate governance as well as comments and information on each item in the recommendations. the 
report is available here on Össur’s website. 
governance structure
shareholders’ meetings
the supreme authority in Össur’s affairs is in the hands of lawful shareholders’ meetings, within the limits provided for in 
the company’s articles of association and law. 
at each annual general meeting the shareholders confirm the company’s consolidated financial statements, approve the 
company’s remuneration policy and decide on remuneration for the board of directors. the board of directors and an 
auditor are also elected at the annual general meeting, for a term of one year. other resolutions are made on an ad-hoc 
basis, such as amendments to the company’s articles of association (including capital reductions or authorizations for 
the board of directors to increase share capital) as well as authorizations to the board of directors (including to purchase 
own shares, initiate share buyback programs, or initiate share incentive programs). 
resolutions at shareholders’ meetings generally require a simple majority. however, resolutions to amend the company’s 
articles of association usually require two-thirds of the votes cast and capital represented. 
william demant invest a/s holds the voting majority at Össur’s shareholders’ meetings due to its majority ownership of 
the company. 
minutes of shareholders’ meetings are available here on Össur’s website.
50
corporate matters
niels jacobsen
kristján tómas 
ragnarsson
arne boye nielsen
guðbjörg edda 
eggertsdóttir
svafa grönfeldt
board member
chairman of the 
board
vice chairman of the 
board
chairman of the audit 
committee
member of the audit 
committee
member of the audit 
committee
responsibilities
no
no
no
yes
no
independent
danish
icelandic
danish
icelandic
icelandic
nationality
denmark
usa
denmark
iceland
usa
residence
2005
1999
2009
2013
2008
board tenure
board of directors
the board of directors is the supreme authority in Össur’s affairs between shareholders’ meetings. the board has various 
roles and responsibilities, including establish goals for the company and formulate the policy and strategy to achieve 
those goals, hire a ceo to manage the company’s daily operations, supervise the company’s activities and ensure that the 
company’s organization and operations are in good and proper order, ensure adequate surveillance of the accounting 
and financial management of the company, and evaluate the company’s capital structure as well as the performance of 
the board and the ceo. the board’s roles and responsibilities are further described in the board’s rules of procedure, 
which are available here on Össur’s website.
quarter 1
february meeting
• full -year results
• corporate governance statement
• capital structure and dividend
  policy
• agenda for the annual general
  meeting
annual general meeting
march meeting
• election of chairman and vice
  chairman
• appointment of audit committee
• review of internal rules
quarter 2
april meeting
• quarterly results
quarter 3
july meeting
• half-year results
september meeting
• strategy
quarter 4
october meeting
• quarterly results
december meeting
• strategy and forecast
• performance evaluation
• diversity discussions
the board of directors’ annual schedule
51
annual report 2020
the board of directors is composed of five individuals, all elected by the shareholders at the annual general meeting for 
a term of one year. the board shall be represented by at least 40% of each gender, and currently there are three men 
and two women on the board. the board members have all served for several years, which ensures consistency and good 
insights into the company’s business and markets.
the chairman and the vice chairman of the board of directors are elected each year following the company’s annual 
general meeting. the chairman’s main responsibility is to ensure that the board performs its duties in an orderly and 
efficient manner. in the absence of the chairman, the vice chairman performs his duties. niels jacobsen has served as 
the chairman since 2006 and kristján tómas ragnarsson as the vice chairman since 2012.
the board of directors conducts a performance evaluation each year, which includes evaluation of individual 
contribution, co-operation within the board and with the ceo, the chairman’s leadership and setup of meetings, quality 
of board material, committee structure, etc. the board also evaluates its composition each year to ensure that the 
members of the board have between them the relevant knowledge, professional experience, expertise and skills required 
to perform the board’s tasks in the best interest of the company. the chairman oversees the evaluation process and 
proposes the actions to be taken, if any. the chairman shall seek external assistance at least every three years.
further information on each member of the board of directors is available here on Össur’s website.
niels jacobsen
kristján tómas ragnarsson
arne boye nielsen
guðbjörg edda eggertsdóttir
svafa grönfeldt
board member
board meetings attended
52
niels jacobsen*
kristján tómas ragnarsson*
arne boye nielsen
guðbjörg edda eggertsdóttir
svafa grönfeldt
board member
audit committee meetings attended
audit committee
the audit committee acts as an advisor to the board of directors but has no authority to take any decision on behalf 
of the board. the principal duty of the audit committee is to ensure good quality of the company’s consolidated 
financial statements and other financial information as well as the independence of the company’s auditors. the audit 
committee’s role and responsibilities are further described in the audit committee’s rules of procedure, which are 
available here on Össur’s website.
the audit committee is composed of three board members. the majority of the audit committee shall be independent of 
the company, the ceo and the auditor. the members of the audit committee shall possess the knowledge and expertise 
needed to perform the tasks of the audit committee. at least one member of the audit committee shall have solid 
knowledge and experience in the field of financial statements or auditing. arne boye nielsen has served as the chairman 
of the audit committee since 2012.
further information on each member of the audit committee is available here on Össur’s website.
executive board
according to Össur’s articles of association the executive board is formally composed of the ceo alone. he is not a 
member of the board of directors.
the ceo is responsible for the company’s daily operations and is obliged to follow the board of directors’ policy and 
directions, within the limits provided for by the company’s articles of association and law. the daily operations do not 
include measures that are unusual or extraordinary, which may generally only be taken if specially authorized by the 
board.
the board of directors evaluates the ceo’s performance each year and then the chairman of the board and the ceo have 
a meeting to discuss the results of the evaluation and the actions to be taken, if any.
*attends the meeting in his capacity as chairman or vice chairman of the board.
corporate matters
53
annual report 2020
Össur also has a wider executive committee consisting of the ceo, the cfo and executive vice presidents (“executive 
management”). the executive management generally meets every week and collectively prepares and implements the 
company’s strategic plans. the ceo is responsible for the work and results of the executive management. the ceo evaluates 
the performance of the executive management each year and discusses the results of the evaluation with each member and 
the actions to be taken, if any.
further information on each member of the executive management is available here on Össur’s website.
54
corporate social responsibility
Össur joined the un global compact in 2011 and signed the un women’s empowerment principles in 2014. in 2019, 
Össur evaluated its impact on the un sustainable development goals and selected four goals to support. initiatives 
related to the selected goals started in 2020 and therefore this is the first time Össur reports on the progress. this 
chapter will give a high-level overview of the selected sdg’s and esg measurements in accordance with the nasdaq 
esg guidance. Össur publishes annually a separate progress report on its sustainability efforts which discusses the 
company’s initiatives and progress in more detail.   
Össur’s contribution to the un sustainable development 
goals (sdg)
Össur’s largest impact on society is through the company’s innovative products, research activities and expertise in the 
field of prosthetics and bracing and supports. Össur works with individuals, clinicians, and diverse communities around 
the world to support a better quality of life and increase the mobility of millions of people. consequently, Össur’s greatest 
impact is on goal 3, good health and well-being. additionally, Össur will also contribute to goal 5 on gender equality, 
goal 12 on responsible consumption and production and goal 13 on climate action. Össur’s sustainability vision is to 
provide products and services that contribute to good health, using responsible production methods and supporting 
climate action, while being a sponsor for gender equality. 
access to healthcare for elderly amputees
Össur’s main initiative supporting this goal is to design products that offer additional benefits for the 
elderly, increasing their independency and quality of life. to secure access and availability of these 
solutions, Össur works closely with healthcare professionals in its field. at the end of 2020, Össur had 
already launched three products that are specially designed for this user group, and 30% of ongoing 
clinical investigations were related to this subject which will deliver valuable information and insights to 
further understand the need and potential benefits.  
the numbers in the table below show the status at year-end 2020. as this is the first year Össur reports 
on these initiatives, these results serve as a baseline and next year will demonstrate the progress achieved. 
corporate matters
availability of products* 
availability of products and services** 
* 
percentage of countries where Össur products are available
** percentage of countries where Össur provides both products and services (direct sales)
2020 
status
new products specially designed for 
elderly users
 4 new products 
by 2024
3
ongoing prosthetic studies which will inform 
developers about the elderly customer group
 30%
44% 
25% 
target
actions 
and progress
55
annual report 2020
our ongoing commitment 
Össur believes in diversity in its broadest sense and the importance of gender equality and women’s 
positive contribution to the workplace and the society. main targets supporting this goal is to maintain 
an even gender split amongst employees (+/-10%), increase management positions held by women, and 
continue to encourage greater diversity and inclusiveness in the industry.
reducing the environmental footprint of our products 
Össur is taking a product-centric approach to environmental management and aims to reduce the 
product’s environmental footprint throughout the full lifecycle, from development, through production, 
use and disposal. our approach is to start initiatives with selected product lines and expand into the 
portfolio going forward.
Össur’s women’s leadership initiative (Öwli)
encourage greater diversity and inclusiveness in 
the industry
target
target
actions 
and progress
actions 
and progress
2020 
status
2020 
status
gender split among employees
sustainable product 
design 
• establish data on carbon 
footprint of the current product 
portfolio 
• identify opportunities for 
carbon footprint reduction
• build internal development 
processes to act on carbon 
footprint of future products 
• eliminate single use plastic
• reduce total material 
consumption
• selected products in current 
product portfolio analyzed with 
respect to their carbon footprint 
• opportunities for carbon 
footprint reduction of selected 
products identified
• internal education and 
awareness
• sustainability workshops
• pro-flex foot line packaging re-design: 
 o 100% reduction in polyurethane 
 o 10% less in total material  
 o 50% recycled material
• recycling information incorporated
50% 
(+/- 10%)
50% 
(+/- 10%)
annual 
conferences* and 
webinars
46% female
54% male
female managers (percentage of total number 
of managers)
reduce material in 
product packaging
 36%
6 webinars
* annual Öwli conference postponed 2020 due to covid19
56
corporate matters
actively working towards a carbon neutral operation
Össur is committed to reducing its greenhouse gas emissions and improving the efficiency of its energy 
and resource consumption. 
in recognition of our commitment to sustainable development and to commemorate Össur’s 50th 
anniversary, Össur will be carbon neutral in 2021 for energy and fuel consumption, waste generation, 
business travel and transportation of goods. this represents direct and indirect emissions (scope 1 and 2) 
and selected scope 3 emissions, according to greenhouse gas protocol. 
Össur has partnered with first climate, a leading service provider of carbon emissions management, to 
achieve carbon neutrality. Össur aims to source all electricity from renewable sources and offset emissions 
through vcs and gold standard projects to support the un sustainable development goals. 
the un global compact asks companies to embrace, support and enact, 
within their sphere of influence, a set of core values in the areas of human 
rights, labor standards, the environment and anti-corruption.
target
actions 
and progress
2020 
status
continuously improve 
Össur‘s greenhouse gas 
emission reporting 
establish an overview of 
Össur‘s carbon footprint
100%
-10%
carbon neutral in 
2021
emission data added for: 
• 6 Össur locations
• transportation of goods
• clinics 
• car fleet
• finished goods suppliers 
electricity consumption
24% of electricity with 
guarantee of origin (go) 
certification
40% reduction, reflecting 
covid-19 impacts on business 
travel (70% reduction)
• partner selected (first climate)
• emissions calculations verified by 
first climate
source electricity 
from renewable 
energy sources
reduce emissions 
from business 
travel and freight.
carbon neutral 
company
57
annual report 2020
energy 
consumption
outbound
freight
inbound and
intercompany freight
business travel
waste
clinics
products 
on the 
market
finished goods
suppliers 
raw 
material
suppliers
how will 
we do it?
reduce waste by focusing 
on raw material efficiency 
and maximize waste 
recovery, supporting a 
circular economy.
offset the remaining 
emissions with verified 
carbon removal projects 
and solutions.
actively reduce emissions 
from business travel and 
inbound, outbound and 
intercompany freight.
improve energy efficiency at our 
locations and work towards 100% 
renewable energy sources. we are 
currently using 100% renewable 
energy in iceland and solar panels 
are used at our eindhoven facility.
within scope
outside
scope
outside
scope
58
environment
below reporting on environmental metrics is in accordance with the nasdaq esg guidance. Össur strives to continuously 
improve its greenhouse gas emission reporting with more extensive data from suppliers and service providers.  
environment
connection to 
frameworks
2019
2020
e-1
ghg emissions in tonnes co2 equivalents (tco2e) *
ungc p7
1.1
scope 1 - direct emissions, tco2e
 360 
 1.800 
gas consumption for heating
 360 
 500 
fuel consumption in vehicle fleet
 n.a. 
 1.300 
1.2
scope 2 - indirect emissions, tco2e
 3.600 
 5.000 
purchased electricity and heat
 3.600 
 5.000 
1.3
scope 3 - other relevant indirect emissions, tco2e
 7.090 
 9.330 
finished goods suppliers electricity consumption
 n.a. 
 2.200 
transportation of goods
 n.a. 
 4.700 
waste treatment
 190 
 130 
business travel
 6.900 
 2.300 
e-2
emissions intensity
sdg 13, ungc p7, 
p8
2.1
total ghg emissions per revenue, tco2e/usd million
 16 
 26 
e - 3
energy usage
sdg 12, ungc p7, 
p8
3.1
total energy directly consumed (mwh)
 2.340 
 7.030 
gas consumption for heating
 2.340 
 2.230 
fuel consumption of vehicle fleet
n/a  
 4.800 
e - 4
energy intensity
sdg 12, ungc p7, 
p8 
total energy usage per revenue, mwh/usd million
 3 
 11 
e - 5
energy mix
% electricity from renewable sources  **
n/a
24%  
% electricity from other energy sources 
n/a
76%  
e - 6
water usage
6.1
total amount of water consumed (m3) ***
 95.400 
 87.000 
e - 7
environmental operations
7.1
does Össur follow a formal environmental policy?
yes
yes
7.2
does Össur follow specific waste, water, energy, and/or recycling polices? 
yes
yes
7.3
does Össur use a recognized energy management system? 
yes
yes
e - 8
climate oversight / board
does Össur board of directors oversee and/or manage climate-related risks?
no
no
e - 9
climate oversight / management
does senior management team oversee and/or manage climate-related 
risks? 
no
no
e - 10
climate oversight / management
ungc p9
total amount invested, annually, in climate-related infrastructure, resilience, 
and product development.
n/a  
n/a  
* 
in 2020, the scope of emission monitoring was extended to include 6 additional Össur locations, transportation of goods, clincs, car fleet and finished 
goods suppliers. this extension to the monitoring scope explains higher emissions in 2020 compared to 2019.  
 
**  electricity consumption in iceland, guarantee of origin (go) certified for the first time  
 
***  includes 7 of 10 m&o operational sites 
 
 
corporate matters
59
annual report 2020
rudy garcia-tolson
“a brave heart is a powerful weapon, and people should never let their 
challenges define who they are” 
at an age when most children must be reminded to brush their teeth or 
take out the trash, rudy garcia-tolson was charting his course to ironman® 
triathlon victory and paralympic gold.   born with multiple birth defects, rudy 
endured 15 surgeries by the age of five before telling his parents he would 
prefer a double leg amputation.  soon after, rudy began to swim and run, 
participating in his first triathlon at age 8, as the swimmer in a winning relay 
team.  by age 10, on a visit to Össur in iceland, he provided product input 
which became key in the development of the flex-run™ prosthetic.  shortly 
thereafter, rudy completed the first of many individual triathlons. 
today he is a multi-hyphenate.  rudy is a swimmer, runner, cyclist, triathlete, 
espn’s arete courage in sports award winner, espy nominee, motivational 
speaker and four-time paralympian. 
on a day-to-day basis, rudy uses Össur’s rheo knee® and pro-flex® xc. for 
athletics, he uses Össur’s flex-run. as a four-time paralympian (2004, 2008, 
2012, 2016) and five-time medalist, rudy devotes himself to inspiring the 
younger generation of challenged athletes. today, he is training in hopes of 
competing at his fifth paralympics in tokyo next year. 
“never let people tell you that you can’t do something. prove them wrong. the 
only disability in life is a negative attitude.” 
user stories
in 2020, the scope of emission monitoring was extended which explains higher emissions in 2020, compared to 2019. the 
table only shows two years as the 2018 numbers are not comparable to 2019 and 2020 numbers due to this extension to 
scope. 
Össur has a certified environmental management system in accordance with iso 14001:2015 at the largest manufacturing 
and distribution locations. 
for more detailed information, see Össur’s csr report. 
60
social
below reporting on social metrics in accordance with the nasdaq esg guidance. further details on social initiative are 
discussed in Össur’s csr report. 
social metrics
connection to 
frameworks
2018
2019
2020
s - 1
ceo pay ratio
ungc: principle 6
1)
ceo total compensation to median fte total compensation
22
21
21
2)
does your company report this metric in regulatory filings? 
yes/no
yes
yes
yes
s - 2
gender pay ratio
ungc: principle 6
equal pay audit
yes
yes
yes
s - 3
employee turnover
ungc: principle 6
1)
year-over-year change for full-time employees
15%
10%
17%
2)
year-over-year change for part-time employees
n/a
n/a
n/a
3)
year-over-year change for contractors and/or consultants
n/a
n/a
n/a
s - 4
gender diversity
ungc: principle 6
1)
total enterprise headcount held by men and women
m 51%/ 
f 49%
m 51%/ 
f 49%
m 54%/ 
f 46%
2)
entry- and mid-level positions held by men and women
m64%/ 
f36%
m62%/ 
f38%
m64%/ 
f36%
3)
senior- and executive-level positions held by men and 
women
m80%/ 
f20%
m74%/ 
f26%
m76%/ 
f24%
s - 5
temporary worker ratio
ungc: principle 6
1)
total enterprise headcount held by part-time employees
4,2%
8%
9%
2)
total enterprise headcount held by contractors and/or 
consultants
n/a
124
144
s - 6
non-discrimination
ungc: principle 6
1)
does your company follow a sexual harassment and/or 
non-discrimination policy? yes/no
yes
yes
yes
s - 7
injury rate
sdg 3
1)
total recordable incident rate per 100 employees
1,1
0,6
0,7
s - 8
global health and safety
sdg 3
1)
does your company follow an occupational health and/or 
global health & safety policy? yes/no
yes
yes
yes
s - 9
child & forced labor
ungc: principle 4,5
1)
does your company follow a child and/or forced labor 
policy? yes/no
yes
yes
yes
2)
if yes, does your child and/or forced labor policy see also: 
cover suppliers and vendors? yes/no
yes
yes
yes
s - 10
human rights
ungc: principle 1,2
1)
does your company follow a human rights policy? yes/no
yes
yes
yes
2)
if yes, does your human rights policy see also: cover suppli-
ers and vendors? yes/no
yes
yes
yes
corporate matters
61
annual report 2020
governance metrics
connection to 
frameworks
2018
2019
2020
g - 1
board diversity
1)
percentage: total board seats occupied by women (as compared 
to men)
m 60% / f 
40%
m 60% / f 
40%
m 60% / f 
40%
2)
percentage: committee chairs occupied by women (as compared 
to men) the board has only one committee, audit committee, 
explaining the uneven gender split.
m 100% 
/f 0%
m 100% 
/f 0%
m 100%  
/f 0%
g - 2
board independence
1)
does company prohibit ceo from serving as board chair? yes/no
yes
yes
yes
2)
percentage: total board seats occupied by independents
d 60% /  
i 40%
d 60% /  
i 40%
d 60% /  
i 40%
g - 3
incentivized pay
1)
are executives formally incentivized to perform on sustainability? 
yes/no
no
no
no
g - 4
collective bargaining
ungc: principle 3
1)
total enterprise headcount covered by collective bargaining 
agreement(s)
n/a
41%
39%
g - 5
supplier code of conduct
ungc: principle 
2,3,4,8  sdg 12
1)
are your vendors or suppliers required to follow a code of con-
duct? yes/ n
no
yes
yes
2)
if yes, what percentage of your suppliers have formally certified 
their compliance with the code?
n/a
76%*
76%*
g - 6
ethics & anti-corruption
ungc: principle 10
1)
does your company follow an ethics and/or anti-corruption 
policy? yes/no
yes
yes
yes
2)
if yes, what percentage of your workforce has formally certified 
its compliance with the policy?
91%**
91%**
91%**
g - 7
data privacy
1)
does your company follow a data privacy policy? yes/no
yes
yes
yes
2)
has your company taken steps to comply with gdpr rules? yes/
no
yes
yes
yes
g - 8
esg reporting
ungc: principle 8
1)
does your company publish a sustainability report? yes/no
yes
yes
yes
2)
is sustainability data included in your regulatory filings? yes/no
yes
yes
yes
g - 9
disclosure practices
ungc: principle 8
1)
does your company provide sustainability data to sustainability 
reporting frameworks? yes/no
yes
yes
yes
2)
does your company focus on specific un sustainable develop-
ment goals (sdgs)? yes/no
no
yes
yes
3)
does your company set targets and report progress on the un 
sdgs? yes/no
no
yes
yes
g - 10
external assurance
ungc: principle 8
are your sustainability disclosures assured or validated by a third 
party? yes/no
third party assurance and third party audits are per-
fomed on vast majority of the csr data, further details in 
the csr report
corporate governance
Össur’s corporate governance reporting complies with the danish recommendations on corporate governance. further 
details on the corporate governance reporting can be found in the corporate governance statement on Össur’s website: 
ossur.com/corporate/investor-relations/corporate-governance 
below reporting on governance metrics in accordance with the nasdaq esg guidance. further details on governance 
related initiative are discussed in Össur’s csr report. 
* 
percentage of suppliers categorized as critical suppliers
** 
percentage of key employees in sales and employees with responsibilities in high risk areas
62
corporate matters
63
annual report 2020
board of directors
niels jacobsen
chairman of the board of directors
dr. kristjan tomas ragnarsson
vice chairman of the board of directors
born in 1957
member of the board of directors since the year 2005
education
master’s degree in business administration from the university of aarhus in 
denmark
board positions
kirkbi a/s, deputy chairman   
nissens a/s, chairman   
thomas b. thrige foundation, chairman   
about you holding gmbh, deputy chairman   
additional duties related to william demant invest a/s: 
demant a/s, deputy chairman 
jeudan a/s, chairman   
Össur hf., chairman   
vision rt ltd., chairman   
founders a/s, chairman   
boston holding a/s, board member   
experience
mr. jacobsen has broad management experience both as ceo and as chairman 
in major international companies, he is currently the ceo of william demant 
invest a/s. previous positions include president & ceo of demant a/s (formerly 
william demant holding a/s), president of orion a/s and vice president 
overseeing corporate affairs for both atlas danmark a/s and thrige-titan a/s.  
shares held in Össur
203,330 (incl. related parties). mr. jacobsen holds no share options in the 
company
other
mr. jacobsen has no interest links with the company’s main clients or 
competitors. mr. jacobsen is a dependent member of the board. 
born in 1943
member of the board of directors since the year 1999
education
university of iceland school of medicine and certified by the american board 
of physical medicine and rehabilitation.  
experience
between 1986 and 2016, dr. ragnarsson served as the chairman and lucy 
moses professor of the department of rehabilitation medicine for the mount 
sinai medical center in new york city. he has also served in multiple other 
leadership positions at mount sinai and various professional organizations. 
in 1971-1986 dr. ragnarsson was a resident, fellow, assistant and then 
associate professor rehabilitation medicine, nyu medical center. 
shares held in Össur
dr. ragnarsson holds no shares nor share options in the company.
other
dr. ragnarsson has no interest links with the company’s main clients, 
competitors, or major shareholders. dr. ragnarsson is a dependent member 
of the board.
64
arne boye nielsen
member of the board of directors
dr. svafa grönfeldt
member of the board of directors
born in 1968
member of the board of directors since the year 2009
education
master’s degree in business administration from the copenhagen business 
school in denmark
board positions
epos a/s (chairman)   
revenio group oyj (board member) 
interacoustics a/s (president)   
experience
mr. nielsen has spent his entire career with demant a/s in various and 
expanding roles throughout the world. after working as an interim general 
manager of oticon australia pty ltd. mr. nielsen assumed, in 1996, his current 
position as president of diagnostics and communications in demant, which 
has operations worldwide.   
shares held in Össur
mr. nielsen neither has shares nor share options in the company
other
mr. nielsen has no interest links with the company’s main clients or 
competitors. mr. nielsen is a dependent member of the board.
born in 1965
member of the board of directors since the year 2008
education
doctorate in industrial relations from the london school of economics
board positions  
icelandair (board member)  
origo (board member)  
unicef iceland (board member)  
mynto (board member)
experience
dr. grönfeldt is the senior advisor to the dean at the massachusetts institute 
of technology sa+p, a founding member of mit’s newest innovation 
accelerator designx, and a co-founder of the met fund, a cambridge based 
seed investment fund. previous positions include chief organizational 
development officer of alvogen, president of reykjavik university, deputy 
to the ceo of actavis group, assistant professor of economics and business 
administration at the university of iceland.   
shares held in Össur
dr. grönfeldt holds no shares nor share options in the company
other
dr. grönfeldt has no interest links with the company’s main clients, 
competitors, or major shareholders. dr. grönfeldt is an independent board 
member.
corporate matters
65
annual report 2020
gudbjörg edda eggertsdottir
member of the board of directors
born in 1951
member of the board of directors since the year 2013
education
master’s degree (pharm.) from copenhagen university
board positions
brunnur investment fund (chairman)   
coripharma holding ehf (vice chairman)   
florealis ehf. (chairman)    
orf genetics hf. (board member)    
vistor hf. (board member)    
saga medica ehf. (board member)    
pretium ehf. (chairman)
experience
previous positions include president & evp strategic projects of actavis plc in 
iceland, a global integrated specialty pharmaceutical company; deputy ceo 
and evp third party sales at actavis group hf.; deputy ceo, head of r&d, 
assistant managing director, development manager, regulatory manager and 
marketing manager at delta hf.; and medical representative at pharmaco hf. 
she was the president of the european generic medicines association from 
2011-2013.    
shares held in Össur
26,318 (incl. related parties). ms. eggertsdóttir holds no share options.
other
ms. eggertsdóttir has no interest links with the company’s main clients or 
competitors. ms. eggertsdóttir is an independent member of the board.
66
executive management
egill jonsson
evp of manufacturing and operations
jon sigurdsson
president and ceo
born in 1956
with Össur since the year 1996
education
master’s degree in business administration (mba) from the united states 
international university in san diego.
bachelor degree in industrial engineering from odense technical college in 
denmark.
board positions
vitrolife ab 
the icelandic american chamber of commerce
experience
jón has been the ceo of Össur since 1996 and prior to that he was the 
commercial counselor for the icelandic trade council in new york (1992- 
1996), chief financial officer at Álafoss (1989-1991), head of the international 
division of eimskip (1986-1989) and an engineer for bang and olufsen 
denmark (1982- 1984).
jón’s experience as a member of the board of directors in other companies/
organizations includes:
• rio tinto alcan iceland 2003-2015
• the icelandic chamber of commerce 2002-2012
• reykjavik university from 2002-2009
• samherji hf. from 2002-2006
• the icelandic trade council from 1997-2003
• research liaison office of the university of iceland from 1996-2001
shares held in Össur 
899.474 (incl. related parties) 
born in 1957
with Össur since the year 1996
education
master’s degree in mechanical engineering from the technical university in 
copenhagen (dtu). 
bachelor degree in engineering from the university of iceland
board positions
federation of icelandic industries
technical college reykjavik
experience
egill has led the m&o function since he joined in 1996. he was formerly a 
project manager at vgk hf, an engineering firm in reykjavik (1985-1996).
shares held in Össur
822,749 (incl. related parties)
gudjon g. karason
evp of clinics
born in 1969
with Össur since the year 1998
education
master’s degree in engineering from the university of iceland.
cs degree in mechanical engineering from the university of iceland.
experience
gudjon has been with Össur since 1998, and has since then worked in r&d, 
marketing, sales, and clinics in multiple positions. prior to joining Össur, 
gudjon worked as development manager for a couple of smaller industrial 
companies in iceland.
shares held in Össur
42,743
corporate matters
67
annual report 2020
margret lara fridriksdottir
evp of human resources and corporate strategy
olafur gylfason
evp of sales & marketing
dr. kristleifur kristjansson
evp of research and development
born in 1978
with Össur since the year 2000
education
master’s degree in management and strategy from the university of iceland. 
bachelor degree in business administration from the university of iceland.
experience
margrét has been with Össur since 2000 in various roles in finance and 
human resources.
shares held in Össur
16,300
born in 1955
with Össur since the year 2012
education
medical doctor degree from the university of iceland
board-certified pediatrician from the medical college of georgia
clinical and molecular genetics fellowship from the baylor college of 
medicine in houston, texas
certified pediatrician and clinical geneticist in iceland from 1993
board positions 
skraeda ehf. (chairman) 
experience
dr. kristjansson joined Össur in 2012, for the first 5 years as medical officer and 
another 2 years as medical officer and vp of clinical affairs. dr. kristjansson’s 
previous positions include co-founder and vp of clinical affairs and collaborations 
at decode genetics ehf. 1995 to 2012 and co-founder and ceo of pediatric 
services in iceland 1995 to 2014. dr. kristjansson has acted as a consulting 
pediatrician and clinical geneticist for the university hospital, landspitalinn 
reykjavik iceland, from 1998 to the present, and he is the founder of skraeda ehf.
shares held in Össur 
1,850
born in 1969
with Össur since the year 1997
education
master’s degree in international business economics from alborg university 
in denmark.
bachelor degree in business administration from bifrost school of business 
in iceland.
experience
Ólafur has been with Össur since 1997; from 2001-2013 as the managing 
director of emea and before that in emerging markets.
shares held in Össur
9,517
68
sveinn sölvason
chief financial officer
born in 1978
with Össur since the year 2009
education
master’s degree in finance and accounting (cand.merc.fir) from copenhagen 
business school.
bachelor degree in international business from copenhagen business school.
board positions
icelandic chamber of commerce
experience
sveinn has been with Össur since 2009, previously as director of treasury and 
corporate development. prior to joining Össur he worked at marel, kaupthing 
bank, goldman sachs and hsh nordbank.
shares held in Össur
25,000
christian robinson
evp of bracing & supports and americas 
born in 1982 
with Össur since the year 2012 
education
juris doctorate from harvard law school 
bachelor’s degree in english literature from brigham young university 
board positions
national association for the advancement of orthotics 
and prosthetics (naaop) 
experience
since joining Össur in 2012, christian has served in several roles including 
general counsel americas, vp finance americas, and managing director 
americas. prior to joining Össur he practiced corporate and transactional law 
with international law firm paul hastings llp with a focus on m&a and capital 
markets. 
shares held in Össur
600
corporate matters
70
Össur hf. 
consolidated financial statements 
31 december 2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Össur hf. 
 
consolidated financial statements 
 
31.12.2020 
 
 
 
 
 
 
 
 
 
 
table of contents 
 
 
statement by the board of directors and president and ceo 
1 
independent auditor’s report 
4 
financial highlights and key ratios 
8 
consolidated income statement 
9 
consolidated statement of comprehensive income 
10 
consolidated balance sheet 
11 
consolidated statements of cash flow 
13 
consolidated statement of changes in equity 
14 
notes to the consolidated financial statement 
15 
 
 
 
 
 statement by the board of directors and president and ceo 
 
 
it is the opinion of the board of directors and the president and ceo of Össur hf. (the company), that these consolidated 
financial statements present the necessary information to evaluate the financial position of the company at year end, 
the operating results for the year and financial developments during the year 2020. Össur consolidated financial 
statements are prepared in accordance with international financial reporting standards (ifrs) as adopted by the 
european union and additional danish disclosure requirements for listed companies and additional requirements in the 
icelandic financial statement act no. 3/2006. 
Össur hf. designs, manufactures and sells orthopedic products specializing in prosthetics and bracing and supports 
solutions. the company is headquartered in iceland and the company owns and operates subsidiaries in multiple 
countries around the world. the company sells its products worldwide, but the principal market areas are north 
america and europe. 
 
a requirement to conclude on non-financial information has been made part of icelandic law from 2016 as part of the 
implementation of eu directive 2013/34/eu that became effective for member states in 2017. it is the board of 
directors opinion that necessary information to analyze the environmental, social and employee aspects of the business 
can be obtained by reviewing information in the annual report to help provide fundamental understanding of the 
company’s development, performance and position on non-financial matters. Össur joined the un global compact in 
2011 and signed the un women’s empowerment principles in 2014.  annually, Össur publishes a progress report, 
reporting on the progress of key projects in the four categories set forth by the global compact; environmental 
concerns, labor practices, human rights and anti-corruption. further information about Össur’s corporate social 
responsibilities (csr) activities can be found in the annual report and 2020 progress report, available on the company’s 
website: https://corporate.ossur.com/corporate/our-responsibility 
 
the total sales of the company amounted to usd 629.5 million (2019: usd 686.3 million) and decreased by 8% from  
the preceding year. organic local currency sales decline was 10%. net profit amounted to usd 7.9 million (2019: usd 
68.9 million). diluted earnings per share amounted to us cents 1.9 (2019: us cents 16.2.). earnings before interest, 
taxes, depreciation, impairment and amortization (ebitda) amounted to usd 93.0 million (2019: usd 141.3 million). 
 
the total assets of the company amounted to usd 1,214.3 million at year end, liabilities were usd 637.1 million and 
equity was usd 577.2 million. the equity ratio at year end was 48%, (2019: 52%). 
 
the company employed on average 3,505 employees in 2020 (2019: 3,382) and 3,385 at year end (2019: 3,449). 
 
Össur’s shares are admitted to trading on the nasdaq copenhagen stock exchange. the market value of the company 
at year end was usd 3,380 million (ye 2019: usd 3,340 million) and the share price in dkk decreased by 7,4% during 
the year. at year end, registered shareholders in Össur were 4,512 compared to 4,322 at the beginning of the year. it 
should be noted that due to the concentration of trading in nasdaq copenhagen in 2017, about 1,600 shareholders 
that held shares listed in iceland were consolidated into a few nominee accounts. the ten largest shareholders and 
their ownership percentage are: william demant invest a/s  - 51.8%, islandsbanki bank – 17.2% (nominee), 
arbejdsmarkedets tillægspension (atp) - 5.5%, state street bank – 4,8%,  seb stockholm - 2.2% (nominee, of which the 
vast majority is held by lannebo fonder), landsbankinn bank - 2.1% (nominee), seb sv smabol – 1,4%, clearstream – 
1.3% (nominee), verdipapirfond odin norden – 1.1% and jp morgan bank - 1.1% (nominee).  william demant invest 
a/s (wdi) ownership in Össur exceeded 50% in january 2018.  according to wdi's announcement at the time, their 
intention is to hold 50-60% of Össur’s shares going forward and wdi has no intention of taking over Össur or delisting 
Össur’s shares from nasdaq copenhagen. furthermore, wdi has no intention of making changes to Össur’s strategy, 
management or operations. 
 
Össur consolidated financial statements 2020
1
 
 
 
 statement by the board of directors and president and ceo 
 
in 2020, Össur acquired in total 1,295,450 shares at the average price of dkk 48.57. the share buyback programs are 
managed by nordea, which make its trading decisions independently and without influence by the company regarding  
 
the timing of the purchases. the company’s purchases under the program are announced every monday for the 
previous week. the purpose of the program is to reduce the company’s share capital and adjust the capital structure 
by distributing capital to shareholders in line with the company's capital structure and dividend policy in addition to 
being able to meet the company's share option obligations. it should be noted that the share buyback program was 
temporarily put on hold on 17 march 2020. share options contracts amounting to 1,375,000 Össur shares were 
exercised during the year. 
 
the company follows the danish recommendations for corporate governance issued by the danish committee on 
corporate governance, available at: https://corporategovernance.dk/. the board of directors complies with the 
articles of association of the company and the board of directors' rules of procedure, which address the board’s roles 
and responsibilities etc. the board of directors is composed of five members elected at each annual general meeting 
for a term of one year. the board of directors consists of two women and three men in compliance with icelandic law 
on gender ratio. no Össur employee sits on the board of directors. the audit committee complies with the committee’s 
rules of procedures, which address the committee’s roles and responsibilities etc. the audit committee is composed 
of three members elected by the board. the ceo manages the company’s daily operations. the board has approved an 
equal opportunity policy that prohibits all discrimination. the policy is available on the company’s website: 
https://corporate.ossur.com/corporate/careers/equal-opportunity-policy - and reporting on the progress and 
objectives of the policy is made in the company’s corporate social responsibility report available on the company’s 
website: https://corporate.ossur.com/corporate/our-responsibility . the board approves a corporate governance 
report that includes all the information to be included in the statutory statement referred to in article 66 (c) of the 
icelandic financial statement act no. 3/2006, as well as explanations, comments and information on each 
recommendation in the danish recommendation for corporate governance. the report is available on the company’s 
website: https://corporate.ossur.com/corporate/investor-relations/corporate-governance 
 
the board of directors will not propose to the annual general meeting in 2021 to reduce the share capital because the 
company acquired a limited number of shares in 2020 and they will all be used to fulfill obligations under share option 
agreements that have vested or will be vesting in 2021. the board of directors will not propose to the annual general 
meeting in 2021 to pay cash dividend because the company’s level of interest-bearing debt to ebitda is above the 
target range of 1.5-2.5x.  
 
Össur´s financials 2020 are affected by the covid-19 world wide pandemic. Össur monitor the development of the 
covid-19 pandemic closely with a primary focus on business continuity and the safety of employees and customers. 
guidelines from local and global healthcare authorities are being followed. 
sales in 2020 have been negatively impacted in many of Össur’s main markets as social distancing and lockdown 
measures were implemented. as a result, patient flow and referrals have been impacted with o&p clinics (Össur’s main 
customers) subject to various operational challenges leading to reduced operational capacity, postponement of elective 
surgeries, and access restrictions in hospitals to non-essential care. the combination of these factors had a material 
short-term negative impact on demand. some restrictions are still in place, but o&p clinics have gradually been 
increasing their operational capacity. o&p clinicians have started to be vaccinated in some regions where they work 
closely with hospitals. it should be noted that the long-term prospects or underlying fundamental drivers of the 
prosthetics and b&s markets are not expected to change. the impact from covid-19 is expected to lead to some pent-
up demand. 
 
Össur consolidated financial statements 2020
2
 
 
 
 statement by the board of directors and president and ceo 
 
further information can be found in notes in the company´s consolidated financial statement. 
 
 
the board of directors and president and ceo of Össur hf. hereby confirm the consolidated financial statements of 
Össur for the year 2020 with their signatures. 
 
 
reykjavík, 2 february 2021 
 
 
board of directors 
 
niels jacobsen 
chairman of the board 
 
 
arne boye nielsen  
 
 
 
 
 
kristján t. ragnarsson 
 
 
guðbjörg edda eggertsdóttir  
 
 
 
 
svafa grönfeldt 
 
 
 
president and ceo 
 
jón sigurðsson 
Össur consolidated financial statements 2020
3
 
 
 
 
 independent auditor´s report 
 
 
to the shareholders of Össur hf.  
 
opinion  
we have audited the consolidated financial statements of Össur hf. and its subsidiaries (the company), which comprise 
the  consolidated  balance  sheet  as  at  december  31,  2020,  the  consolidated  income  statement,  the  consolidated 
statement  of  comprehensive  income,  the  consolidated  statement  of  cash  flow,  the  consolidated  statement  of 
changes  in  equity  for  the  year  then  ended,  and  the  notes  to  the  consolidated  financial  statements,  including  a 
summary of significant accounting policies. 
in our opinion, the accompanying consolidated financial statements give a true and fair view of the company financial 
position at december 31, 2020, and its consolidated financial performance and its consolidated cash flows for the year 
then ended in accordance with international financial reporting standards (ifrss) as adopted by the european union, 
additional danish disclosure requirements for listed companies and additional requirements in the icelandic financial 
statement act no. 3/2006. 
our opinion in this report on the consolidated financial statements is consistent with the content of the additional 
report that has been submitted to the parent company´s audit committee in accordance with the eu audit regulation 
537/2014 article 11. 
 
basis for opinion 
we conducted our audit in accordance with international standards on auditing (isas). our responsibilities under those 
standards are further described in the auditor’s responsibilities for the audit of the consolidated financial statements 
section of our report. we are independent of the company in accordance with the international ethics standards board 
for accountants’ code of ethics for professional accountants (iesba code) together with the ethical requirements that 
are relevant to our audit of the financial statements in iceland, and we have fulfilled our other ethical responsibilities 
in accordance with these requirements and the iesba code. this includes that, based on the best of our knowledge and 
belief, no prohibited services referred to in the eu audit regulation 537/2014 article 5.1 has been provided to the 
audited company or, where applicable, its parent company or its controlled companies within the eu. we believe that 
the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. 
 
key audit matters  
key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the 
consolidated financial statements of the current period. these matters were addressed in the context of our audit of 
the consolidated  financial  statements as a whole,  and in  forming our opinion  thereon, and  we do not  provide a 
separate opinion on these matters. 
 
impairment of goodwill  
book value of goodwill at year end amounted to 612 million. the change in goodwill consist of provisional additions 
due  to  current  year  acquisitions  and  adjustments  to  prior  year  provisional  values  amounting  to  80.9  million, 
derecognition on disposal of subsidiary amounting to 5.2 million and currency difference gain amounting to 15.5 million.  
the management consider that each geographical segment constitutes its own cash generating unit (‘cgu’). the key 
assumptions  applied  by  the  managements  in  the  impairment  reviews  are  segment  specific  discount  rates;  future 
revenue growth; and expected future margins. determining whether the carrying value of goodwill is recoverable 
requires management to make significant estimates regarding the future cash flows, discount rates and long‐term 
growth rates based on management’s view of future business prospects. determining whether the carrying value of 
goodwill is recoverable requires management to make significant estimates regarding the future cash flows, discount 
rates and long‐term growth rates based on management’s view of future business prospects.  
Össur consolidated financial statements 2020
4
 
 
 
 
 independent auditor´s report 
 
due to the relative sensitivity of certain inputs to the impairment testing process, in particular the future cash flows of 
the cgus noted above, the valuation of goodwill is considered a key audit matter. 
in order to address this key audit matter, we audited the assumptions used in the impairment model for goodwill. as 
part of our work, we engaged our internal specialists to assist with: 
 
 
critically evaluating whether the model used by management to calculate the value in use of the individual 
cash generating units (cgu’s) complies with the requirements of ias 36 impairment of assets. 
 
validating the assumptions used to calculate the discount rates and recalculating these rates. 
 
considering the projected future cash flows, understanding variances between the forecast and actual results 
for the year ended 31 december 2020 and comparing the forecast growth trends to historic trends. 
 
comparing the long‐term growth rates for each cgu to external market data.    
 
evaluating the appropriateness of the sensitivity analysis applied by management to the impairment testing 
model including considering whether the scenarios reasonably represent possible changes in key assumptions. 
 
performing further sensitivity analysis based on recent trading activity and our understanding of the future 
prospects to identify whether these scenarios could give rise to further impairment; and  
analysing the future projected cash flows used in the models to determine whether they are reasonable and 
supportable given the current macroeconomic climate and expected future performance of the cgu’s.  
we also reviewed the disclosures presented in note 14 to the consolidated financial statements to confirm 
compliance with the requirements within ias 36. 
 
other information 
management is responsible for other information. other information consists of statement by the board of directors 
and president and ceo. our opinion on the consolidation financial statements does not cover the other information 
and we do not express any form of assurance conclusion thereon except the confirmation regarding statement of board 
of  director  and  president  and  ceo  as  stated  below.  in  connection  with  our  audit  of  the  consolidated  financial 
statements, our responsibility is to read the other information and, in doing so, consider whether the other information 
is materially inconsistent with the information in the consolidated financial statements or our knowledge obtained in 
the audit or otherwise appears to be materially misstated. if, based on the work we have performed, we conclude that 
there is a material misstatement of this other information, we are required to report that fact. we have nothing to 
report in this regard. 
in accordance with paragraph 2 article 104 of the icelandic financial statement act no. 3/2006, we confirm to the best 
of our knowledge that the accompanying report of the board of directors includes all information required by the 
icelandic financial statement act that is not disclosed elsewhere in the financial statements. 
 
responsibilities of management and those charged with governance for the consolidated financial statements 
management  and  those  charged  with  governance  is  responsible  for  the  preparation  and  fair  presentation  of  the 
consolidated  financial  statements  in  accordance  with  ifrs  as  adopted  by  the  european  union,  additional  danish 
disclosure requirements for listed companies and additional requirements in the icelandic financial statement act no. 
3/2006, and for such internal control as management and those charged with governance determines is necessary to 
enable the preparation of consolidated financial statements that are free from material misstatement, whether due to 
fraud or error. 
in preparing the consolidated financial statements, management and those charged with governance is responsible 
for assessing the company’s ability to continue as a going concern, disclosing, as applicable, matters related to going 
concern and using the going concern basis of accounting unless management and those charged with governance either 
intends to liquidate the company or to cease operations, or has no realistic alternative but to do so. 
 
 
 
Össur consolidated financial statements 2020
5
 
 
 
 
 independent auditor´s report 
 
 
auditor’s responsibilities for the audit of the consolidated financial statements  
our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole 
are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our 
opinion. reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance 
with isas will always detect a material misstatement when it exists. misstatements can arise from fraud or error and 
are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic 
decisions of users taken on the basis of these consolidated financial statements. 
as part of an audit in accordance with isas, we exercise professional judgment and maintain professional scepticism 
throughout the audit. we are also:  
 
 
identify and assess the risks of material misstatement of the consolidated financial statements, whether due to 
fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is 
sufficient and appropriate to provide a basis for our opinion. the risk of not detecting a material misstatement 
resulting  from  fraud  is  higher  than  for  one  resulting  from  error,  as  fraud  may  involve  collusion,  forgery, 
intentional omissions, misrepresentations, or the override of internal control. 
 
obtain an understanding of internal control relevant to the audit in order to design audit procedures that are 
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the 
company’s internal control. 
 
evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and 
related disclosures made by management. 
 
conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on 
the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast 
significant  doubt  on  the  company’s  ability  to  continue  as  a  going  concern.  if  we  conclude  that  a  material 
uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the 
consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. our conclusions 
are based on the audit evidence obtained up to the date of our auditor’s report. however, future events or 
conditions may cause the company to cease to continue as a going concern. 
 
evaluate the overall presentation, structure and content of the consolidated financial statements, including the 
disclosures,  and  whether  the  consolidated  financial  statements  represent  the  underlying  transactions  and 
events in a manner that achieves fair presentation. 
 
obtain  sufficient  appropriate  audit  evidence  regarding  the  financial  information  of  the  entities  or  business 
activities  within  the  company  to  express  an  opinion  on  the  consolidated  financial  statements.  we  are 
responsible for the direction, supervision and performance of the company audit. we remain solely responsible 
for our audit opinion. 
 
we communicate with those charged with governance regarding, among other matters, the planned scope and timing 
of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during 
our audit. 
we  also  provide  those  charged  with  governance  with  a  statement  that  we  have  complied  with  relevant  ethical 
requirements regarding independence, and to communicate with them all relationships and other matters that may 
reasonably be thought to bear on our independence, and where applicable, related safeguards. 
from the matters communicated with those charged with governance, we determine those matters that were of most 
significance in the audit of the consolidated financial statements of the current period and are therefore the key audit 
matters. we describe these matters in our auditor’s report unless law or regulation precludes public disclosure about 
the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our 
Össur consolidated financial statements 2020
6
 
 
 
 
 independent auditor´s report 
 
report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest 
benefits of such communication. 
in addition to our work as the auditors of Össur hf., deloitte has provided the firm with permitted additional services 
such as other assurance engagements and consultation on tax matters. deloitte has in place internal procedures in 
order to ensure its independence before acceptance of additional services. Össur hf. audit committee also has in place 
internal procedures to approve additional services before they commence. the audit committee also evaluates the 
independence of the company’s auditors on yearly basis in order to ensure their independence and objectivity. 
 
deloitte was appointed auditor of Össur hf. by the general meeting of shareholders on 12 march 2020. deloitte have 
been elected since the company´s founding in 1971. 
 
 
 
kópavogur, 2 february 2021 
 
 
 
deloitte ehf.  
 
 
eyþór guðjónsson 
 
 
 
 
 
guðmundur Örn Árnason  
 
 
 
state authorized public accountant 
 
 
 
state authorized public accountant 
 
 
 
Össur consolidated financial statements 2020
7
financial highlights and key ratios
usd millions
2020
2019
2018
2017
2016
income statement
net sales
630 
686 
613 
569 
521 
gross profit
391 
439 
387 
355 
328 
operating expenses (excl. other income / exp.)
338 
341 
304 
280 
256 
ebitda
93 
141 
107 
97 
94 
ebitda before special items
93 
150 
115 
103 
98 
ebit
28 
98 
79 
75 
72 
net profit
8 
69 
80 
58 
51 
sales growth
sales growth usd
%
(8)
12 
8 
9 
8 
growth breakdown:
   organic growth in lcy
%
(10)
5 
5 
5 
4 
   currency effect
%
0 
(4)
1 
0 
(1)
   acquired/divested business
%
2 
11 
2 
4 
5 
balance sheet
total assets
1,214 
1,091 
914 
793 
746 
equity
577 
569 
538 
500 
467 
net interest‐bearing debt (nibd)
381 
302 
180 
121 
119 
cash flow
cash generated by operations
119 
120 
92 
90 
88 
free cash flow
68 
63 
39 
55 
42 
key ratios
gross profit margin
%
62 
64 
63 
62 
63 
ebit margin
%
4 
14 
13 
13 
14 
ebitda margin
%
15 
21 
18 
17 
18 
ebitda margin before special items
%
15 
22 
19 
18 
19 
equity ratio
%
48 
52 
59 
63 
63 
net debt to ebitda before special items
4.1 
2.0 
1.6 
1.2 
1.2 
effective tax rate
%
38 
24 
18 
16 
25 
return on equity 
%
1 
12 
15 
12 
11 
capex / net sales
%
3.8 
4.6 
5.0 
3.4 
4.7 
full time employees at period end
3,385 
3,449 
3,147 
2,990 
2,799 
full time employees on average
3,505 
3,382 
2,775 
2,948 
2,710 
market
market value of equity
3,380 
3,340 
2,055 
1,871 
1,582 
number of shares in millions
423 
425 
431 
437 
443 
diluted eps in us cents
1.9 
16.2 
18.7 
13.3 
11.6 
Össur consolidated financial statements 2020
8
all amounts in usd '000
notes
2020
2019
3
629,503 
686,264 
(238,268)
(247,614)
gross profit
391,235 
438,650 
6
(24,978)
196 
(229,285)
(233,746)
(31,018)
(31,326)
(77,666)
(76,050)
earnings before interest and tax (ebit)
28,288 
97,724 
1,230 
1,405 
(10,918)
(10,129)
(5,880)
1,269 
9
(15,568)
(7,455)
earnings before tax (ebt)
12,720 
90,269 
10
(4,799)
(21,395)
net profit
7,921 
68,874 
attributable to:
6,214 
66,040 
1,707 
2,834 
net profit
7,921 
68,874 
earnings per share
11
1.9 
16.3 
1.9 
16.2 
general and administrative expenses
financial income
financial expenses
net exchange rate difference
net sales
diluted earnings per share (us cent)
consolidated income statement
owners of the company
non‐controlling interests
earnings per share (us cent)
net financial income / (expenses)
income tax
cost of goods sold
other income / (expenses)
sales and marketing expenses
research and development expenses
Össur consolidated financial statements 2020
9
all amounts in usd '000
2020
2019
net profit 
7,921 
68,874 
items that may be reclassified subsequently to profit or loss:
(400)
1,428 
10,521 
(317)
3,155 
0 
1,989 
(716)
15,265 
395 
total comprehensive income
23,186 
69,269 
attributable to:
21,479 
66,435 
1,707 
2,834 
total comprehensive income
23,186 
69,269 
consolidated statement of comprehensive income
exchange differences on translating foreign operations
change in cash flow hedges 
income tax relating to components of other 
comprehensive income
other comprehensive income, net of income tax
owners of the company
non‐controlling interests
acc.transl.diff. reclassified to profit or loss on disposal of 
foreign operations
Össur consolidated financial statements 2020
10
consolidated balance sheet 
assets
all amounts in usd '000
notes
31.12.2020
31.12.2019
12
58,466 
65,194 
13
112,909 
98,218 
14
612,191 
521,046 
15
59,502 
62,658 
investment in associates
16
13,352 
6,099 
17
3,941 
2,998 
26
27,512 
27,081 
non‐current assets
887,873 
783,294 
18
93,231 
112,013 
19
98,353 
106,588 
20
32,511 
30,168 
21
102,363 
58,611 
current assets
326,458 
307,380 
total assets
1,214,331 
1,090,674 
inventories
accounts receivables
other assets
bank balances and cash equivalents
property, plant and equipment
goodwill
other intangible assets
other financial assets
deferred tax assets
right of use assets
Össur consolidated financial statements 2020
11
consolidated balance sheet 
equity and liabilities
all amounts in usd '000
notes
31.12.2020
31.12.2019
22
74,871 
77,813 
(31,514)
(47,108)
529,155 
533,661 
equity attributable to owners of the company
572,512 
564,366 
4,678 
4,590 
total equity
577,190 
568,956 
24
339,978 
243,928 
25
108,013 
93,010 
26
26,053 
29,670 
27
7,955 
6,535 
28
6,739 
6,801 
29
1,098 
698 
non‐current liabilities
489,836 
380,642 
24
17,545 
7,193 
25
17,857 
16,089 
20,024 
26,675 
4,160 
13,054 
27
11,369 
9,438 
38,226 
41,244 
31
38,124 
27,383 
current liabilities
147,305 
141,076 
total equity and liabilities
1,214,331 
1,090,674 
retained earnings
issued capital and share premium
reserves
borrowings
accounts payable
income tax payable
provisions
accrued salaries and related expenses 
lease liabilities
other liabilities
non‐controlling interest
borrowings
deferred tax liabilities
provisions
other financial liabilities
lease liabilities
deferred income
Össur consolidated financial statements 2020
12
all amounts in usd '000
notes
2020
2019
28,288 
97,724 
12, 13, 14, 15
64,699 
43,556 
12,750 
(14,667)
18,445 
(11,226)
(7,905)
898 
2,259 
3,694 
cash generated by operations
118,536 
119,979 
1,086 
1,533 
(10,441)
(10,129)
(16,940)
(16,104)
net cash provided by operating activities
92,241 
95,279 
12, 15
(24,022)
(31,850)
acquisition / divestment of subsidiaries, net of cash in acq. entities
32
(76,286)
(30,447)
0 
134 
(6,141)
(201)
cash flows to investing activities
(106,449)
(62,364)
74,881 
55,202 
(30,629)
(21,580)
23,421 
(31,685)
(9,276)
(9,058)
increase in subsidiaries that does not affect control
(2,546)
(258)
dividends from subsidiaries paid to non‐controlling interests
(48)
(1,318)
(3,943)
(20,601)
cash flows from / (to) financing activities
51,860 
(29,298)
37,652 
3,617 
1,965 
(677)
4,135 
(35)
58,611 
55,706 
cash at end of period
102,363 
58,611 
change in payables
change in inventories
change in receivables
effects of exchange rate changes on:
 balance of cash held in foreign currencies
proceeds from long‐term borrowings
repayments of long‐term borrowings
payment of dividends
change in treasury shares
 other items held in foreign currencies
cash at beginning of period
net change in cash
dividend received
other operating activities
consolidated statement of cash flow 
changes in revolving credit facility
other investing activities
interest paid
income tax paid
purchase of fixed and intangible assets
interest received
earnings before interests and tax (ebit)
depreciation, amortization and impairment
Össur consolidated financial statements 2020
13
consolidated statement of changes in equity
attributable to
non‐
share
share
statutory
share option
fair value
translation accumulated
owners of
controlling
total
all amounts in usd '000
capital
premium
reserve
reserve
reserve
reserve
profits
the parent
interests
equity
balance at 1 january 2019
4,811 
88,956 
1,267 
3,285 
(627)
(50,321)
487,090 
534,461 
3,076 
537,537 
effect of implementation of ifrs 16
(7,797)
(7,797)
(7,797)
adjusted balance at 1 january 2019
4,811 
88,956 
1,267 
3,285 
(627)
(50,321)
479,293 
526,664 
3,076 
529,740 
net profit
66,040 
66,040 
2,834 
68,874 
change in cash flow hedges 
1,143 
1,143 
1,143 
(748)
(748)
(748)
0 
0 
0 
0 
1,143 
(748)
66,040 
66,435 
2,834 
69,269 
payment of dividends
(9,058)
(9,058)
(1,318)
(10,376)
share option charge for the period
1,063 
1,063 
1,063 
share option vested during the period
21 
14,102 
(2,170)
(2,356)
9,597 
9,597 
change in non‐controlling interests
(258)
(258)
(2)
(260)
purchase of treasury shares
(38)
(30,039)
(30,077)
(30,077)
balance at 31 december 2019
4,794 
73,019 
1,267 
2,178 
516 
(51,069)
533,661 
564,366 
4,590 
568,956 
net profit 
6,214 
6,214 
1,707 
7,921 
change in cash flow hedges
(320)
(320)
(320)
12,430 
12,430 
(0)
12,430 
3,155 
3,155 
3,155 
0 
0 
0 
0 
(320)
15,585 
6,214 
21,479 
1,707 
23,186 
payment of dividends
(9,276)
(9,276)
(48)
(9,324)
share option charge for the period
1,321 
1,321 
1,321 
share option vested during the period
11 
6,357 
(992)
(10)
5,366 
0
5,365 
change in non‐controlling interests
(1,434)
(1,434)
(1,179)
(2,613)
purchase of treasury shares
(10)
(9,299)
(9,309)
(9,309)
0 
(391)
(391)
balance at 31 december 2020
4,794 
70,077 
1,267 
2,507 
196 
(35,484)
529,155 
572,512 
4,678 
577,190 
in june 2016 the icelandic parliament passed a legal reform of the icelandic financial statements act no. 3/2006 which became effective on january 1, 2016. the requirement is that retained earnings are separated into two categories:
restricted and unrestricted retained earnings. unrestricted retained earnings consist of undistributed profits and losses accumulated by the company, less transfers to the company's statutory reserve and other restricted retained
earnings categories. the amount of restricted retained earnings is usd 307 million at year end (2019: usd 300 million). 
transl. diff. of shares in subsidiaries
total comprehensive income
transl. diff. of shares in subsidiaries
total comprehensive income
minority interest arising on acquisition
acc.transl.diff. reclassified to profit or 
loss on disposal of subsidiaries
Össur consolidated financial statements 2020
14
notes to the consolidated financial statements
1.
general information
2.
quarterly statements
unaudited
full year
q4
q3
q2
q1
2020
2020
2020
2020
2020
net sales
629,503 
169,571 
171,786 
134,553 
153,593 
cost of goods sold
(238,268)
(60,230)
(63,897)
(56,391)
(57,750)
gross profit
391,235 
109,341 
107,889 
78,162 
95,843 
gross profit margin
62%
64%
63%
58%
62%
other income / (expenses)
(24,978)
(8,823)
(662)
(15,550)
57 
sales and marketing expenses
(229,285)
(59,664)
(57,689)
(53,525)
(58,407)
research and development expenses
(31,018)
(8,435)
(7,731)
(7,429)
(7,423)
general and administrative expenses
(77,666)
(22,336)
(16,987)
(18,776)
(19,567)
ebit
28,288 
10,083 
24,820 
(17,118)
10,503 
net financial income / (expenses)
(9,688)
(2,303)
(2,603)
(2,710)
(2,072)
net exchange rate difference
(5,880)
(4,073)
(1,905)
(842)
940 
ebt
12,720 
3,707 
20,312 
(20,670)
9,371 
income tax
(4,799)
190 
(5,437)
2,774 
(2,326)
net profit / (loss)
7,921 
3,897 
14,875 
(17,896)
7,045 
ebitda
92,987 
23,644 
35,549 
12,060 
21,734 
ebitda margin
15%
14%
21%
9%
14%
Össur is a limited liability company incorporated and domiciled in iceland. the address of its registered office is grjothals 5,
reykjavik. its ultimate controlling party is william demant invest a/s. the consolidated financial statements of the company
as at and for the year ended 31 december 2020 comprise the company and its subsidiaries (together referred to as "the
company" or "Össur”).  
the company is a global orthopaedics company, specializing in the design, development, manufacturing and sales of
prosthetics and bracing and supports products. the company sells its products worldwide, but the principal market areas are
north america and europe. 
the consolidated financial statements are presented in us dollars and all values are rounded to the nearest thousand (’000),
except when otherwise indicated. in preparing the consolidated financial statements, the company has applied the concept
of materiality to the presentation and level of disclosure. it is the option of management that essential and mandatory
information is disclosed which is relevant to an understanding by the reader of these consolidated financial statements. 
these consolidated financial statements have been approved for issue by the board of directors and ceo on 2 february
2021. the consolidated financial statements as presented in this report are subject to approval by the annual general
meeting of shareholders, to be held on 8 march 2021.
the company is listed on the nasdaq copenhagen stock exchange.
management monitors the performance measure ebitda before special items, at a consolidated level and considers the
measure relevant to an understanding of the company's financial performance as it facilitates a better comparison of the
consolidated income statement between periods. special items comprise material amounts of a non‐recurring nature, such
as costs relating to divestments, closure or restructuring, lawsuits, etc. 
no special items are shown in 2020 despite cost related to divestments, acquisitions and legal settlements (usd 11 million ) as
this year’s whole operation can be considered extraordinary due to covid‐19.
ebitda is calculated as earnings before interest, taxes, depreciation, impairment and amortization. financial items and share
in net profit or loss of associated companies are not included in the ebitda measurement.
Össur consolidated financial statements 2020
15
notes to the consolidated financial statements
3.
net sales
2020
2019
americas
307,135 
327,503 
emea
266,902 
304,002 
apac
55,466 
54,759 
total
629,503 
686,264 
prosthetics
372,058 
378,072 
bracing and supports
257,445 
308,192 
total
629,503 
686,264 
timing of revenue recognition
4.
segment information
2020
americas
emea
apac
eliminations
consolidated
sales
external sales
307,135 
266,902 
55,466 
0 
629,503 
inter‐segment sales
90,941 
360,397 
8,625 
(459,963)
(0)
total sales
398,076 
627,299 
64,091 
(459,963)
629,503 
results
segment results
5,878 
14,920 
7,489 
0 
28,288 
net financial income / (expenses)
(15,568)
ebt
12,720 
income tax
(4,799)
net profit
7,921 
balance sheet 31.12.2020
assets
segment assets
616,806 
539,113 
58,412 
0 
1,214,331 
liabilities
segment liabilities
151,706 
468,843 
16,592 
0 
637,141 
other information 2020
capital additions
3,164 
18,558 
2,300 
0 
24,022 
depreciation and amortization
17,728 
45,634 
1,337 
0 
64,699 
all sales are from contracts with customers.
revenues from additional sold warranties and service checks included in standard warranties are released over warranty
period. refer to note 39.7 for accounting policy on revenue recognition and note 28 for breakdown of revenues recognised
over time and amounts deferred and released during the year. all other revenues are released at point in time.
information reported to the president and ceo for the purposes of resource allocation and assessment of segment
performance focuses on geographical markets from the location of customers. the geographical segments are emea (europe
middle‐east and africa), americas and apac (asia‐pacific). 
specified according to product lines:
specified according to geographical segments:
the majority of inter‐segment sale prices are set using the transactional net margin method (tnmm). 
Össur consolidated financial statements 2020
16
notes to the consolidated financial statements
2019
americas
emea
apac
eliminations
consolidated
sales
external sales
327,503 
304,002 
54,759 
0 
686,264 
inter‐segment sales
105,717 
405,428 
8,900 
(520,045)
0 
total sales
433,220 
709,430 
63,659 
(520,045)
686,264 
results
segment results
43,710 
43,356 
10,657 
0 
97,724 
net financial income/(expenses)
(7,455)
ebt
90,269 
income tax
(21,395)
net profit
68,874 
balance sheet 31.12.2019
assets
segment assets
588,071 
451,795 
50,808 
0 
1,090,674 
liabilities
segment liabilities
147,361 
362,729 
11,628 
0 
521,718 
other information 2019
capital additions
4,437 
26,451 
962 
0 
31,850 
depreciation, impairment and amortization
16,101 
26,440 
1,015 
0 
43,556 
5.
sales and expenses split by main currencies
lcy
usd
%
lcy
usd
%
sales
usd
293,548 
293,548 
47%
311,841 
311,841 
45%
eur
120,125 
136,888 
22%
144,979 
162,345 
24%
isk
277,592 
2,056 
0%
240,947 
1,966 
0%
nordic curr. (sek, nok, dkk)
91,602 
14%
96,374 
14%
other (gbp, aud, cad & other)
105,409 
17%
113,738 
17%
total
629,503 
100%
686,264 
100%
cogs and opex
usd
293,249 
293,249 
49%
264,326 
264,326 
45%
eur
103,458 
117,080 
19%
101,972 
114,185 
19%
isk
8,176,402 
60,642 
10%
7,780,363 
63,493 
11%
nordic curr. (sek, nok, dkk)
84,001 
14%
85,345 
15%
other (gbp, mxn, cad & other)
46,244 
8%
61,191 
10%
total
601,215 
100%
588,540 
100%
currency split is derived by using best available information at each time.
6.
other income / (expenses)
other income / (expenses) consists mainly of cost related to divestment of subsidiaries, as described in note 32.
2019
2020
Össur consolidated financial statements 2020
17
notes to the consolidated financial statements
7.
salaries
2020
2019
salaries 
219,485 
227,634 
salary‐related expenses 
49,258 
51,087 
268,743 
278,721 
full time employees (fte) on average
3,505 
3,382 
full time employees at period end
3,385 
3,449 
salaries and salary‐related expenses, classified by functional category:
2020
2019
cost of goods sold 
65,201 
70,041 
sales and marketing expenses
137,396 
140,231 
research and development expenses
20,422 
21,841 
general and administrative expenses
45,724 
46,607 
268,743 
278,721 
management salaries and benefits
board of directors:
2020
2019
2020
2019
niels jacobsen ‐ chairman of the board(i)
100
97
219.493.992
219,493,992 
kristján tómas ragnarsson ‐ vice chairman
60
58
0 
0 
arne boye nielsen
40
39
0 
0 
guðbjörg edda eggertsdóttir
40
39
26,318 
26,318 
svafa grönfeldt
40
39
0 
0 
salaries
the board of directors did not hold any share option contracts at the end of the current period nor at the end of the prior
year period. 
(i) shares owned by william demant invest a/s which niels jacobsen represents on the board. niels and financially related
parties own personally 203,330 shares (2019: 203,330 shares).
(ii) shares owned are displayed in total number of owned shares, not rounded to the nearest thousand. 
shares owned (ii)
included in salary‐related expense are pension related expenses amounting to usd 14.0 million (2019: usd 14.8 million).
Össur consolidated financial statements 2020
18
notes to the consolidated financial statements
2020
fixed base
cash based
other 
share based
total
salary
incentive
pension
benefits
incentive
remuneration
executive management:
jón sigurðsson president and ceo(i)
956 
0 
0 
163 
330 
1,448 
executive management (7 people) (ii)
2,031 
0 
252 
52 
536 
2,871 
2,987 
0 
252 
214 
866 
4,319 
2019
fixed base
cash based 
other 
share based
total
salary
incentive
pension
benefits
incentive
remuneration
executive management:
jón sigurðsson president and ceo(i)
1,083 
289 
0 
177 
145 
1,694 
executive management (6 people) (ii)
2,020 
236 
218 
107 
514 
3,096 
3,103 
525 
218 
285 
659 
4,790 
8.
fees to auditors
2020
2019
audit of financial statements
1,459 
1,489 
other services
592 
726 
2,051 
2,215 
9.
financial income / (expenses)
2020
2019
interests on bank deposits
459 
1,021 
share in profit of associated companies
290 
258 
other financial income
481 
126 
financial income
1,230 
1,405 
interests on loans
(5,158)
(4,350)
interest on leases
(4,453)
(3,984)
other financial expenses
(1,307)
(1,795)
financial expenses
(10,918)
(10,129)
net exchange rate differences
(5,880)
1,269 
net financial expenses
(15,568)
(7,455)
accumulated translation difference amounting to usd 3.2 million loss, relating to divestment of subsidiaries, has been
reclassified from equity to net exchange difference.
(i)  shares owned by jón sigurðsson 899,474 (2019: 525,540)
(ii) shares owned by members of executive management at year end 918,759 (2019: 918,159).
Össur consolidated financial statements 2020
19
notes to the consolidated financial statements
10. income tax
2020
2019
current tax expenses
(9,002)
(22,640)
deferred tax expenses
4,203 
1,245 
(4,799)
(21,395)
amount
%
amount
%
earnings before taxes
12,720 
90,269 
income tax calculated at 20%
(2,544)
20% 
(18,054)
20% 
effect of different tax rates of other jurisdictions
224 
(2%)
(3,692)
4% 
effect of non‐deductible expenses / non‐taxable income
(3,137)
25% 
221 
(0%)
effect of change in tax rate
(41)
0% 
(14)
0% 
other effects
699 
(5%)
144 
(0%)
(4,799)
38% 
(21,395)
24% 
deferred tax:
2020
2019
origination and reversal of temporary differences
4,162 
1,259 
effect of changes in tax rate
41 
(14)
4,203 
1,245 
the 20% tax rate used for 2020 and 2019 in the above tax rate reconciliation is the statutory corporate income tax rate
applicable to entities subject to tax in iceland. taxation for other jurisdictions is calculated at the rates prevailing in the
respective jurisdictions. 
2020
2019
Össur consolidated financial statements 2020
20
notes to the consolidated financial statements
2020
1.1.2020
recognized in 
income 
statement
recognized 
directly in 
equity
acquisitions / 
disposals
exc. rate 
difference
31.12.2020
goodwill
(7,617)
(2,449)
 
 
(56)
(10,122)
intangible assets
(9,638)
3,118 
 
(1,133)
(257)
(7,910)
property, plant and equipment
(2,888)
858 
 
81 
(30)
(1,979)
tax loss carry forward
836 
3,001 
 
(1,051)
111 
2,897 
inventories
5,818 
(1,484)
 
(4)
7 
4,337 
provisions
2,159 
(46)
 
(8)
46 
2,151 
current liabilities
3,996 
182 
 
643 
(7)
4,814 
receivables
1,485 
266 
 
232 
10 
1,993 
other
3,260 
757 
1,559 
(316)
18 
5,278 
total
(2,589)
4,203 
1,559 
(1,556)
(158)
1,459 
2019
1.1.2019
recognized in 
income 
statement
recognized 
directly in 
equity
acquisitions / 
disposals
exc. rate 
difference
31.12.2019
goodwill
(5,554)
(2,079)
 
16 
(7,617)
intangible assets
(6,964)
(950)
 
(1,732)
8 
(9,638)
property, plant and equipment
(3,657)
762 
 
 
7 
(2,888)
tax loss carry forward
709 
307 
(314)
135 
(1)
836 
inventories
4,334 
1,466 
 
18 
5,818 
provisions
1,651 
499 
 
9 
2,159 
current liabilities
2,867 
429 
 
737 
(37)
3,996 
receivables
832 
694 
 
 
(41)
1,485 
other
715 
117 
2,466 
 
(38)
3,260 
total
(5,067)
1,245 
2,152 
(860)
(59)
(2,589)
11. earnings per share
2020
2019
net profit
7,921 
68,874 
421,775 
423,384 
422,725 
424,571 
earnings per share (us cent)
1.9 
16.3 
diluted earnings per share (us cent)
1.9 
16.2 
deferred tax recognized in the consolidated income statement:
the company has unused tax losses available for which no deferred tax asset is recognized. at year end 2020 these unused
tax losses amount to usd 15.1 million (2019: usd 5.3 million). of this amount, usd 6.5 million of unused tax losses will expire
in 5‐10 years (2019: usd 3.3 million). the remaining tax losses carry an indefinite term.
total weighted average number of ordinary shares (in '000)
total weighted avg. number of shares incl. potential shares (in '000)
Össur consolidated financial statements 2020
21
notes to the consolidated financial statements
12. property, plant and equipment
2020
buildings & 
sites
machinery & 
equipment
fixtures & 
office equip.
computer 
equipment
total
cost
at 1 january
12,498 
89,640 
48,869 
16,089 
167,096 
additions
136 
6,037 
5,215 
2,380 
13,768 
acquired on acquisition of subsidiary
2,000 
2,270 
1,064 
185 
5,519 
exchange rate differences
619 
1,726 
1,524 
530 
4,399 
eliminated on disposal/divestment
(13,002)
(19,735)
(3,438)
(1,532)
(37,707)
fully depreciated assets
0 
(10,284)
(8,041)
(1,951)
(20,276)
at 31 december 2020
2,251 
69,654 
45,193 
15,701 
132,799 
depreciation
at 1 january
9,563 
55,610 
26,445 
10,283 
101,901 
charge for the period
197 
9,684 
5,111 
3,334 
18,326 
exchange rate differences
453 
1,322 
832 
361 
2,968 
eliminated on disposal/divestment
(9,980)
(15,167)
(2,151)
(1,288)
(28,586)
fully depreciated assets
0 
(10,284)
(8,041)
(1,951)
(20,276)
at 31 december 2020
233 
41,165 
22,196 
10,739 
74,333 
at 31 december 2020
2,018 
          
28,489 
22,997 
4,962 
58,466 
depreciation classified by functional category:
2020
2019
cost of goods sold 
9,925 
9,303 
sales and marketing expenses 
3,328 
3,551 
research and development expenses
1,190 
1,219 
general and administrative expenses 
3,883 
3,423 
total
18,326 
17,496 
2019
buildings & 
sites
machinery & 
equipment
fixtures & 
office equip.
computer 
equipments
total
cost
at 1 january
12,711 
93,436 
45,212 
16,313 
167,671 
reclassification
0 
(1,734)
1,707 
27 
0 
additions
0 
10,339 
6,410 
3,140 
19,889 
acquired on acquisition of subsidiary
0 
126 
443 
14 
583 
exchange rate differences
(210)
(647)
(16)
(156)
(1,029)
eliminated on disposal
(3)
(2,266)
(956)
(1,331)
(4,556)
fully depreciated assets
0 
(9,614)
(3,931)
(1,918)
(15,463)
at 31 december 2019
12,498 
89,640 
48,869 
16,089 
167,095 
depreciation
at 1 january
9,464 
59,532 
25,043 
10,600 
104,639 
reclassification
0 
(1,304)
1,266 
38 
0 
charge for the period
291 
9,424 
5,055 
2,726 
17,496 
exchange rate differences
(190)
(507)
(57)
146 
(608)
eliminated on disposal
(2)
(1,921)
(931)
(1,309)
(4,163)
fully depreciated assets
0 
(9,614)
(3,931)
(1,918)
(15,463)
at 31 december 2019
9,563 
55,610 
26,445 
10,283 
101,901 
at 31 december 2019
2,935 
34,030 
22,424 
5,806 
65,194 
none of the company's property, plant and equipment are pledged. major divestments are subject to bank approval.
Össur consolidated financial statements 2020
22
notes to the consolidated financial statements
13. right of use assets
2020
buildings & 
sites
machinery & 
equipment
total
cost
at 1 january
109,166 
5,710 
114,876 
additions
19,354 
794 
20,148 
acquired on acquisition of subsidiary
12,212 
0 
12,212 
exchange rate differences
4,620 
511 
5,131 
divestments
(4,029)
(1,219)
(5,248)
at 31 december 2020
141,323 
5,796 
147,119 
depreciation
at 1 january
14,375 
2,283 
16,658 
charge for the period
16,545 
1,910 
18,455 
exchange rate differences
1,281 
334 
1,615 
divestments
(2,052)
(466)
(2,518)
at 31 december 2020
30,149 
4,061 
34,210 
at 31 december 2020
111,174 
1,735 
112,909 
depreciation classified by functional category:
2020
2019
cost of goods sold 
7,381 
6,625 
sales and marketing expenses 
3,690 
3,312 
research and development expenses
2,214 
1,987 
general and administrative expenses 
5,170 
4,654 
total
18,455 
16,578 
amounts recognized in income statement:
2020
2019
depreciation expense from right of use assets
18,455 
16,578 
interest expense and exchange difference on lease liabilities
4,453 
3,327 
681 
1,151 
total
23,589 
21,056 
2019
buildings & 
sites
machinery & 
equipment
total
cost
at 1 january
84,144 
4,316 
88,460 
additions
18,802 
1,466 
20,268 
acquired on acquisition of subsidiary
8,065 
0 
8,065 
exchange rate differences
(1,845)
(72)
(1,917)
at 31 december 2019
109,166 
5,710 
114,876 
depreciation
at 1 january
0 
0 
0 
charge for the period
14,306 
2,272 
16,578 
exchange rate differences
69 
11 
80 
at 31 december 2019
14,375 
2,283 
16,658 
at 31 december 2019
94,791 
3,427 
98,218 
short‐term and low value lease expenses not included in lease liabilities
Össur consolidated financial statements 2020
23
notes to the consolidated financial statements
14. goodwill
2020
2019
at 1 january
521,046 
500,842 
arising on acquisition of subsidiaries
87,733 
30,098 
purchase price allocation
(6,815)
(8,093)
exchange rate differences
15,474 
(1,801)
impairment
(5,247)
0 
at 31 december
612,191 
521,046 
the carrying amount of goodwill was allocated to the following cash‐generating units:
wacc %
31.12.2020
31.12.2019
americas
8.1 / 9.6
383,011 
348,534 
emea
8.1 / 8.8
211,652 
156,442 
apac
9.0 / 9.9
17,528 
16,070 
total
612,191 
521,046 
cash flow projections in the forecast are based on the same expected gross margins and raw material prices throughout the
period. cash flows beyond 2025 have been extrapolated using a steady 2,5% per annum growth rate for all cash‐generating
units. this growth rate does not exceed the long‐term average growth rate for the market in each market area. management
believes that any reasonable change in the key assumptions on which the recoverable amount is based would not cause the
carrying amount to exceed its recoverable amount. management believes that covid‐19 has only short‐term impact on the
company's financials and does not expect changes in long‐term market fundamentals.
during the year, the company assessed the recoverable amount of goodwill and determined that none of the company's cash‐
generating units have suffered an impairment loss. the company recognized usd 5.2 million impairment related to
divestment of subsidiaries during the year, the impairment is shown as part of other income / (expenses) in the income
statement 2020. 
the recoverable amount of the cash‐generating units is determined based on a value in use calculation which uses cash flow
projections based on the financial forecast for 2021 approved by management and the board of directors. the discount rate
of 8.1 ‐ 9.0% (2019: 8.8 ‐ 9.9%) per annum was used.
the initial accounting for the acquisitions has been provisionally determined at balance sheet date. the fair value of assets
and liabilities related to recent acquisitions has been provisionally determined to be around usd 2 million based on
management's best estimate. fair value changes related to prior year acquisitions amounted to usd 1.7 million. 
Össur consolidated financial statements 2020
24
notes to the consolidated financial statements
15. other intangible assets
2020
cust./distrib. 
relationships
patents
trademarks
software and 
other
total
cost
at 1 january
42,983 
16,257 
13,806 
48,073 
121,119 
reclassification
699 
0 
0 
(699)
0 
additions
30 
517 
36 
1,876 
2,459 
additions ‐ internally generated
0 
0 
0 
7,795 
7,795 
acquired on acquisition of subsidiary
0 
367 
104 
2,133 
2,604 
purchase price allocation
4,789 
1,223 
1,028 
0 
7,040 
eliminated on disposal/divestment
(19)
(227)
(1,181)
(3,414)
(4,841)
fully amortized assets
(10,568)
(301)
(11,974)
(11,671)
(34,514)
exchange rate differences
2,112 
527 
757 
424 
3,820 
at 31 december 2020
40,026 
18,363 
2,576 
44,517 
105,482 
amortization
at 1 january
29,057 
4,100 
395 
24,909 
58,461 
reclassification
699 
0 
0 
(699)
0 
charge for the period
4,225 
1,060 
134 
5,925 
11,344 
impairment
0 
0 
11,327 
0 
11,327 
eliminated on disposal/divestment
0 
0 
0 
(3,309)
(3,309)
fully amortized assets
(10,568)
(301)
(11,974)
(11,671)
(34,514)
exchange rate differences
1,126 
59 
754 
732 
2,671 
at 31 december 2020
24,539 
4,918 
636 
15,887 
45,980 
at 31 december 2020
15,487 
13,445 
1,940 
28,630 
59,502 
amortization and impairment classified by functional category:
2020
2019
cost of goods sold
144 
814 
other income / (expenses)
11,327 
0 
sales and marketing expenses
6,703 
4,924 
research and development expenses
1,473 
1,521 
general and administrative expenses
3,024 
2,223 
total
22,671 
9,482 
during the year management decided to divest the gibaud sas subsidiary. following the decision the gibaud trademark was
impaired. the impairment is shown as part of other income / (expenses) in the income statement 2020. 
Össur consolidated financial statements 2020
25
notes to the consolidated financial statements
2019
cust./distrib 
relationships
patents
trademarks
software and 
other
total
cost
at 1 january
37,717 
14,009 
16,370 
47,094 
115,190 
additions
0 
0 
0 
3,409 
3,409 
additions ‐ internally generated
0 
0 
0 
8,552 
8,552 
acquired on acquisition of subsidiary
0 
2,461 
0 
4 
2,465 
purchase price allocation
11,063 
0 
(2,366)
0 
8,697 
fully amortized assets
(5,251)
(321)
0 
(10,945)
(16,517)
exchange rate differences
(546)
108 
(198)
(41)
(677)
at 31 december 2019
42,983 
16,257 
13,806 
48,073 
121,119 
amortization
at 1 january
31,218 
3,508 
334 
31,020 
66,080 
charge for the period
3,305 
895 
0 
5,282 
9,482 
fully amortized assets
(5,251)
(321)
0 
(10,945)
(16,517)
exchange rate differences
(215)
18 
61 
(448)
(584)
at 31 december 2019
29,057 
4,100 
395 
24,909 
58,461 
at 31 december 2019
13,926 
12,157 
13,411 
23,164 
62,658 
16. investment in associates
2020
2019
6,099 
5,998 
additions due to acquisition
6,850 
0 
290 
258 
dividend received
0 
(134)
113 
(23)
13,352
6,099 
17. other financial assets
31.12.2020
31.12.2019
421 
1,185 
3,520 
1,813 
3,941 
2,998 
restricted cash
other financial assets
at 1 january
share in net profit
exchange rate differences
at 31 december
Össur consolidated financial statements 2020
26
notes to the consolidated financial statements
18. inventories 
31.12.2020
31.12.2019
raw material
24,120 
29,280 
work in progress
11,812 
12,098 
finished goods 
57,299 
70,635 
93,231 
112,013 
19. accounts receivables
31.12.2020
31.12.2019
nominal value
103,019 
110,381 
allowances for doubtful accounts
(4,666)
(3,793)
98,353 
106,588 
movement in the allowance for doubtful accounts
2020
2019
(3,793)
(5,115)
(1,397)
1,041 
561 
258 
(37)
23 
at 31 december
(4,666)
(3,793)
gross 
carrying 
amount at 
default
expected 
credit loss 
rate
collective 
allowance 
(lifetime ecl)
individual 
allowance
net carrying 
amount
not past due
80,135 
2.3%
1,828 
0 
78,307 
less than six months past due
18,127 
4.0%
154 
578 
17,395 
six to twelve months past due
1,889 
13.7%
234 
25 
1,630 
2,868 
64.4%
1,679 
168 
1,021 
103,019 
3,895 
771 
98,353 
impairment (losses)/gains recognized on receivables
exchange rate difference
inventories of usd 13.5 million (2019: usd 14.1 million) are expected to be sold or used in production after more than twelve
months.
in the preparation of the consolidated financial statements, accumulated gains in inventories from intercompany
transactions amounting to usd 24.3 million (2019: usd 27.9 million) were eliminated. this has an effect on the income tax
expense of the consolidated companies, and an adjustment of usd 5.7 million (2019: usd 6.5 million) is made in the
consolidated financial statements to adjust income tax expense.
the average credit period on sales of goods is 46.9 days (2019: 46.4 days). allowance has been made for doubtful accounts,
this allowance has been determined by management in reference to future expectations. management considers that the
carrying amount of receivables approximates their fair value. 
the cost of inventories recognized as an expense includes usd 2.1 million (2019: usd 2.0 million) in respect of write‐downs of
inventory to net realizable value. reserve for obsolete inventories at year end is usd 5.5 million compared to usd 3.7 million
in 2019.
accounts receivables
amounts written off as uncollectable
more than twelve months past due
31.12.2020
at 1 january
Össur consolidated financial statements 2020
27
notes to the consolidated financial statements
gross 
carrying 
amount at 
default
allowance 
(lifetime ecl)
net carrying 
amount
not past due
73,252 
223 
73,029 
less than six months past due
33,497 
335 
33,162 
six to twelve months past due
957 
560 
397 
2,675 
2,675 
0 
110,381 
3,793 
106,588 
 
20. other assets
31.12.2020
31.12.2019
prepaid expenses
12,844 
14,761 
receivables related to divestment of subsidiaries
10,924 
0 
vat refundable
2,719 
9,670 
other
6,024 
5,737 
32,511 
30,168 
21. bank balances and cash equivalents
31.12.2020
31.12.2019
bank accounts
102,236 
58,290 
cash and other cash equivalents
127 
321 
102,363 
58,611 
accounts receivables
more than twelve months past due
31.12.2019
the expected credit loss (ecl) on trade receivables is estimated using a provision matrix by reference to past default
experience, general economic conditions and an assessment of both the current as well as expected conditions, including
time value of money where appropriate. individual allowance and adjustments to the collective bad debt provision are made
based on the individual assessment of customers' situation and probability of incoming payments. refer to note 39.17 for
further details. 
due to the covid‐19 pandemic payment terms have been extended resulting in higher risk of bad debt. the expected credit
loss rate was increased due to this uncertainty. the company writes off a trade receivable when there is information
indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the debtor
has been placed under liquidation or has entered into bankruptcy proceedings.
to mitigate the liquidity risk due to covid‐19, the company secured additional financing of usd 225 million. at period end
the company had a total liquidity of usd 275.6 million, consisting of undrawn revolving credit facilities of usd 173.2 million
(2019: usd 32.4 million) and cash and cash equivalents of usd 102.4 million.
Össur consolidated financial statements 2020
28
notes to the consolidated financial statements
22. issued capital and share premium
common stock is as follows in thousands of shares:
issued shares
treasury 
shares
total
balance at 1 january 2019
430,808 
(6,705)
424,103 
(5,430)
5,430 
0 
2,700 
2,700 
purchased treasury shares
(4,785)
(4,785)
425,378 
(3,360)
422,018 
(2,378)
2,378 
0 
1,375 
1,375 
(1,295)
(1,295)
423,000 
(902)
422,098 
start date
end date
shares
average
share price
aquired own shares
26 nov 2019
14 feb 2020
955,169
50.15
aquired own shares
18 feb 2020
17 mar 2020
340,281
44.12
total Össur shares aquired in 2020
1,295,450
48.57
movement in issued capital is as follows in usd thousands:
share
share
capital
premium
total
balance at 1 january 2019
4,811 
88,956 
93,767 
21 
14,102 
14,123 
(38)
(30,039)
(30,077)
4,794 
73,019 
77,813 
11 
6,357 
6,368 
(10)
(9,299)
(9,309)
4,794 
70,077 
74,871 
purchased treasury shares
balance at 31 december 2019
balance at 31 december 2020
purchased treasury shares
sold treasury shares
sold treasury shares
balance at 31 december 2020
purchased treasury shares
sold treasury shares
the share buyback programs are managed by nordea, which make its trading decisions independently and without influence
by the company regarding the timing of the purchases. the company’s purchases under the program are announced every
monday for the previous week. the purpose of the program is to reduce the company’s share capital and adjust the capital
structure by distributing capital to shareholders in line with the company's capital structure and dividend policy in addition to
being able to meet the company's share option obligations. it should be noted that the share buyback program was
temporarily put on hold on 17 march 2020. share options contracts amounting to 1,375,000 Össur shares were exercised
during the year.
sold treasury shares
cancellation of own shares
balance at 31 december 2019
cancellation of own shares
in 2020, Össur acquired in total 1,295,450 shares at the average price of dkk 48.57 in the following share buyback programs:
Össur consolidated financial statements 2020
29
notes to the consolidated financial statements
23. share option contracts
the following share‐based payment arrangements were in existence at balance sheet date:
number of 
shares
grant/issue 
year
exercise        
year
exercise  price 
(in dkk)
fair value at 
grant date   (in 
dkk)
issued to executive management:
jón sigurðsson president and ceo
1,000,000 
2018 ‐ 2020
2021 ‐ 2023
27.7‐46.3
28.0‐47.5
members of executive management (2 persons)
450,000 
2017
2020
28.1
26.7
members of executive management (5 persons)
550,000 
2018
2021
28.5/27.7
27.7/28.0
members of executive management (3 persons)
320,000 
2019
2022
32.3/45.5
33.5/47.9
members of executive management (4 persons)
550,000 
2020
2023
38.5‐46.3
38.6‐47.5
2,870,000 
issued to management team:
three managers
125,000 
2017
2020
26.6‐30.0
28.4‐29.9
eleven managers
480,000 
2018
2021
27.5‐32.3
27.7‐32.2
eleven managers
338,000 
2019
2022
32.3‐49.8
33.5‐52.3
twenty‐two managers
650,000 
2020
2023
38.5‐46.3
38.6‐47.5
1,593,000 
total issued option contracts
4,463,000 
 movements in share options during the period:
number of 
shares
weighted 
average 
contract rate 
(in dkk)
number of 
shares
weighted 
average 
contract rate 
(in dkk)
3,971,000 
29.6 
6,013,000 
25.6 
granted during period 
1,867,000 
42.9 
768,000 
41.4 
forfeited during period 
0 
0.0 
(110,000)
45.5 
exercised during period
(1,375,000)
25.9 
(2,700,000)
23.5 
outstanding at 31 december
4,463,000 
36.3 
3,971,000 
29.6 
the company has in place a share option plan, approved at the company's annual general meetings, under which managers
may be granted options to purchase ordinary shares at an exercise price, determined by the average closing price on shares
traded on the omx copenhagen stock exchange over the 20 trading days prior to the issue date. the employee must remain
continuously employed with the company until expiring date, either as an employee or in any other way, deemed satisfactory
by the company. 
each employee share option converts into one ordinary share on exercise. no amounts are paid or payable by the recipient to
the company on receipt of the option. the options carry neither rights to dividends nor voting rights and are valued using the
black‐scholes pricing model. the expected volatility assumptions used to value the options range from 30.67% to 31.25% and
the annual discount rate range from ‐0.7% to ‐0.5%. the options expire one year after the exercise date. if a share option
vests during a closed period for insider trading the vesting period is automatically extended until the next open window for
insider trading.
2020
2019
outstanding at 1 january
estimated remaining cost due to the share option contracts is usd 2.5 million. an expense of usd 1.3 million (2019: usd 1.1
million) is recognized in the income statement for the period. exercise period of the share options contracts is 2021‐2024.
Össur consolidated financial statements 2020
30
notes to the consolidated financial statements
24. borrowings
current
non‐current
current
non‐current
loans in usd
0 
99,016 
1,262 
29,556 
loans in eur
17,545 
125,066 
5,931 
128,284 
revolver in usd
0 
30,000 
0 
53,000 
revolver in eur
0 
85,896 
0 
33,088 
17,545 
339,978 
7,193 
243,928 
aggregated maturities of borrowings are as follows:
31.12.2020
31.12.2019
in 2021 / 2020
17,545 
7,193 
in 2022 / 2021
14,371 
9,219 
in 2023 / 2022
186,912 
147,420 
in 2024 / 2023
1,171 
31,168 
later
137,524 
56,121 
357,523 
251,121 
31.12.2019
cash flows
acquisition
exchange rate
transaction 
cost
31.12.2020
borrowings
251,121 
84,716 
5,429 
17,016 
(760)
357,523 
25. lease liabilities
current
non‐current
current
non‐current
lease liabilities in usd
6,290 
45,696 
5,010 
44,137 
lease liabilities in eur
4,697 
16,668 
4,072 
14,555 
lease liabilities in other currencies
6,870 
45,649 
7,007 
34,318 
total
17,857 
108,013 
16,089 
93,010 
aggregated maturities of lease liabilites are as follows:
31.12.2020
2019
in 2021 / 2020
17,857 
16,089 
in 2022 / 2021
17,508 
15,155 
in 2023 / 2022
16,574 
13,802 
in 2024 / 2023
15,771 
13,019 
later
58,160 
51,034 
total
125,870 
109,099 
31.12.2019
the maturity of the revolving credit facility is q1 2023. the company has classified the revolving credit facility as non‐current
liability as the intention is to use it to finance further growth of the company.
31.12.2020
Össur has a multicurrency term and revolving credit facility with nordea and danske bank with for a total amount of usd
344.7 million (usd 171.6 million outstanding and usd 173.2 million undrawn). in addition, the company has two loans with
the nordic investment bank for a total amount of usd 102 million and one loan with the european investment bank for a total
amount of usd 75 million. all loans contain covenants that place various financial and operational restrictions on the
company and are in line with market standards for investment grade rated companies. in order to meet any possible
covenant breaches due to covid‐19, the company put in place a covenant amendment with all its lenders that is in effect
throughout 2021. current weighted average interest terms on floating rate loans are <110 bps +libor/euribor, changing in
line with financial leverage.
the table below shows how cash and non‐cash changes affect borrowings within the company.
non‐cash changes
2019
31.12.2020
Össur consolidated financial statements 2020
31
notes to the consolidated financial statements
26. deferred tax asset / (liability)
2020
2019
at beginning of period
(2,589)
(5,067)
income tax payable for the period
9,002 
22,640 
calculated tax for the period
(4,799)
(21,395)
arising on acquisition of a subsidiary
(1,556)
(860)
recognized directly through equity
1,559 
2,152 
exchange rate differences
(158)
(59)
at 31 december
1,459 
(2,589)
deferred tax in the balance sheet:
deferred tax asset
27,512 
27,081 
deferred tax liabilities
(26,053)
(29,670)
1,459 
(2,589)
the following are the major deferred tax liabilities and assets recognized:
31.12.2020
assets
liabilities
net
5,747 
(15,869)
(10,122)
2,281 
(10,191)
(7,910)
453 
(2,432)
(1,979)
3,032 
(135)
2,897 
4,873 
(536)
4,337 
2,151 
0 
2,151 
5,087 
(273)
4,814 
1,993 
0 
1,993 
5,318 
(40)
5,278 
30,935 
(29,476)
1,459 
(3,423)
3,423 
0 
27,512 
(26,053)
1,459 
31.12.2019
assets
liabilities
net
5,724 
(13,341)
(7,617)
1,425 
(11,063)
(9,638)
387 
(3,275)
(2,888)
836 
0 
836 
6,036 
(218)
5,818 
2,217 
(58)
2,159 
5,628 
(1,632)
3,996 
1,564 
(79)
1,485 
3,850 
(590)
3,260 
27,667 
(30,256)
(2,589)
(586)
586 
0 
27,081 
(29,670)
(2,589)
goodwill
intangible assets
other
inventories
tax loss carry forward
property, plant and equipment
inventories
provisions
tax asset and liabilities offsetting
provisions
total tax assets / (liabilities)
receivables
current liabilities
other
current liabilities
total tax assets / (liabilities)
property, plant and equipment
tax loss carry forward
receivables
goodwill
tax asset and liabilities offsetting
intangible assets
Össur consolidated financial statements 2020
32
notes to the consolidated financial statements
27. provisions
warranty
other
2020
provisions
provisions
total
5,522 
10,451 
15,973 
5,120 
7,751 
12,871 
(4,186)
(5,573)
(9,759)
16 
223 
239 
6,472 
12,852 
19,324 
3,116 
4,840 
7,955 
3,357 
8,013 
11,369 
6,472 
12,852 
19,324 
warranty
other
2019
provisions
provisions
total
6,245 
7,454 
13,699 
7,105 
7,816 
14,921 
(7,846)
(4,771)
(12,617)
18 
(48)
(30)
5,522 
10,451 
15,973 
2,776 
3,759 
6,535 
2,746 
6,692 
9,438 
5,522 
10,451 
15,973 
28. deferred income
2020
2019
8,917 
5,183 
3,789 
6,660 
(3,331)
(2,880)
459 
(46)
9,834 
8,917 
6,739 
6,801 
3,095 
2,116 
9,834 
8,917 
the warranty provision represents management's best estimate of the company's liability under warranties granted on
prosthetic products, based on past experience.
deferred income
released from deferred income
exchange rate differences
at 31 december
non‐current
current
at 31 december
deferred income relates to sale of additional warranty for prosthetic products and service checks included in standard
warranty. income from additional warranty is deferred when sold and released on a straight line basis within the warranty
period. income from service checks is deferred when sold and released when the service has been rendered. additional
warranties range from 2‐6 years.
non‐current
at 1 january
at 31 december 2019
current
at 1 january
additional provision recognized
utilization of provision
other provisions represents earn outs related to acquisitions and divestments of companies and restructuring provisions.
current
at 31 december 2019
non‐current
at 1 january
exchange rate differences
utilization of provision
additional provision recognized
at 31 december 2020
at 31 december 2020
exchange rate differences
Össur consolidated financial statements 2020
33
notes to the consolidated financial statements
29. other financial liabilities
30. related party transactions
2020
2019
867 
873 
2,188 
1,883 
848 
422 
31. other liabilities
31.12.2020
31.12.2019
accrued expenses
17,771 
13,513 
sales tax and vat
4,686 
4,144 
deferred income
3,095 
2,116 
sales return accrual
1,943 
1,840 
other
10,629 
5,770 
38,124 
27,383 
for disclosures relating to key management positions, refer to note 7.
balances and transactions between the company and its subsidiaries, which are related parties of the company, have been
eliminated in consolidation and are not disclosed in this note. 
transactions and balances with related parties:
other financial liabilities consist of fair value of hedge contracts and fair value of a purchase option of minority shares
amounting to usd 1.1 million (2019: usd 0.7 million).
the company engages in transactions with some of its associated companies and other related parties. the transactions
consist of, among others, sale of Össur products where commercial terms and market prices apply. 
one of the company´s distribution companies in the us was sold at the end of the year to associated company.
purchases
sales of products
receivables at 31 december
Össur consolidated financial statements 2020
34
notes to the consolidated financial statements
32. business combinations
americas
emea
total
current assets
12,010 
18,872 
30,882 
561 
31,443 
non‐current assets
3,523 
5,215 
8,738 
7,040 
15,778 
non‐current liability
0 
(15,648)
(15,648)
(786)
(16,434)
current liabilities
(5,339)
(9,820)
(15,159)
0 
(15,159)
non controlling interest
0 
391 
391 
0 
391 
10,194 
(990)
9,204 
6,815 
16,019 
consideration
96,937 
book value of identifiable net assets acquired
(9,204)
fair value of identifiable net assets acquired
(6,815)
goodwill arising on acquisition
80,918
consideration
96,937
deferred payment
‐2,394
cash from acquired companies
‐11,943
consideration shown in cash flow
82,600
Össur made acquisitions during 2019 to strengthen the company's sales channels. one of the companies has minority
shareholders but the others were acquired in full. in the income statement of the year 2019, sales amounting to usd 8 million
and net profit of usd 1.5 million were related to these acquisitions. usd 1.7 million was expensed as special items in relation
to the acquisitions during the year and classified as general and administrative expenses in the income statement.
total
fair value
book value at
 acquisition date   
assets acquired and liabilities 
recognized at the date of 
acquisition:
fair value 
changes
acquisition of subsidiaries
Össur made acquisitions during 2020 to strengthen the company's sales channels. one of the companies has minority 
shareholders but the others were acquired in full. in the income statement of the year 2020, sales amounting to usd 11.9 
million and net profit of usd 0.9 million were related to these acquisitions. usd 0.8 million was expensed in relation to the 
acquisitions during the year and classified as general and administrative expenses in the income statement.
the purchase price allocation (ppa) for assets and liabilities acquired in 2019 was finalized during 2020. the initial accounting 
for the acquisitions at yearend 2020 has been provisionally determined at balance sheet date. the ppa will be finalized in 
2021.
the total ppa amounted to usd 6.8 million, mainly related to intangible assets. amortization of intangibles relating to the ppa 
was recognized in the income statement for usd 0.2 million during 2020.
2020
Össur consolidated financial statements 2020
35
notes to the consolidated financial statements
2019
americas
emea
total
current assets
4,517 
2,317 
6,834 
623 
7,457 
non‐current assets
617 
2,567 
3,184 
8,533 
11,717 
non‐current liability
(145)
(105)
(250)
(1,063)
(1,313)
current liabilities
(1,909)
(1,415)
(3,324)
0 
(3,324)
non controlling interest
0 
(226)
(226)
0 
(226)
3,080 
3,138 
6,218 
8,093 
14,311 
consideration
36,316 
book value of identifiable net assets acquired
(6,218)
fair value of identifiable net assets acquired
(8,093)
goodwill arising on acquisition
22,005
consideration
36,316
deferred payment
(5,115)
cash from acquired companies
(754)
consideration shown in cash flow
30,447
divestment of subsidiaries
2020
current assets
44,458 
non‐current assets
11,206 
non‐current liability
(1,741)
current liabilities
(22,735)
31,188 
loss on disposal
(5,369)
total consideration
25,820
cash and cash equivalents
11,980 
deferred payment
13,840 
total consideration
25,820
consideration received in cash and cash equivalents
11,980 
less cash and cash equivalents disposed of
(5,667)
consideration shown in cashflow
6,314
assets acquired and liabilities 
recognized at the date of 
acquisition:
fair value 
changes
total
fair value
Össur divested subsidiaries during 2020 to sharpen the focus and align with bracing and support go‐to market strategy.
assets and liabilities disposed at 
the date of divestment:
in 2020 the company finalized the purchase price allocation (ppa) relating to acquisitions done in 2019 resulting in fair value
changes of 1.7 million, mainly relating to fair value recognition of other intangible assets.
book value at
 divestment date
book value at
 acquisition date   
in the income statement of the year 2020, sales amounting to usd 51.5 million were related to these divestments.
contribution to net profit from the divested subsidiaries was negative during the year.
there were no disposals of subsidiaries made in 2019.
assets eliminated and impairment related to divestments usd 17.8 million and cost related to divestment usd 5.1 million are
shown as part of other income / (expenses) in the income statement 2020.
Össur consolidated financial statements 2020
36
notes to the consolidated financial statements
33. financial instruments
33.1 capital risk management
net debt to ebitda before special items ratio
the net debt to ebitda before special items at period end was as follows:
31.12.2020
31.12.2019
net debt
381,030 
301,609 
ebitda before special items
92,987 
149,622 
net debt/ebitda before special items
4.1 
2.0 
33.2 significant accounting policies
33.3 financial risk management objectives
the company is exposed to normal business risk in collecting accounts receivable. adequate allowance is made for bad debt
expenses.  
details of the significant accounting policies and methods adopted, including the criteria for recognition, the basis of
measurement and the basis on which income and expenses are recognized, in respect of each class of financial asset, financial
liability and equity instrument are disclosed in note 39 to the consolidated financial statements.
the company's corporate finance function provides services to the business, coordinates access to domestic and
international financial markets, monitors and manages the financial risks relating to the operations of the company through
internal risk reports which analyze exposures by degree and magnitude of risks. these risks include liquidity risk, interest rate
risk, foreign exchange risk and counterparty credit risk.
the general policy is to apply natural hedging to the extent possible but Össur has decided to amend its hedging policy and
allow for active hedging of currency exposure that is not covered by the natural hedge in sales and costs by currency. the use
of financial derivatives is governed by the company's policies approved by the board of directors, which provide written
principles on foreign exchange risk, interest rate risk, credit risk, the use of financial derivatives and non‐derivative financial
instruments and the investment of excess liquidity. the company does not enter into or trade financial instruments, including
derivative financial instruments, for speculative purposes.
the capital structure of the company consists of debt, which includes the borrowings disclosed in note 24, cash and cash
equivalents and equity attributable to equity holders of the parent, comprising issued capital, reserves and retained earnings
as disclosed in the equity overview.
the company manages capital to ensure that affiliates within the consolidation will be able to continue as a going concern
while maximizing the return to stakeholders through the optimization of the debt and equity balance. the company's overall
strategy remains unchanged from 2019.
company's management continuously reviews the capital structure. as a part of this review, the management considers,
amongst other, the cost of capital and net debt to ebitda before special items.
Össur consolidated financial statements 2020
37
notes to the consolidated financial statements
33.4 foreign currency risk management
31.12.2020
31.12.2019
31.12.2020
31.12.2019
eur
266,675 
208,171 
64,731 
36,392 
usd
222,452 
170,490 
100,274 
93,710 
isk
30,292 
29,118 
12,699 
12,285 
sek
26,634 
27,414 
13,075 
13,260 
gbp
5,565 
5,115 
8,772 
7,368 
other
32,310 
28,266 
37,616 
35,349 
583,928 
468,576 
237,168 
198,365 
foreign currency sensitivity analysis
2020
2019
2020
2019
net profit
1,236 
3,709 
(3,628)
(4,730)
equity
(1,248)
576 
(2,136)
(746)
the company operates on a global market, hence exposure to exchange rate fluctuations arises. exchange rate exposures are
managed within approved policy parameters. the general policy is to apply natural exchange rate hedging to the extent
possible.
Össur currently uses a twelve month, quarterly layered hedging strategy to limit isk and eur exposure. this is done with
forward currency contracts where Össur sells eur for isk. at each balance sheet date Össur has outstanding contracts
covering appr. 50% of yearly isk costs. due to the layered approach, hedge ratio of closed contracts is approximately 80% of
isk costs. at balance sheet date eleven forward contracts are open. the fair value of the contracts is positive of usd 0.1
million at year end 2020.
isk (ii)
(i) 20% (2019: 19%) of the company's cogs and opex is in eur against 22% (2019: 24%) of its sales causing an increase in profit if the usd
decreases against the eur.
(ii) 10% (2019: 11%) of the company's cogs and opex is in isk against 0.3% (2019: 0.3%) of its sales causing a decrease in profits if the usd
decreases against the isk.
the company is hedging approximately 80% of its isk exposure using forward currency contracts. this is not considered in the above
calculations. 
the carrying amounts of the company's foreign currency denominated monetary assets and monetary liabilities at the
reporting date are as follows:
liabilities
the company is mainly exposed to the fluctuation of the iceland (isk) and the eurozone (eur) currency.
the following table details the company's sensitivity to a 10% decrease in usd against the relevant foreign currencies with all
other variables fixed. the sensitivity analysis includes all foreign currency denominated items and adjusts their translation at
the period end for a 10% change in foreign currency rates. the table below indicates the effect on profit or loss and other
equity where usd weakens 10% against the relevant currency. for a 10% strengthening of usd against the relevant currency,
there would be an equal and opposite impact on the profit or loss and other equity.
eur (i)
assets
Össur consolidated financial statements 2020
38
notes to the consolidated financial statements
33.5 interest rate risk management
33.6 liquidity risk management
weighted 
average 
effective 
interest
less than 1 
year
1‐5 years
5+ years
total
31.12.2020
borrowings
1.6%
23,687 
353,105 
72 
376,864 
lease liabilities
4.0%
22,874 
77,950 
45,978 
146,802 
non‐interest bearing liabilities
‐
96,373 
11,410 
0 
107,784 
142,935 
442,465 
46,050 
631,450 
31.12.2019
borrowings
1.9%
12,300 
255,822 
0 
268,122 
lease liabilities
3.95%
20,401 
67,155 
39,826 
127,382 
non‐interest bearing liabilities
‐
95,303 
8,393 
0 
103,696 
128,004 
331,370 
39,826 
499,200 
the company is exposed to interest rate risks as funds are borrowed at floating interest rates. interest rate risk is managed by
the company´s treasury function and fixed rate loans or interest rate swap contracts may be used to maintain an appropriate
mix between fixed and floating rate borrowings. hedging activities are evaluated regularly to align with interest rate views and
defined risk appetite, ensuring optimal hedging strategies are applied. the company did not have interest rate swap
agreements outstanding during the year.
the company's exposures to interest rates on financial assets and financial liabilities are detailed in the liquidity risk
management section of this note.
management believes that realistic changes in floating interest rates will not materially affect the income statement or the
company´s equity.
the company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by
monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. to mitigate the
liquidity risk due to covid‐19, the company secured additional financing of usd 225 million. at period end the company had
a total liquidity of usd 275.6 million, consisting of undrawn revolving credit facilities of usd 173.2 million (2019: usd 32.4
million) and cash and cash equivalents of usd 102.4 million.
the following tables detail the company's remaining contractual maturity for its non‐derivative financial liabilities. the tables
have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the
company can be required to pay. the table includes both interest and principal cash flows.
Össur consolidated financial statements 2020
39
notes to the consolidated financial statements
33.7 credit risk management
33.8 fair value of financial instruments
carrying 
amount
fair value
carrying 
amount
fair value
financial liabilities:
borrowings
357,523
359,041
251,121
251,879
34. litigation
35. other information
unusual conditions caused by the covid‐19 pandemic are resulting in uncertainty in the company´s economic environment
and are impacting the financial performance of the company. it is, however, the opinion of the company's management that
this does not effect the company's ability to continue operating on a going concern basis. management believes that covid‐
19 has only short‐term impact on the company's financials and does not changes in long‐term market fundamentals.
in november 2019, vincent systems gmbh (“vincent systems”) filed a patent infringement action against Össur in the us.
vincent systems contended that Össur willfully infringed a us patent by selling certain products, including i‐digits and i‐limb
prosthetic hands. the litigation was settled in q3 2020. 
31.12.2020
except as detailed in the following table, management considers that the carrying amounts of financial assets and financial
liabilities recognized in the consolidated financial statements approximate their fair values. 
the company does not undertake trading activity in financial instruments.
accounts receivables consist of a large number of customers spread across geographical areas. ongoing credit evaluation is
performed on the financial condition of accounts receivables. refer to note 19 for assessment of expected credit loss (ecl)
and accounting policy on impairment on financial assets.
book value of financial assets measured at amortized cost represents the maximum exposure to credit risk.
31.12.2019
Össur consolidated financial statements 2020
40
notes to the consolidated financial statements
36. the consolidation
name of company
place of 
registration 
and operation
ownership %
principal activity
apc prosthetics pty ltd
australia
100%   
sales, distribution and services
Össur americas inc
usa
100%   
sales, r&d, distribution and services
Össur australia pty ltd
australia
100%   
sales, distribution and services
Össur canada inc
canada
100%   
sales, distribution and services
college park industries, inc
usa
100%   
sales, distribution and manufacturer
och ortopedi as
norway
100%   
sales, distribution and services
ortos a/s
denmark
100%   
sales, distribution and services
Össur deutschland gmbh
germany
100%   
sales, distribution and services
Össur europe bv
netherlands
100%   
sales, distribution and services
Össur france sarl
france
100%   
sales, distribution and services
Össur hong kong ltd
hong kong
100%   
sales, distribution and services
Össur iceland ehf
iceland
100%   
r&d and manufacturer
 
Össur mexico s. de r.l. de c.v.
mexico
100%   
manufacturer
Össur nordic ab
sweden
100%   
sales, distribution and services
Össur prosth. & rehabilition co ltd
china
100%   
sales, distribution and services
Össur uk ltd
uk
100%   
sales, distribution and services
teamolmed ab
sweden
100%   
sales, distribution and services
touch bionics ltd
uk
100%   
manufacturer and r&d
37. insurance
insurance
book
insurance
book
value
value
value
value
fixed assets and inventories
244,239 
157,196 
233,914 
180,934 
31.12.2019
the company has purchased a property damage & business interruption insurance intended to compensate for damages on
owned property and temporary loss of income due to such loss. additionally Össur has numerous insurances in place as are
necessary to insure against the risks to its operations, including but not limited to product and professional liability insurance,
product recall insurance, directors & officers liability and certain types of frauds towards the company. 
31.12.2020
at end of september 2020 Össur completed the divestment of gibaud sas in france. gibaud and Össur will continue to be
business partners for a selected b&s product range.
touch bionics ltd, Össur uk ltd and uk holding ltd. are claiming exemption from preparing individual audited accounts based on section
479a of the uk companies act 2006.
information about the main composition of the company at the end of the reporting period is as follows:
Össur consolidated financial statements 2020
41
 
 
 
               notes to the consolidated financial statements 
 
38. adoption of new and revised standards  
38.1 new and amended ifrs standards that are effective for the current year 
 
the following amendments to ifrs standards became mandatorily effective in the current year. the application of the 
below amendments has minor effects on the consolidated financial statements: 
 
• amendments to ifrs 3 ‐ business combination, definition of a business; 
 
• amendments to ias 1 ‐ presentation of financial statements & ias 8 ‐ accounting policies, change in accounting 
estimates and errors, definition of 'material‘ 
 
38.2 new and revised ifrs standards in issue but not yet effective 
 
at the date of authorization of these financial statements, the company has not applied new and revised ifrs standards 
that have been issued but are not yet effective. 
 
management of the company does not expect that the adoption of the standards will have a material impact on the 
financial statements of the company in future periods. 
 
39.  summary of significant accounting policies 
39.1 statement of compliance 
 
the  consolidated  financial  statements  have  been  prepared  in  accordance  with  international  financial  reporting 
standards as adopted by the european union, additional danish disclosure requirements for listed companies and 
additional requirements in the icelandic financial statement act no. 3/2006. 
 
39.2 basis of preparation 
 
the consolidated financial statements have been prepared under the historical cost basis except for certain financial 
instruments that are measured at fair values. historical cost is generally based on the fair value of the consideration 
given in exchange for assets. fair value is the price that would be received to sell an asset or paid to transfer a liability 
in an orderly transaction between market participants at the measurement date, regardless of whether that price is 
directly observable or estimated using another valuation technique. in estimating the fair value of an asset or a liability, 
the  company  considers  the  characteristics  of  the  asset  or  liability  as  market  participants  would  take  those 
characteristics into account when pricing the asset or liability at the measurement date. fair value for measurement 
and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share‐
based payment transactions that are within the scope of ifrs 2 and measurements that have some similarities to fair 
value but are not fair value, such as net realizable value of inventories in ias 2 or value of assets in use in ias 36. 
 
39.3 basis of consolidation 
 
the consolidated financial statements incorporate the financial statements of the company and entities controlled by 
the company and its subsidiaries. control is achieved when the company: 
• has power over the investee; 
• is exposed, or has rights, to variable returns from its involvement with the investee; and  
• can use its power to affect its returns.  
 
the company reassesses whether it controls an investee if facts and circumstances indicate that there are changes to 
one or more of the three elements of control listed above.  
when the company has less than a majority of the voting rights of an investee, it has power over the investee when 
the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. 
the company considers all relevant facts and circumstances in assessing whether the company's voting rights in an 
investee are sufficient to give it power, including:  
Össur consolidated financial statements 2020
42
 
 
 
               notes to the consolidated financial statements 
 
• the size of the company's holding of voting rights relative to the size and dispersion of holdings of the other vote 
holders;  
• potential voting rights held by the company, other vote holders or other parties;  
• rights arising from other contractual arrangements; and  
• any additional facts and circumstances that indicate that the company has, or does not have, the current ability to 
direct  the  relevant  activities  at  the  time  that  decisions  need  to  be  made,  including  voting  patterns  at  previous 
shareholders' meetings.  
 
consolidation of a subsidiary begins when the company obtains control over the subsidiary and ceases when the 
company loses control of the subsidiary. specifically, income and expenses of a subsidiary acquired or disposed of 
during the year are included in the consolidated statement of profit or loss and other comprehensive income from the 
date the company gains control until the date when the company ceases to control the subsidiary.  
 
profit or loss and each component of other comprehensive income are attributed to the owners of the company and 
to the non‐controlling interests. when necessary, adjustments are made to the financial statements of subsidiaries to 
bring their accounting policies in line with the company's accounting policies. all intercompany assets and liabilities, 
equity, income, expenses and cash flows relating to transactions between members of the company are eliminated in 
full on consolidation. 
 
changes in the company's ownership interests in subsidiaries that do not result in the company losing control over the 
subsidiaries are accounted for as equity transactions. the carrying amounts of the company's interests and the non‐
controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. any difference 
between the amount by which the non‐controlling interests are adjusted and the fair value of the consideration paid or 
received is recognized directly in equity and attributed to owners of the company. 
 
39.4 business combination 
 
acquisitions of businesses are accounted for using the acquisition method. the consideration transferred in a business 
combination is measured at fair value, which is calculated as the sum of the acquisition‐date fair values of the assets 
transferred by the company, liabilities incurred by the company to the former owners of the acquiree and the equity 
interests issued by the company in exchange for control of the acquiree. acquisition‐related costs are recognized in 
profit or loss as incurred. 
 
the acquiree's identifiable assets, liabilities and contingent liabilities that meet the conditions for recognition under 
ifrs 3 are recognized at their fair value at the acquisition date, except that: 
• deferred tax assets or liabilities and liabilities or assets related to employee benefit arrangements are recognized and 
measured in accordance with ias 12 income taxes and ias 19 employee benefits respectively; 
•  liabilities  or  equity  instruments  related  to  share‐based  payment  arrangements  of  the  acquiree  or  share‐based 
payment arrangements of the company entered into to replace share‐based payment arrangements of the acquiree 
are measured in accordance with ifrs 2 share‐based payment at the acquisition date; 
• assets (or disposal groups) that are classified as held for sale in accordance with ifrs 5 non‐current assets held for 
sale and discontinued operations are measured in accordance with that standard. 
 
goodwill arising on acquisition is recognized as an asset and initially measured at cost, being the excess of the purchase 
price of the business combination over the company's interest in the net fair value of the identifiable assets, liabilities, 
contingent liabilities, the amount of any non‐controlling interests in the acquiree, and the fair value of the acquirer's 
previously held equity interest in the acquiree. if, after reassessment, the company's interest in the net fair value of the 
acquiree's identifiable assets, liabilities and contingent liabilities exceeds the cost of the business combination, the 
excess is recognized immediately in profit or loss. non‐controlling interests that are present ownership interests and 
entitle their holders to a proportionate share of the entity's net assets in the event of liquidation may be initially 
measured either at fair value or at the non‐controlling interests' proportionate share of the recognized amounts of the 
acquiree's identifiable net assets. the choice of measurement basis is made on a transaction‐by‐transaction basis. other 
types of non‐controlling interests are measured at fair value or, when applicable, on the basis specified in another ifrs. 
 
Össur consolidated financial statements 2020
43
 
 
 
               notes to the consolidated financial statements 
 
when the consideration transferred by the company in a business combination includes assets or liabilities resulting 
from a contingent consideration arrangement, the contingent consideration is measured at its acquisition‐date fair 
value and included as part of the consideration transferred in a business combination. changes in the fair value of the 
contingent  consideration  that  qualify  as  measurement  period  adjustments  are  adjusted  retrospectively,  with 
corresponding  adjustments  against  goodwill.  measurement  period  adjustments  are  adjustments  that  arise  from 
additional information obtained during the ‘measurement period’ about facts and circumstances that existed at the 
acquisition date. 
the  subsequent  accounting  for  changes  in  the  fair  value  of  the  contingent  consideration  that  do  not  qualify  as 
measurement period adjustments depends on how the contingent consideration is classified. contingent consideration 
that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted 
for within equity. contingent consideration that is classified as an asset or a liability is remeasured at subsequent 
reporting  dates  in  accordance  with  ifrs  9,  or  ias  37  provisions,  contingent  liabilities  and  contingent  assets,  as 
appropriate, with the corresponding gain or loss being recognized in profit or loss. 
 
if the initial accounting for a business combination is incomplete by the end of the reporting period in which the 
combination occurs, the company reports provisional amounts for the items for which the accounting is incomplete. 
those provisional amounts are adjusted during the measurement period (see below), or additional assets or liabilities 
are recognized, to reflect new information obtained about facts and circumstances that existed at the acquisition date 
that, if known, would have affected the amounts recognized at that date. 
 
when a business combination is achieved in stages, the company's previously held equity interest in the acquire is 
remeasured to fair value at the acquisition date (i.e., the date when the company obtains control) and the resulting 
gain or loss, if any, is recognized in profit or loss. amounts arising from interests in the acquire prior to the acquisition 
date that have previously been recognized in other comprehensive income are reclassified to profit or loss where such 
treatment would be appropriate if that interest were disposed of. 
 
the  measurement  period  is  the  period  from  the  date  of  acquisition  to  the  date  the  company  obtains  complete 
information about facts and circumstances that existed as of the acquisition date – and is subject to a maximum of one 
year. 
 
39.5 investments in associates 
 
an  associate  is  an  entity  over  which  the  company  has  significant  influence.  significant  influence  is  the  power  to 
participate in the financial and operating policy decisions of the investee but is not control or joint control over those 
policies.  
the results, assets and liabilities of associates are incorporated in the consolidated financial statements using the 
equity method of accounting. under the equity method, investments in associates are initially recognized in the balance 
sheet and adjusted for post‐acquisition changes in the company's share of the net assets of the associate, less any 
impairment in the value of individual investments. losses of an associate more than the company's interest in that 
associate are recognized only to the extent that the company has incurred legal or constructive obligations or made 
payments on behalf of the associate. 
 
any excess of the cost of acquisition over the company's share of the net fair value of the identifiable assets, liabilities 
and contingent liabilities of the associate recognized at the date of acquisition is recognized as goodwill. the goodwill 
is included within the carrying amount of the investment and is assessed for impairment as part of that investment. any 
excess of the company's share of the net fair value of the identifiable assets, liabilities and contingent liabilities over 
the cost of acquisition, after reassessment, is recognized immediately in profit or loss. 
 
the requirements of ias 36 are applied to determine whether it is necessary to recognize any impairment loss with 
respect to the company's investment in an associate. when necessary, the entire carrying amount of the investment 
(including goodwill) is tested for impairment in accordance with ias 36 impairment of assets as a single asset by 
comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount. 
any impairment loss recognized forms part of the carrying amount of the investment. any reversal of that impairment 
loss is recognized in accordance with ias 36 to the extent that the recoverable amount of the investment subsequently 
increases 
Össur consolidated financial statements 2020
44
 
 
 
               notes to the consolidated financial statements 
 
upon loss of significant influence over the associate, the company measures and recognizes any retained investment 
at its fair value. any difference between the carrying amount of the associate upon loss of significant influence and the 
fair value of the retained investment and proceeds from disposal is recognized in profit or loss. 
 
39.6 goodwill 
 
goodwill is initially recognized as an asset at cost and is subsequently measured at cost less any accumulated impairment 
losses.  
 
goodwill is not amortized but is reviewed for impairment at least annually. for impairment testing, goodwill is allocated 
to  each of the company's cash‐generating units expected  to benefit from  the  synergies of the combination.  cash‐
generating units to which goodwill has been allocated are tested for impairment annually, or more frequently when 
there is an indication that the unit may be impaired. if the recoverable amount of the cash‐generating unit is less than 
its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the 
unit and then to the other assets of the unit pro‐rata on the basis of the carrying amount of each asset in the unit. any 
impairment loss for goodwill is recognized directly in profit or loss in the consolidated income statement. an impairment 
loss recognized for goodwill is not reversed in a subsequent period. 
 
on disposal of the relevant cash‐generating unit, the attributable amount of goodwill is included in the determination 
of the profit or loss on disposal. 
 
the company's policy for goodwill arising on the acquisition of an associate is described at 39.5 above. 
 
39.7 revenue recognition 
 
revenue is measured at the fair value of the consideration received or receivable. revenue is reduced for estimated 
customer returns, rebates and other similar allowances. 
 
sale of goods and services 
 
the company sells bracing and support products and prosthetics products and related services both as wholesaler and 
directly to customers through its own distribution channels.  
 
revenue is recognized for the sale of products including standard warranty when control of the goods has transferred. 
control is considered transferred when the goods have been shipped or directly delivered to retail customer. following 
shipment, it is considered that our customers have full discretion over the manner of distribution and price to sell the 
goods, have the primary responsibility when selling the goods, and bear the risks of obsolescence and loss in relation to 
the goods. a receivable is recognized by the company when the goods are shipped to the customer as this represents 
the point in time at which the right to consideration becomes unconditional, as only the passage of time is required 
before payment is due. sales related standard warranties serve as an assurance that the products sold comply with 
agreed‐upon specifications, those warranties are accounted for in accordance with ias 37 provisions.  
 
for some prosthetics products, a service check is included in the standard warranty and is treated as a distinct service 
and is accounted  for as a  separate performance obligation. the  customer has  an option to purchase  an additional 
warranty which is treated as a distinct service because the company promises to provide the service to the customer in 
addition to the product and the standard warranty. that warranty is accounted for as a separate performance obligation.  
revenues from the sale of additional warranties are deferred when sold and released on a straight‐line basis within the 
warranty period. revenues from service checks included in the standard warranty are deferred when sold and released 
when the service has been rendered or the service obligation has ended. deferred revenues are shown separately within 
liabilities in the balance sheet  
 
under the company’s standard contract terms, customers have a right of return within 30‐90 days. at the point of sale, 
a refund liability and a corresponding adjustment to revenue is recognized for those products expected to be returned.  
 
Össur consolidated financial statements 2020
45
 
 
 
               notes to the consolidated financial statements 
 
the company uses its accumulated historical experience to estimate the number of returns on a portfolio level using the 
expected value method. it is considered highly unlikely that a significant reversal in the cumulative revenue recognized 
will occur given the consistent level of returns over previous years. 
 
royalties 
 
royalty revenue is recognized on an accrual basis in accordance with the substance of the relevant agreement. royalties 
determined  on  a  time  basis  are  recognized  on  a  straight‐line  basis  over  the  period  of  the  agreement.  royalty 
arrangements that are based on production, sales, and other measures are recognized by reference to the underlying 
arrangement (provided that it is probable that the economic benefits will flow to the company and the amount of 
revenue can be measured reliably).  
 
 
 
 
interest revenue and dividend 
 
interest income from a financial asset is recognized when it is probable that the economic benefits will flow to the 
company and the amount of income can be measured reliably. interest income is accrued on a time basis, by reference 
to  the  principal  outstanding  and  at  the  effective  interest  rate  applicable,  which  is  the  rate  that  exactly  discounts 
estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on 
initial recognition. dividend income from investments is recognized when the shareholder's right to receive payment 
has been established.  
 
39.8 right of use asset and lease liabilities 
 
the company assesses whether a contract is or contains a lease, at inception of the contract. the company recognizes 
a right of use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, 
except for short‐term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. 
for these leases, the company recognizes the lease payments as an operating expense on a straight‐line basis over the 
term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits 
from the leased assets are consumed. 
 
the lease liability is initially measured at the present value of the lease payments that are not paid at the commencement 
date, discounted by using the rate implicit in the lease. if this rate cannot be readily determined, the company uses its 
incremental borrowing rate. the lease payments included in the measurement of the lease liability comprise fixed 
payments less any incentives, variable lease payments that depend on an index or rate, expected residual guarantees 
and the exercise price of purchase options if the company expects to exercise the option. 
 
the lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability 
(using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. the 
company remeasures the lease liability if the lease term has changed, when lease payments changes in an index or rate 
or when a lease contract is modified, and the modification is not accounted for as a separate lease. 
 
right of use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. if a lease 
transfers ownership of the underlying asset or the cost of the right‐of‐use asset reflects that the company expects to 
exercise a purchase option, the related right‐of‐use asset is depreciated over the useful life of the underlying asset. the 
depreciation starts at the commencement date of the lease. 
 
variable rents that depend on usage are not included in the measurement of the lease liability and the right of use asset. 
the related payments are recognized as an expense in the period in which the event or condition that triggers those 
payments occurs. 
 
as a practical expedient, ifrs 16 permits a lessee not to separate non‐lease components, and instead account for any 
lease and associated non‐lease components as a single arrangement. the company has used this practical expedient. 
Össur consolidated financial statements 2020
46
 
 
 
               notes to the consolidated financial statements 
 
 
39.9 foreign currencies 
 
for consolidation purposes, the assets and liabilities of the company's foreign operations are expressed in usd using 
exchange rates prevailing at the balance sheet date.  
income and expense items are translated at the average exchange rates for each month. exchange differences arising, 
if  any,  are  classified  as  equity  and  transferred  to  the  company's  translation  reserve  (attributed  to  non‐controlling 
interests as appropriate).  
 
goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities 
of the foreign operation and translated at the closing rate. exchange differences arising, if any, are recognized in equity. 
 
exchange differences are recognized in the income statement in the period they occur, except for exchange differences 
on  monetary  items  receivable  from  or  payable  to  a  foreign  operation,  which  are  recognized  initially  in  other 
comprehensive income and reclassified from equity to profit or loss on repayment of the monetary items. 
 
transactions in currencies other than local currency are initially recorded at the rates of exchange prevailing on the dates 
of the transactions. other assets, such as inventories and operating fixed assets, purchased in foreign currencies are to 
be valued at cost at the exchange rate prevailing on the date of the transaction. 
 
39.10 share‐based payments 
 
equity‐settled share‐based payments to employees and others providing similar services are measured at the fair value 
of the equity instruments at the grant date. details regarding the determination of the fair value of equity‐settled share‐
based transactions are set out in note 23. 
 
the fair value determined at the grant date of the equity‐settled share‐based payments is expensed on a straight‐line 
basis over the vesting period, based on the company's estimate of equity instruments that will eventually vest, with a 
corresponding increase in equity. at the end of each reporting period, the company revises its estimate of the number 
of equity instruments expected to vest. the impact of the revision of the original estimates, if any, is recognized in profit 
or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the equity‐
settled employee benefits reserve. 
 
39.11 taxation 
 
income tax expense represents the sum of the tax currently payable and deferred tax. 
 
current tax 
 
the tax currently payable is based on taxable profit for the period. taxable profit differs from net profit as reported in 
the consolidated income statement because it excludes items of income or expense that are taxable or deductible in 
other periods and it further excludes items that are never taxable or deductible. the company's current tax is calculated 
using tax rates that have been enacted or substantively enacted by the end of the reporting period. 
 
deferred tax 
 
deferred  tax  is  recognized  on  temporary  differences  between  the  carrying  amounts  of  assets  and  liabilities  in  the 
consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. deferred 
tax liabilities are generally recognized for all taxable temporary differences. deferred tax assets are generally recognized 
for all deductible temporary differences to the extent that it is probable that taxable profits will be available against 
which those deductible temporary differences can be utilized. such deferred tax assets and liabilities are not recognized 
if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of 
other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. 
 
Össur consolidated financial statements 2020
47
 
 
 
               notes to the consolidated financial statements 
 
deferred tax liabilities are recognized for taxable temporary differences associated with investments in subsidiaries, 
except where the company is able to control the reversal  of  the  temporary difference  and it  is probable that the 
temporary difference will not reverse in the foreseeable future. deferred tax assets arising from deductible temporary 
differences associated with such investments and interests are only recognized to the extent that it is probable that 
there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are 
expected to reverse in the foreseeable future. 
 
the carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is 
no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. 
 
deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the 
liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted 
at the balance sheet date. the measurement of deferred tax liabilities and assets reflects the tax consequences that 
would follow from the manner in which the company expects, at the reporting date, to recover or settle the carrying 
amount of its assets and liabilities.  
 
deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against 
current tax liabilities and when they relate to income taxes levied by the same taxation authority and the company 
intends to settle its current tax assets and liabilities on a net basis. 
 
in  the  preparation  of  the  consolidated  financial  statements,  accumulated  gains  in  inventories  from  intercompany 
transactions are eliminated. this influences the income tax expenses of the consolidated companies, and an adjustment 
is included in the deferred tax asset. income tax expense is calculated in accordance with tax rates in the countries where 
the inventories are purchased. 
 
current and deferred tax for the year 
 
current and deferred tax are recognized in profit or loss, except when they relate to items that are recognized in other 
comprehensive income or directly in equity, in which case, the current and deferred tax are also recognized in other 
comprehensive  income or directly in  equity  respectively. where current  tax or  deferred tax arises from the initial 
accounting for a business combination, the tax effect is included in the accounting for the business combination. 
 
39.12 property, plant and equipment 
 
property, plant and equipment are recognized as an asset when it is probable that future economic benefits associated 
with the asset will flow to the company and the cost of the asset can be measured in a reliable manner. 
 
property, plant and equipment which qualify for recognition as an asset are initially measured at cost. the cost of a 
property, plant and equipment comprises its purchase price and any directly attributable cost of bringing the asset to 
working condition for its intended use. 
 
the depreciable amount of the asset is allocated on a straight‐line basis over its useful life. the depreciation charge for 
each period  is  recognized  as  an  expense. the  estimated  useful  lives,  residual  values  and  depreciation  method  are 
reviewed at each balance sheet date, with the effect of any changes in estimate accounted for on a prospective basis. 
 
the following useful lives are used in the calculation of depreciation: 
 
buildings & sites   
 
25 ‐ 50 years 
machinery and equipment  
  5 ‐ 10 years 
fixtures and office equipment 
  3 ‐ 10 years 
 
computer equipment 
 
  2 ‐ 5 years 
 
the gain or loss arising on the disposal or retirement of an asset is determined as the difference between the sales 
proceeds and the carrying amount of the asset at the date of the sale transaction and is recognized in the consolidated 
income statement. 
Össur consolidated financial statements 2020
48
 
 
 
               notes to the consolidated financial statements 
 
 
39.13 intangible assets 
 
intangible assets acquired separately 
 
intangible assets with finite useful life are reported at cost less accumulated amortization and accumulated impairment 
losses. amortization is allocated on a straight‐line basis over their estimated useful lives. the estimated useful life and 
amortization method are reviewed at the end of each balance sheet date, with the effect of any changes in estimate 
being  accounted  for  on  a  prospective  basis.  intangible  assets  with  indefinite  useful  lives  are  carried  at  cost  less 
accumulated impairment losses.  
 
intangible assets with finite useful lives are amortized on a straight‐ line basis over their useful lives. 
 
the following useful lives are used in the calculation of amortization: 
 
customer and distribution relationships 
4 ‐ 10 years 
patents   
 
 
 
5 – 50 years 
trademarks 
 
 
 
3 – infinitive 
software and other 
 
 
2 ‐ 10 years 
 
 
internally generated intangible assets 
 
expenditure on research activities is recognized as an expense in the period in which it is incurred. 
 
an internally‐generated intangible asset arising from the company's development is recognized only if all of the following 
conditions are met: the technical feasibility of completing the intangible asset so that it will be available for use or sale; 
the intention to complete the intangible asset and use or sell it; the ability to use or sell the intangible asset; the 
intangible asset will generate probable future economic benefits; the availability of adequate technical, financial and 
other resources to complete the development and to use or sell the intangible asset and the ability to measure reliably 
the expenditure attributable to the intangible asset during its development. 
 
the amount initially recognized for internally generated intangible assets is the sum of the expenditure incurred from 
the  date  when  the  intangible  asset  first  meets  the  recognition  criteria  listed  above.  where  internally  generated 
intangible asset cannot be recognized, development expenditure is charged to profit or loss in the period in which it is 
incurred. 
 
after initial recognition, internally generated intangible assets are reported at cost less accumulated amortization and 
accumulated impairment losses, on the same basis as intangible assets acquired separately. 
 
intangible assets acquired in a business combination 
 
intangible assets acquired in a business combination are identified and recognized separately from goodwill where they 
satisfy the definition of an intangible asset and their fair values can be measured reliably. the cost of such intangible 
assets is their fair value at the acquisition date.  
 
after initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated 
amortization and accumulated impairment losses, on the same basis as intangible assets acquired separately.   
 
derecognition of intangible assets 
 
an intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. 
gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal 
proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized. 
 
Össur consolidated financial statements 2020
49
 
 
 
               notes to the consolidated financial statements 
 
39.14 impairment of tangible and intangible assets excluding goodwill 
 
at each balance sheet date, the company reviews the carrying amounts of its tangible and intangible assets to determine 
whether there is any indication that those assets have suffered an impairment loss. if any such indication exists, the 
recoverable amount of the asset is estimated to determine the extent of the impairment loss. where it is not possible 
to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash‐
generating unit to which the asset belongs. where a reasonable and consistent basis of allocation can be identified, 
assets are also allocated to individual cash‐generating units, or otherwise they are allocated to the smallest group of 
cash‐generating units for which a reasonable and consistent allocation basis can be identified. 
 
intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment 
annually, and whenever there is an indication that the asset may be impaired. 
 
recoverable amount is the higher of fair value less costs to sell and value in use. in assessing value in use, the estimated 
future  cash  flows  are  discounted  to  their  present  value  using  a  pre‐tax  discount  rate  that  reflects  current  market 
assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows 
have not been adjusted. 
 
if the recoverable amount of an asset (or cash‐generating unit) is estimated to be less than its carrying amount, the 
carrying  amount  of  the  asset  (cash‐generating  unit)  is  reduced  to  its  recoverable  amount.  an  impairment  loss  is 
recognized immediately in profit or loss. 
 
39.15 inventories 
 
inventories are stated at the lower of cost and net realizable value. costs, including an appropriate portion of fixed and 
variable overhead expenses, are assigned to inventories held by the method most appropriate to the class of inventory, 
with the majority being valued on a standard cost basis. net realizable value represents the estimated selling price for 
inventories less all estimated costs of completion and costs necessary to make the sale. 
 
39.16 provisions 
 
provisions are recognized when the company has a present obligation as a result of a past event, it is probable that the 
company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. 
 
the amount recognized as a provision is the best estimate of the consideration required to settle the present obligation 
at the balance sheet date, considering the risks and uncertainties surrounding the obligation. where a provision is 
measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of 
those cash flows. 
 
when some or all of the economic benefits required to settle a provision are expected to be recovered from a third 
party, the receivable is recognized as an asset if it is virtually certain that reimbursement will be received and the amount 
of the receivable can be measured reliably. 
 
warranties 
 
warranty provision includes expected warranty costs for products sold with standard warranty and are recognized at 
the date of sale of the relevant products, at management´s best estimate of the expenditure required to settle the 
company's obligation.  
 
other 
 
other provisions are mainly related to restructuring and earnouts related to acquisitions of companies. restructuring 
provision is recognized when the company has developed a detailed formal plan for the restructuring and has started 
to implement it or announcing its main features to those affected by it. the measurement of a restructuring provision 
Össur consolidated financial statements 2020
50
 
 
 
               notes to the consolidated financial statements 
 
includes only the direct expenditures arising from the restructuring, which are those amounts that are both necessarily 
entailed by the restructuring and not associated with the ongoing activities of the entity. 
 
39.17 financial instruments 
 
financial assets and financial liabilities are recognized in the company’s balance sheet when the company becomes 
a party to the contractual provisions of the instrument. financial assets and financial liabilities are initially measured at 
fair value. transaction costs that are directly attributable to the acquisition or issue of financial assets and financial 
liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted 
from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. transaction costs 
directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are 
recognized immediately in profit or loss. 
 
effective interest method 
 
the effective interest method is a method of calculating the amortized cost of a debt instrument and of allocating 
interest income over the relevant period. the effective interest rate is the rate that exactly discounts estimated future 
cash receipts (including all fees on points paid or received that form an integral part of the effective interest rate, 
transaction  costs  and  other  premiums  or  discounts)  through  the  expected  life  of  the  debt  instrument  or,  where 
appropriate, a shorter period to the net carrying amount on initial recognition. 
 
income is recognized on an effective interest basis for debt instruments other than those financial assets classified as at 
fair value through profit or loss (fvtpl). 
 
 
financial assets 
 
all regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. regular way 
purchases  or  sales  are  purchases  or  sales  of  financial  assets  that  require  delivery  of  assets  within  the  time  frame 
established by regulation or convention in the marketplace. all recognized financial assets are measured subsequently 
in their entirety at either amortized cost or fair value, depending on the of the financial assets. 
 
classification of financial assets 
 
debt instruments that meet the following conditions are measured subsequently at amortized cost: 
•  the financial asset is held within a business model whose objective is to hold financial assets to collect contractual 
cash flows; and 
•  the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of 
principal and interest on the principal amount outstanding. 
 
financial assets that do not meet the criteria for being measured at amortized cost are measured at fvtpl. financial 
assets at fvtpl are measured at fair value at the end of each reporting period, with any fair value gains or losses 
recognized in profit or loss to the extent they are not part of a designated hedging relationship. the net gain or loss 
recognized in profit or loss includes any dividend or interest earned on the financial asset. fair value is determined in 
the manner described in note 39.2. 
 
impairment of financial assets 
 
the  company  recognizes  a loss  allowance  for  expected  credit  losses  on  investments  in  debt  instruments  that  are 
measured at amortized cost and account receivables. the amount of expected credit loss is updated at each reporting 
date  to  reflect  changes  in  credit  risk  from  initial  recognition  of  the  respective  financial  instrument.  the  company 
measures the collective allowance for trade receivables at an amount equal to lifetime expected credit loss (ecl). the 
expected credit loss on trade receivables is estimated using a provision matrix by reference to past default experience, 
general economic conditions and an assessment of both the current as well as expected conditions, including time value 
of money where appropriate. individual allowance and adjustments to the collective bad debt provision are made based 
Össur consolidated financial statements 2020
51
 
 
 
               notes to the consolidated financial statements 
 
on the individual assessment of customers' situation and probability of incoming payments. as the company´s historical 
credit loss experience does not show significantly different loss patterns for different customer segments, the provision 
for loss allowance based on past due status is not further distinguished between the company´s different customer 
segments. 
 
a financial asset is credit‐impaired when one or more events that have a detrimental impact on the estimated future 
cash flows of that financial asset have occurred. evidence that a financial asset is credit‐impaired includes observable 
data about significant financial difficulty of the borrower. an allowance for credit‐impaired financial assets is measured 
on an individual basis. 
 
the company writes off a financial asset when there is information indicating that the debtor is in severe financial 
difficulty and there is no realistic prospect of recovery, e.g., when the debtor has been placed under liquidation or has 
entered into bankruptcy proceedings. financial assets written off may still be subject to enforcement activities under 
the  company’s  recovery  procedures,  taking  into  account  legal  advice  where  appropriate.  any recoveries  made  are 
recognized in profit or loss. 
 
derecognition of financial assets 
 
the company derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire, or 
when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another 
entity.  
 
on  derecognition  of  a  financial  asset,  the  difference  between  the  asset's  carrying  amount  and  the  sum  of  the 
consideration received and receivable is recognized in profit or loss.   
 
financial liabilities 
 
all financial liabilities are measured subsequently at amortized cost using the effective interest method or at fvtpl.  
 
financial liabilities are classified as at fvtpl when the financial liability is (i) contingent consideration of an acquirer in 
a business combination, (ii) held for trading or (iii) it is designated as at fvtpl. 
 
a financial liability is classified as held for trading if: 
•  it has been acquired principally for the purpose of repurchasing it in the near term; or 
•  on initial recognition it is part of a portfolio of identified financial instruments that the company manages together 
and has a recent actual pattern of short-term profit-taking; or 
•  it is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging 
instrument. 
 
derecognition of financial liabilities 
 
the  company  derecognizes  financial  liabilities  when,  and  only  when,  the  company’s  obligations  are  discharged, 
cancelled or have expired. the difference between the carrying amount of the financial liability derecognized and the 
consideration paid and payable is recognized in profit or loss. when the company exchanges with the existing lender 
one debt instrument into another one with the substantially different terms, such exchange is accounted for as an 
extinguishment of the original financial liability and the recognition of a new financial liability. similarly, the company 
accounts for substantial modification of terms of an existing liability or part of it as an extinguishment of the original 
financial liability and the recognition of a new liability. it is assumed that the terms are substantially different if the 
discounted present value of the cash flows under the new terms, including any fees paid net of any fees received and 
discounted using the original effective rate is at least 10 per cent different from the discounted present value of the 
remaining cash flows of the original financial liability. if the modification is not substantial, the difference between: (1) 
the carrying amount of the liability before the modification; and (2) the present value of the cash flows after modification 
should be recognized in profit or loss as the modification gain or loss within other gains and losses. 
 
39.18 employee benefits 
Össur consolidated financial statements 2020
52
 
 
 
               notes to the consolidated financial statements 
 
 
retirement benefit costs and termination benefits 
 
the company has defined contribution retirement benefit plans in place. payments to defined contribution retirement 
benefit plans are recognized as an expense when employees have rendered service entitling them to the contributions. 
 
a liability for a termination benefit is recognized at the earlier of when the entity can no longer withdraw the offer of 
the termination benefit and when the entity recognizes any related restructuring costs. 
 
39.19 derivative financial instruments 
 
the company enters into derivative financial instruments to manage its exposure to currency risk. further details of 
derivative financial instruments are disclosed in note 33. 
 
derivatives are initially recognized at fair value at the date a derivative contract is entered into and are subsequently 
remeasured to their fair value at each balance sheet date. the resulting gain or loss is recognized in profit or loss 
immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the 
recognition in profit or loss depends on the nature of the hedge relationship. the company designates certain derivatives 
as either hedges of cash flow of recognized liabilities or hedges of net investments in foreign operations. 
 
a derivative is presented as a non‐current asset or a non‐current liability if the remaining maturity of the instrument is 
more than 12 months and it is not expected to be realized or settled within 12 months. other derivatives are presented 
as current assets or current liabilities. 
 
hedge accounting 
 
the  company  designates  certain  hedging  instruments,  which  include  derivatives  and  non‐derivatives  in  respect  of 
foreign currency risk, as either cash flow hedges or hedges of net investment in foreign operations. 
 
at the inception of the hedge relationship the entity documents the relationship between the hedging instrument and 
hedged item, along with its risk management objectives and its strategy for undertaking various hedge transactions. 
furthermore, at the inception of the hedge and on an ongoing basis, the company documents whether the hedging 
instrument that is used in a hedging relationship is effective in offsetting changes in fair values or cash flows of the 
hedged item attributable to the hedge risk, which is when the hedging relationships meet all of the following hedge 
effectiveness requirements:  
 
•  there is an economic relationship between the hedged item and the hedging instrument; 
•  the effect of credit risk does not dominate the value changes that result from that economic relationship; and  
•  the hedge ratio of the hedging relationship is the same as that resulting from the quantity of the hedged item that the 
company actually hedges and the quantity of the hedging instrument that the company actually uses to hedge that 
quantity of hedged item.  
 
if a hedging relationship ceases to meet the hedge effectiveness requirement relating to the hedge ratio but the risk 
management objective for that designated hedging relationship remains the same, the company adjusts the hedge ratio 
of the hedging relationship (i.e., rebalances the hedge) so that it meets the qualifying criteria again. 
 
the hedging reserve within equity represents the cumulative portion of gains and losses on hedging instruments deemed 
effective in cash flow hedges. the cumulative deferred gain or loss on the hedging instrument is reclassified to profit or 
loss only when the hedged transaction affects the profit or loss, or is included as a basis adjustment to the non‐financial 
hedged item, consistent with the relevant accounting policy. 
 
hedges of net investments in foreign operations 
 
any gain or loss on the hedging instrument relating to the effective portion of the hedge is recognized in equity in the 
foreign currency translation reserve.  
Össur consolidated financial statements 2020
53
 
 
 
               notes to the consolidated financial statements 
 
 
gains and losses deferred in the foreign currency translation reserve are recognized in profit or loss on disposal of the 
foreign operation. 
 
cash flow hedges 
 
the effective portion of changes in the fair value of derivatives, that are designated and qualify as cash flow hedges, is 
recognized in other comprehensive income and accumulated under the heading of hedging reserve. the gain or loss 
relating to the ineffective portion is recognized immediately in profit or loss, and is included in the ‘other financial 
expense / income' line item. 
 
amounts previously recognized in other comprehensive income and accumulated in equity are reclassified to profit or 
loss in the periods when the hedged item is recognized in profit or loss, in the same line of the income statement as the 
recognized hedged item. however, when the hedged forecast transaction results in the recognition of a non‐financial 
asset  or  a  non‐financial  liability,  the  gains  and  losses  previously  recognized  in  other  comprehensive  income  and 
accumulated in equity are transferred from equity and included in the initial measurement of the cost of the non‐
financial asset or non‐financial liability. 
 
hedge accounting is discontinued when the company revokes the hedging relationship, when the hedging instrument 
expires, is sold, terminated, exercised, or when it no longer qualifies for hedge accounting. any gain or loss recognized 
in other comprehensive income and accumulated in equity at that time remains in equity and is recognized when the 
forecast transaction is ultimately recognized in profit or loss. when a forecast transaction is no longer expected to occur, 
the gain or loss accumulated in equity is recognized immediately in the income statement. 
 
39.20 significant accounting judgments, estimates and assumptions 
 
in the application of the company's accounting policies, which are described in note 39, management is required to 
make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily 
apparent from other sources. the estimates and associated assumptions are based on historical experience and other 
factors that are considered to be relevant. actual results may differ from these estimates.  
 
the estimates and underlying assumptions are reviewed on an ongoing basis. revisions to accounting estimates are 
recognized in the period in which the estimate is revised. revision of accounting estimates can also affect future periods. 
 
determining whether goodwill is impaired requires an estimation of the value in use of the cash‐generating units to 
which goodwill has been allocated. the value in use calculation requires the entity to estimate the future cash flows 
expected to arise from the cash‐generating unit and a suitable discount rate in order to calculate present value. details 
of impairment calculations are set out in note 14. 
 
as described in note 39.12, the company reviews the estimated useful lives of property, plant and equipment at the end 
of each balance sheet date. 
 
39.21 government grants 
 
government grants are not recognized until there is reasonable assurance that the company will comply with the set 
conditions and that the grants will be received. government grants are recognized in profit or loss in the periods in which 
the company recognizes the related expenses for which the grants are intended to compensate. government grants 
that are received as compensation for expenses or losses already incurred or for the purpose of giving immediate 
financial support to the company with no future related costs are recognized in profit or loss in the period in which they 
are received. government grants that are compensating for revenue loss are presented as other income / (expenses) in 
the income statement. 
 
Össur consolidated financial statements 2020
54
© Össur, 02. 2021
